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Cellulose ethers are widely used in a variety of pharmaceutical
applications.  The purpose of this research was to investigate the use of cellulose
ether polymers to formulate different oral pharmaceutical dosage forms, and to
control the release of active ingredient from the specific drug delivery system
over an extended period of time.  In this study, applications of the cellulose ether
polymer in matrix tablets and multiparticulate dosage forms, were investigated.
Specifically, ethylcellulose (EC) used in aqueous polymeric coating, and
hydroxypropyl methylcellulose (HPMC) used in hydrophilic matrix tablets, were
investigated in this study.  Formulations and processing parameters were
developed and optimized in order to achieve the desirable rate of drug release
from each drug delivery system.
ix
For the matrix tablet system, an efficient method to achieve complete
recovery of alprazolam from powder blends and tablets containing HPMC was
developed and qualified.  Formulation parameters, including tablet size, polymer
levels, excipient type and level, molecular weight type of HPMC, and dissolution
media, were investigated and optimized during development of the drug delivery
systems.  Finally, two oral controlled release tablet formulations (containing
different molecular weight types of HPMC) with equivalent dissolution profiles
were developed and used for in vivo bioequivalence study.  Molecular weight
types of HPMC did not influence in vitro or in vivo performance of controlled
release tablets and provided bioequivalent results in both fed and fasted states.
For the multiparticulate system, the amount of drug release from EC
coated matrix beads was influenced by drug type, plasticization, water-soluble
additive, and curing condition.  Optimum curing conditions were determined in
order to ensure complete film coalescence without disrupting film integrity.
Additionally, the amount of theophylline released from EC coated beads was
manipulated by the inclusion of different types and levels of water-soluble
additives.
As found for both controlled release drug delivery systems, formulation
and processing parameters must be investigated and optimized in order to achieve
desirable release profiles and stabilize the amount of drug released throughout the
shelf-life of the product.
x
This research study provided useful information on preformulation and
formulation optimization during development of controlled drug delivery systems
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1.1 HISTORICAL REVIEW OF CELLULOSE AND CELLULOSE ETHERS
Cellulose has been the primary component of the human diet since the
early human history and it is the most abundant natural polymeric raw material
(i.e. wood source) available.  Cellulose is also a primary source for all cellulose
derivatives that are considered safe and acceptable for use in food,
pharmaceutical, medical, cosmetic, and agricultural applications [Nevell and
Zeronian, 1985].  Structurally, cellulose consists of repeating units of anhydro ß-
D glucopyranose, bonded together by ß-1,4-glycosidic linkage, non-reducing end
unit on one side, determined number-average degree of polymerization, and
reducing end unit on another side of the cellulose chain, exhibited the chemical
properties similar to those of the glucose molecule.  Due to a high degree of
polymerization, physicochemical properties of cellulose, determined by the
intermediate backbone, are high crystallinity, high cohesive density, are water
insoluble, but are water absorbable. Cellulose structure can be chemically
modified and classified by methods of preparation into four groups of cellulose
derivatives - hydrocellulose (hydrolysis method), cellulose esters (esterification
method; non-enteric and enteric subgroups), cellulose ethers (etherification or
nucleophilic substitution method), and oxycellulose (oxidation method).
Cellulose ethers currently described in the USP/NF, such as methylcellulose
2
(MC), hydroxypropyl methylcellulose (HPMC), ethylcellulose (EC),
hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), sodium
carboxymethylcellulose (NaCMC), and calcium carboxymethylcellulose
(CaCMC), are most widely used in a variety of pharmaceutical applications,
including solid dosage forms (i.e. tablets, pellets, microparticles), liquid or semi-
solid dosage forms (i.e. solution, gel, emulsion, suspension), and taste or odor
masking.  As shown in Figure 1.1, different types of cellulose ethers are
commonly prepared by a nucleoophilic substitution method.  Except for EC
polymer, which is soluble in a variety of organic solvents (e.g. esters, aromatic
hydrocarbons, alcohols, chlorinated solvents), other cellulose ethers are water
soluble and the viscosity of aqueous solutions depends on polymer concentration,
molecular weight, and temperature.  Hydration rates of each type of cellulose
ether depend on the nature of the substitution unit present, degree of substitution
(i.e. moles of substitution), pH and temperature of dissolution media, and particle
size.  For example, the hydroxypropoxyl group is more hydrophilic than the
methoxyl group; therefore, HPMC is more readily hydrated than MC.  Cellulose
ethers serve multiple functions in pharmaceutical dosage forms.  MC (Methocel
A, The Dow Chemical Company) can be used as a binder and thickening agent.
EC powder (Aqualon®, Hercules Inc., Ethocel, The Dow Chemical Company) can
be used for solvent granulation for water sensitive drugs, tablet coatings,
microencapsulation, taste masking, controlled release matrix tablets, and binder,
whereas EC aqueous colloidal dispersion (Aquacoat® ECD, FMC Corporation;
Surelease®, Colorcon) can be used for coating, granulation, and taste masking.
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HEC (Natrosol®, Hercules Inc.), HPC (Klucel®, Hercules Inc.), and NaCMC
(AqualonTM Cellulose Gum, Hercules Inc.) function as thickening agents,
protective colloidal agents, suspending agents, and emulsion stabilizers.  The
crossed-link form of NaCMC or croscarmellose sodium type A (Ac-Di-Sol, FMC
Corporation) can be used as a dissolution aid or as a disintegrant in tablets or
capsules.  HPMC (Methocel E, F, K, J, The Dow Chemical Company) is used as a
binder, coatings, and controlled release polymer [Kumar and Banker, 1993].  In
this study, applications of the cellulose ether polymers in two types of controlled
release solid dosage forms, including single unit system and multiparticulate
system, were investigated.  Specifically, EC, a water insoluble cellulose ether,
which is widely used in aqueous polymeric coating, and HPMC, a water soluble
cellulose ether, which is commonly used in hydrophilic matrix drug delivery
systems, were used in this study.
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Cellulose Ether Type         Substitution Unit
Methylcellulose (MC)         R = -H, -CH3
Ethylcellulose (EC)         R = -H, -C2H5
Hydroxyethylcellulose (HEC)         R = -H, -CH2CH2OH,
   -(CH2)2O(CH2)2OH
Hydroxypropylcellulose (HPC)         R = -H, -CH2CH(OH)CH3
Hydroxypropyl methylcellulose (HPMC)         R = -H, -CH3, -CH2CH(OH)CH3
Sodium carboxymethylcellulose (NaCMC)         R = -H, -CH2 OONa















1.2 CELLULOSE ETHERS IN CONTROLLED RELEASE DRUG DELIVERY
Novel drug delivery devices available today are administered by oral,
buccal, transdermal, parenteral, ocular, implantable, intravaginal, or intrauterine.
These devices are constructed from two types of controlled release drug delivery
systems: capsule-type drug delivery systems and matrix-type drug delivery
systems [Chien, 1982].  Controlled release solid dosage forms become important
for the oral administration of many drug substances because they provide more
consistency in blood levels [Pather et al., 1998].  Oral controlled release solid
dosage forms can also be classified into two systems as follow:
- Single unit system (i.e. film coated tablets, matrix tablets, film coated
hard and soft gelatin capsules)
- Multiparticulate system (i.e. film coated beads)
In this research study, the use of cellulose ether polymers in both systems,
including matrix tablets (HPMC polymer) and film coated matrix beads (EC
polymer), was investigated.
1.2.1 Single Unit System (Matrix Tablets)
Hydrophilic matrix drug delivery systems consist of a hydrophilic
polymer, drug, and other excipients distributed throughout the matrix.  This
system is dependent on polymer wetting, polymer hydration, and polymer
dissolution for the controlled release of drug.  At the same time, other soluble
excipients or drug substances comprising the tablet will also become wet,
dissolve, and diffuse out of the matrix, while insoluble excipients or drug
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substances will be held in place until the surrounding polymer/excipient/drug
complex erodes or dissolves away (Figure 1.2) [The Dow Chemical Company,
2000].
Hydrophilic matrix drug delivery systems are widely used to control drug
release due to their major advantages over other delivery systems, including
[Vazquez et al., 1992; Alderman, 1984]:
- Desirable drug release profile can be obtained due to high flexibility of
the system.
- Reproducible drug release profiles can be obtained by properly
controlling the formulation parameters.  Variability is slightly lower than coated
dosage forms.
- Risk of dose dumping can be minimized since the drug release is
controlled by diffusion through the hydrophilic gel layers or polymer erosion.
- Cost effectiveness is considered low since most products can be
manufactured using inexpensive gelling agents with broad FDA acceptance and
by using direct compression.
- Wide range of drug loading can be incorporated into the system and
large doses of active drug substances can be delivered.
HPMC, one of the commercially available hydrophilic polymers, is
commonly used to prepare hydrophilic drug delivery systems.
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Figure 1.2 Hydrophilic matrix system [Alderman, 1984]
Dry Tablet
Ingestion of TabletInitial wetting
Expansion of gel layer
Gel layer
Tablet Erosion
Soluble Drug - Diffusion Insoluble Drug - Diffusion
                         - Erosion
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Hydroxypropyl Methylcellulose (HPMC) Polymer
HPMC, a non-ionic cellulose ether, is a mixed alkyl hydroxyalkyl
cellulose ether containing methoxyl and hydroxypropoxyl groups.  The hydration
rate of HPMC depends on the nature of these substituents, such as the molecular
structure and the degree of substitution.  Specifically, the hydration rate of HPMC
increases with an increase in the hydroxypropoxyl content [The Dow Chemical
Company, 1995].  The gelation temperature of HPMC ranges between 58-90˚C,
depending on the hydroxypropoxyl and methoxyl contents [The Dow Company,
1988].  The solubility of HPMC is pH independent [Alderman, 1984].  HPMC can
be slowly dissolved in cold water to form a viscous solution, but is not very
soluble in hot water.  Additionally, it can be dissolved in most polar organic
solvents or binary systems of methylene chloride or chloroform and alcohol
[Budavari et al., 1996; Kumar and Banker, 1993; Archer, 1992].  It is practically
insoluble in pure chloroform, ethanol and ether [Kibbe, 2000].  Therefore, the
recommended method to prepare HPMC aqueous solutions is to first thoroughly
disperse and hydrate the powder in a portion of hot water (about one-third of the
total volume) heated above 90˚C with vigorous stirring to prevent lumping.
Complete solubilization is then accomplished by adding the remaining cold water
(two-thirds of the total volume) to lower the temperature of the dispersion.  As the
temperature is lowered, a point is reached where HPMC becomes water soluble,
resulting in increased viscosity ("hot/cold" techniques)  [The Dow Chemical
Company, 1988].  The viscosity of the aqueous solution can be increased by
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increasing the molecular weight distribution of the polymer, the concentration of
the polymer or decreasing the temperature of the solution.
According to the USP Official Monograph, HPMC polymer is classified
into four types based on percent of methoxyl and hydroxypropoxyl substitution
groups.  They include HPMC substitution types 1828, 2208, 2906, and 2910.
Percent of each substitution group for each HPMC type is shown in Table 1.1
[United States Pharmacopeial Convention, 1999].  Examples of commercially
available cellulose ether products, under the tradename of Methocel, from the
Dow Chemical Company (Midland, MI, USA), that corresponds to each USP
type, are also included in Table 1.1.  For Methocel products, each letter identifies
the type of cellulose ether.  Specifically, "A" identifies MC products, whereas
"E", "F", "J", and "K" identify HPMC products.  Each type of cellulose ether has
a different rate of hydration due to variation of the substitution level within the
molecule.  The methoxyl substituent is a relatively hydrophobic component and
does not contribute to the rate of hydration as greatly as the hydrophilic
hydroxypropoxyl substituent does.  In addition to the letter-identified type, the
number that follows identifies the viscosity in millipascal-seconds (mPa.s) or
centipoises (cPs) of that product measured at 2% concentration in water at 20˚C
(68˚F).  The letters "C" and "M" represent "100" and "1000" in designating
viscosity, respectively.  While the letters "P", "LV", and "CR" stand for "Premium
grade" for food and pharmaceutical application, "Low Viscosity", and "Controlled
Release grade", respectively.  For example, Methocel K100LVP is the HPMC
Premium grade product with low viscosity around 100 cPs measured at 2%
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concentration in water at 20 ˚C.  Methocel K4MP is the HPMC Premium grade
product with viscosity around 4000 cPs measured at 2% concentration in water at
20˚C [The Dow Chemical Company, 1988; The Dow Chemical Company, 1995;
Kibbe, 2000].
HPMC polymers are widely used in controlled release dosage forms due
to its nontoxic nature, its capacity to accommodate high levels of drug loading,
and its non-pH dependence [Helena Amaral et al., 2001].  In this study, the use of
HPMC in the controlled release matrix tablet is investigated in different areas
within the following sections.
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Table 1.1 Type of Cellulose Ethers Specified in USP 24/NF 19 and
Commercially Available Products from The Dow Chemical
Company [United States Pharmacopeial Convention, 1999 ; The






%Methoxyl %Hydroxypropoxyl Relative Rate
of Hydration
MC Methocel A 27.5-31.5 0.0 Slowest
HPMC
1828 Methocel J 16.5-20.0 23.0-32.0 Fastest
2208 Methocel K 19.0-24.0 7.0-12.0 Next Fastest
2906 Methocel F 27.0-30.0 4.0-7.5 Slower
2910 Methocel E 28.0-30.0 7.0-12.0 Slow
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1.2.1.1 Drug Recovery from Hydrophilic Matrix Tablets
In tablet manufacturing, quantification of the drug substance (i.e. content
uniformity or composite assay) in the drug product is a mandatory requirement for
release.  Typically, a content uniformity assay is performed by pulverizing a tablet
into powder and extracting the drug substance using an organic solvent(s) with
sonication or mechanical stirring [Dortunc et al., 1998].  However, extracting a
lipophilic drug substance from gelling HPMC tablets is much more complicated
due to the highly lipophilic nature of the drug substance and the gelling properties
of HPMC polymer.  Dortunc et al. described a content uniformity method for
hydrophilic matrix tablets containing HPMC K4M or K15M and pindolol in a
buccoadhesive matrix tablet.  A pulverized tablet was treated with enough pH 6.8
phosphate buffer solution:methanol mixture (98:2), in which pindolol had a high
solubility (222.2 µg/ml) when compared to its solubility in pH 6.8 buffer solution
alone (8.2 µg/ml).  However, the percent drug recovery and drug content
uniformity results were not reported [Dortunc et al., 1998].  Also, quantification
of acetazolamide in matrix tablets containing HPMC K4M or K15M was
reported, but the quantitative assay method and drug content uniformity results
were not reported [Dortunc and Gunal, 1997].  A review of the literature indicated
that no specific method has been reported for quantification of a lipophilic drug
substance contained in HPMC matrix tablets.
In order to develop a method to recover a lipophilic drug from controlled
release matrix tablets containing HPMC, alprazolam, a benzodiazepine, was
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chosen as the model drug in this study.  Alprazolam is classified as a DEA
controlled substance Schedule IV.  It has a rapid onset of action coupled with a
relatively short half-life, and is indicated for the management of anxiety or panic
disorders, anxiety associated with depression, and neurosis.  The exact
mechanism of action for alprazolam is unknown; however, literature indicates its
proposed mechanism by binding to stereospecific receptors at several sites within
the central nervous system (CNS).  It may interact allosterically with the GABAA
receptor by modulating GABAA receptor to increase activity, increasing chloride
channel activity, and potentiating GABA effects throughout nervous system.
Therapeutic effect is a dose-related response.  A major metabolite, α-
hydroxyalprazolam, has about 50% pharmacological activity of the parent
compound.  Another metabolite, benzophenone, is an inactive metabolite.  Drug is
readily absorbed (more than 90%) after oral administration (bioavailability (F) =
0.88) and widely distributed (volume of distribution about 1 L/kg in a healthy
human).  Peak plasma concentrations occur 1 to 2 hours after oral administration
of immediate release dosage forms, whereas the elimination half-life is about 11.2
hours (with a range of 6.3 to 26.9 hours).  Alprazolam and its metabolites are
excreted primarily in the urine.  Some may be excreted in human milk, which is
similar to other benzodiazepines.  Drug absorption is delayed when alprazolam is
taken after fed state than fasted state, but total absorption remains unchanged.
High fat diet may have a potential for drug-food interactions and may alter drug
absorption [United States Pharmacopeial Convention, 1999; FDA, 1996;
Greenblatt and Wright, 1993; Charman, 2000].
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Alprazolam occurs as a white to off-white crystalline powder and melts in
the range of 228-229˚C [Budavari et al., 1996].  Greenblatt et al. reported the high
value of the partition ratio between n-octanol and aqueous buffer at physiological
pH 7.4 of alprazolam to be about 18, indicating its high degree of lipophilicity
[Greenblatt et al., 1983; Garzone and Kroboth, 1989].  Also, Carelli et al.
determined the partition coefficient of alprazolam between n-octanol and normal
saline containing 0.035% formaldehyde (as a preservative) of the drug from their
permeation study through hairless mouse skin to be about 132 [Carelli et al.,
1992].  In addition, it has been reported that the partition coefficient of alprazolam
between human callus (tissue) and the normal saline containing 0.035%
formaldehyde determined from a permeation study through human skin in vitro
was about 17.5 ml/g [Carelli et al., 1994].  Alprazolam is insoluble in water,
soluble in chloroform and alcohol, and slightly soluble in acetone and ethyl
acetate.  The solubility and intrinsic rate of dissolution of alprazolam are pH
dependent [Laihanen et al., 1996a].  The structure of alprazolam, a triazo analog
of the 1,4-benzodiazepine class of compounds, is shown in Figure 1.3.
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1.2.1.2 Investigation of Formulation Parameters on Drug Release
The release of drug from a controlled release dosage form is influenced by
factors relating to the physicochemical properties of the drug substance and to the
dosage forms.  The properties of the drug substance influencing the dissolution
rate and subsequent bioavailability include solubility, particle size distribution
[Ford et al., 1985a; Ford et al., 1987], and crystalline state, such as polymorphism,
state of hydration, and complexation [Abdou, 1989].
The dosage form is influenced by its composition and processing
parameters.  Several studies have reported on the effect of formulation
composition and processing parameters on the properties of the hydrophilic
matrix tablets [Alderman, 1984; Vazquez et al., 1992].  Processing parameters,
such as processing procedure [Alderman, 1984], compression force [Hirschorn
and Kornblum, 1971; Velasco et al., 1999], and tablet characteristics (shape [Ford
et al., 1987], size [Hirschorn and Kornblum, 1971], surface area [Alderman,
1984], and hardness [Huber and Christenson, 1968]), have been investigated.
Factors associated with drug in the formulations, such as drug concentration
[Mitchell et al., 1993a; Xu and Sunada, 1995] and drug particle size [Velasco et
al., 1999], also had an impact on the drug release from tablets containing either
HPMC or MC.  Factors associated with polymers, such as molecular weight type
(nominal viscosity) [Huber and Christenson, 1968; Harwood and Schwartz, 1982;
Nakano et al., 1983; Daly et al., 1984; Ford et al., 1985b; Cheong et al., 1992;
Tahara et al., 1995; Krogel and Bodmeier, 1999], concentration [Ford et al,
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1985a; Ford et al, 1985b; Cheong et al., 1992; Shah et al., 1993; Xu and Sunada,
1995; Velasco et al., 1999; Helena Amaral et al., 2001], degree of substitution
[Alderman, 1984; Mitchell et al., 1993b], and particle size [Alderman, 1984;
Velasco et al., 1999], have been shown to have a significant influence on drug
release.  However, the most important factor that affects the drug release rate
from HPMC matrices is the polymer concentration or drug:polymer ratio [Ford et
al., 1985a; Ford et al., 1985b; Xu and Sunada, 1995; Velasco et al., 1999; Helena
Amaral et al., 2001].
In this formulation investigation study, alprazolam was also selected as the
model drug because it is highly lipophilic and compatible with other excipients.
No drug/excipient incompatibilities have been reported between alprazolam and
the excipients, lactose, microcrystalline cellulose, magnesium stearate, or
dicalcium phosphate dihydrate [Laihanen and Yliruusi, 1996b].
In this research study, the influence of the excipient and the molecular
weight type (nominal viscosity) of HPMC polymer on a lipophilic drug released
from a matrix tablet are the main focuses.  Therefore, a literature review of the
previous studies on these parameters will be provided in detail within the
following sections.
Excipient Type
Lapidus and Lordi showed that the replacement of HPMC (15,000 cPs) by
either a soluble lactose or insoluble tricalcium phosphate similarly increased the
dissolution rate of water-soluble chlorpheniramine maleate from matrix tablets
[Lapidus and Lordi, 1968].  Similarly, Ford et al. reported differences in release
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rates of the water-soluble drug, promethazine hydrochloride, from tablets
containing either lactose or calcium phosphate in combination with HPMC
polymer.  However, differences in release rates occurred only when the tablets
contained high levels of the diluents [Ford et al., 1987].  Also, the presence of
soluble lactose or insoluble dibasic calcium phosphate did not impact the
naproxen release rate from the matrix tablets containing HPMC K100M (nominal
viscosity of 100000 cPs) [Helena Amaral et al., 2001].  In contrast, Alderman
reported that the use of swellable, insoluble excipients (i.e. microcrystalline
cellulose or cross linked carboxymethylcellulose) in tablet formulations
containing 10% HPMC 2208 tended to cause expansion of the gel layer resulting
in greater release of insoluble riboflavin in the early stages of dissolution (burst
effect) due to their disintegrating property [Alderman, 1984].  In another study, it
was found that the greater the dilution of the poorly water soluble drug,
quinazolinone, with water soluble lactose, the faster the drug release since the
excipient assisted the solvent to better wet and dissolve the drug within the matrix
[Hirschorn and Kornblum, 1971].  In comparison between tablet formulations
containing different viscosity grades of HPMC, it is found that the excipient type
had more of an influence on release of chlorpheniramine maleate from tablets
containing the lower viscosity grade polymer, HPMC E5 [Krogel and Bodmeier,
1999].  Additionally, the incorporation of additives such as surfactants [Daly et
al., 1984], ion-exchange resins, or ionic additives to modify polymer thermal
gelling temperature, and pH adjusting agents has been reported to modify the
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release profiles of the active from the matrix tablet formulations [Vazquez et al.,
1992 ].
As can be seen, no studies to date have systematically investigated the
influence of excipient type and level on the release of lipophilic drugs.
Additionally, results from previous studies on the influence of excipient on drug
release remained unclear.
HPMC Molecular Weight Type (Nominal Viscosity)
During polymerization, each HPMC molecule may be different in terms of
the degree of polymerization resulting in different molecular weight types, which
is reflected in the nominal viscosity of an aqueous solution [The Dow Chemical
Company, 2000].  The influence of molecular weight types or viscosity grades of
HPMC polymer on the release rate of drug was investigated by several
researchers.  Huber and Christenson reported the slower release of a tartrazine dye
from tablets containing high viscosity grade (i.e. HPMC 15000 cPs) when
compared to the release from tablets containing low viscosity grade (i.e. HPMC
100 cPs or HPMC 4000 cPs) [Huber and Christenson, 1968].  Similar to the
HPMC system, the release rate of theophylline was delayed when higher viscosity
grades of HPC were used in the tablet formulations.  By mixing between low and
medium-viscosity grades of HPC, the release rate of drug can be modified.
[Nakano et al., 1983].  The sustained release of drug from both systems was
achieved by the polymer swelling to a gel-like consistency at the tablet periphery
and forming a barrier to drug diffusion.  Additionally, Daly et al. reported similar
findings on the influence of the viscosity grade of HPMC 2910 USP (Methocel
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E5, E15, E50, and E4M) on the release of chlorpheniramine maleate from matrix
tablets.  The results showed that the drug release was significantly slower when
the higher viscosity grade of HPMC was used.  The fastest to the slowest drug
release obtained from the tablets containing increased viscosity grade of HPMC
was in the following order: HPMC E5 >HPMC E15 > HPMC E50 > HPMC E4M
[Daly et al., 1984].  Similar results were also reported for ophthalmic HPC matrix
compression molded films.  The release of pilocarpine was slower for the higher
viscosity grades [Harwood and Schwartz, 1982].  Another study investigated the
relationship between viscosity of HPMC 2208 USP (i.e. Metolose K4 (4380 cPs),
K15 (18200 cPs), K30 (35800 cPs), K50 (44400 cPs), and K100 (100000 cPs),
Shin-Etsu Chemical, Japan) and drug release from a matrix system.  Results
indicated that the larger the amount or the higher the viscosity grade of the HPMC
present in the matrix, the greater the solution viscosity of the gel layer and the
more resistant the gel layer is to diffusion.  Therefore, drug release from a matrix
with a diffusion-controlled release mechanism is retarded [Cheong, 1992].  In
addition, viscosity of HPMC 2910 USP also had a large influence on the erosion
rate of the matrix tablet.  Specifically for poorly water-soluble drugs, a low
viscosity grade of HPMC was desirable since the drug release rate was controlled
by the rate of tablet erosion.  Therefore, the tablet erosion rate can also be
optimized by the choice of HPMC viscosity grade or by using the combination of
different viscosity grades [Tahara et al., 1995].  In the recent development study
on a multifunctional matrix drug delivery system based on HPMC-matrices
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surrounded by an imperable cylinder, the lower the HPMC viscosity grade, the
higher the drug release from the system [Krogel and Bodmeier, 1999].
In contrast, Ford et al. found that the formulation containing the lowest
viscosity grade of HPMC (i.e. HPMC K100, 106 cPs for 2% aqueous solution)
had the highest release rates at constant HPMC:drug promethazine hydrochloride
ratio.  While the other grades including HPMC K4M (3850 cPs), K15M (12449
cPs), and K100M (93000 cPs) showed similar release rates despite the variation in
molecular size of the polymers.  This may be due to HPMC K100 possessing a
higher apparent diffusion coefficient for the drug promethazine HCl, while other
grades possessed an equivalent apparent diffusion coefficient.  The viscosities of
the hydrated higher molecular weight matrices may be identical, even though they
were apparently different in their viscosity grades [Ford et al., 1985b].  The main
factor controlling drug release was the drug promethazine hydrochloride:HPMC
ratio.  When the polymer content increased, the dissolution rate of drug decreased
[Ford et al., 1985a].
In Vitro Release Study
In the hydrophilic matrix tablet formulation, the release of active drug can
be controlled by a partially hydrated gel layer of the tablet surface formed upon
contact with aqueous gastric media following ingestion and the continuous
formation of additional gel layers to control the drug release.  During the
manufacturing process of the hydrophilic cellulose ether polymers, variations,
such as degree of chemical substitution, and molecular weight type, may cause
concern as to their impact on product manufacturability, reproducibility, and
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clinical performance.  In some cases, these differences may not be acceptable by
formulators since they have the potential to influence drug release rate from a
dosage form, and consequently the bioavailability.
More recently, comparison of dissolution profiles is recommended in the
release guidelines by the FDA [FDA, 1997a; FDA, 1995; FDA, 1997b; FDA,
1997c].  For the composition, equipment, batch size, manufacturing site, or
process changes, a comparison of dissolution profiles between pre-change and
post-change formulations is recommended as it provides a more precise
measurement of product similarity using dissolution characteristics [FDA, 1995].
Dissolution profiles comparison is useful for accepting product sameness under
SUPAC-related changes, waiving bioequivalence requirements for lower
strengths of a dosage form, and supporting waivers for other bioequivalence
requirements.  Dissolution profiles may be considered similar by virtue of (1)
overall profile similarity; and (2) similarity at every dissolution sample time point
[FDA, 1997b].  Several methods for the comparison of dissolution profiles,
including model independent and model dependent methods, were proposed
[FDA, 1997b; Shah et al., 1987; Sathe et al., 1996; Moore and Flanner, 1996;
Tsong et al., 1996; Chow and Ki, 1997].  However, the major drawback was the
quantification of the comparison of dissolution profiles [Shah et al., 1998].  In
order to statistically quantify the comparison of dissolution profiles, a simple
model-independent approach using mathematical indices to define the similarity
factor (f2 factor) is widely acceptable.  The similarity factor (f2) is used to
quantitate agreement between two dissolution profiles.  If the f2 value approaches
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100, the two profiles are nearly identical.  In general, the FDA standard for f2
ranging between 50-100 (≤ 10% average difference) indicates similarity between
two dissolution profiles [FDA, 1995; FDA, 1997b; Shah et al., 1998; Shah et al.,
1999; Moore and Flanner, 1996].  Similarity factor assessment will be described
in detail in the next chapter.
Bioequivalence Study
Bioequivalence can be defined as the drug substance in two or more
similar dosage forms reaches the systemic circulation at the same relative rate and
to the same relative extent [Abdou, 1989].  The current FDA guidelines for
bioequivalence are that two formulations whose rate and extent of absorption
differ by  -20% to +25% or less are generally considered bioequivalent.  This is
based on the concept that a difference of -20% to +25% would not lead to change
in therapy for a patient.  Additionally, the difference in area-under-the-curve
(AUC), maximal concentration (Cmax), and time of maximal concentration
(Tmax) of the two formulations are within 80% to 125% of a reference standard.
The therapeutic efficacy of pharmaceutical formulations is governed by
factors related to both in vitro dissolution characteristics of the drug substance and
its in vivo bioavailability.  Due to the interdependency within the drug-patient
biosystem as a major concern, the in vitro/in vivo correlation studies become
more important in pharmaceutical development [Abdou, 1989].  The correlation
between in vitro dissolution tests and in vivo  plasma drug levels as a function of
time has proven to be a better assessment of bioavailability and bioequivalence
[Shah et al., 1981].
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In the hydrophilic matrix tablet formulation, the release of active drug can
be controlled by a partially hydrated gel layer of the tablet surface formed upon
contact with aqueous gastric media following ingestion and the continuous
formation of additional gel layers to control the drug release.  Lot-to-lot variations
of the hydrophilic cellulose ether polymers such as degree of chemical
substitution, molecular weight type (nominal viscosity), and particle size may
cause concern as to their impact on product manufacturability, reproducibility,
and clinical performance.  These differences may not be acceptable by
formulators since they have a potential to affect the drug release rate from a
dosage form, and consequently the bioavailability.
In reality, the differences in molecular weight types of the HPMC polymer
probably do not significantly influence the bioavailability of a drug substance (i.e.
two different molecular weight types would be bioequivalent), but this must be
investigated and confirmed in a well-controlled clinical study.  This would be of
great significance to pharmaceutical scientists to determine exactly what degree of
variability could be allowed without influencing the in vivo bioequivalence.  As
can be seen from the investigation of hard gelatin capsules, the results from
gamma scintigraphy indicated that there are no significant differences in the i
vivo disintegration properties of the cross-linked and non cross-linked hard gelatin
capsules, even though the in vitro dissolution data of both capsules was
significantly different [Brown et al., 1998].
In addition, drug release from a matrix tablet may be influenced by the
presence of food in the stomach since it may alter the stomach environment.
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Previous studies showed that food prolongs the residence time of a dosage form
administered during or immediately after a meal by keeping the dosage form in
the upper half of the stomach [Hardy et al., 1989; Davis et al., 1990].  Long
retention time of drug product in the stomach provides more time for the dosage
form to have intimate contact with the stomach contents.  Normally, dosage forms
pass through the stomach rapidly during the fasting state and they are retained
longer in the stomach during the fed state.  The release of drug from the dosage
form, absorption and subsequent bioavailability are varied depending on the
physiological changes that occur in the gastrointestinal tract during the two states
[Williams et al., 1993].  Therefore, the dosage form should not be susceptible to
food present in the stomach, in order to eliminate or minimize its influence on
drug release.  Several studies reported that a high-fat meal caused increased
absorption of drug from a bead or tablet formulation [Vaughan et al., 1984;
Theobault et al., 1987; McLachlan et al., 1993; Borin  et al., 1995; Paintaud et al.,
1995], whereas some studies found no influence of food on the in vivo
pharmacokinetics of drug from a formulation [DeVane et al., 1990; Kenyon et al.,
1995].  Therefore, the food effect on the release of specific drug from the specific
matrix tablet formulation should be investigated since the effect of food on drug
release seems to be influenced by drug substance type and formulation.
26
1.2.2 Multiparticulate System (Film-Coated Beads)
Recently, several new developed solid dosage forms have been produced
in the form of film-coated pellets or beads, either of which can be filled into hard
gelatin capsules or compressed into tablets.  Multiparticulate pellet systems are
claimed to have numerous advantages over single unit dosage forms.  The use of
these systems allows for distribution of the drug over a large surface area, thus
minimizing the risk of local damage caused by dose dumping of the single unit,
less tendency to cause gastric irritation, less variability, more uniform drug
release and less dependence on gastric transit time.  They may attain more
constant plasma levels, achieve a slow-release effect, extend the duration of
action of a sustained release dosage form, provide highly accurate dose-to-dose
reproducibility, and cause less of a decrease in bioavailability  [Tapia et al., 1993;
Bechgaard, 1982; Eskilson, 1985; Dechesne and Dellattre, 1987; Story, 1977].
Coating Technology  [Williams III and Mahaguna, 2000]
The purpose of coating is to [Cole, 1995; Bauer et al., 1998; Mehta and
Jones, 1985]:
-  Enhance palatability and mask the unpleasant taste and odor of the
active drug substance
-  Enhance the stability of an active drug substance during exposure to
light, moisture and atmospheric oxygen
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-  Increase the mechanical integrity of the tablet during manufacturing,
packaging (i.e. reduce friction and increase the production rate during
high-speed processing) and shipping
- Increase the elegance and glossy appearance of the tablet or pellet core
- Protect the patient’s clothes and hands from staining due to colored or
migrating active drug substance
-  Modify the drug release profile, such as enteric coating, sustained
release coating, osmotic pumps, etc.
- Avoid side effects caused by the active drug substance (i.e. prevention of
gastric irritation by employing an enteric polymer coating)
- Avoid incompatibility of active drug substances by physical separation
into the core and coat
- Use for product identification unique to each company
Types of Pharmaceutical Coating Processes
There are two major types of coating processes used in pharmaceutical
applications: sugar coating and film coating.  Film coating process is the main
focus of this research study.  Therefore, this process will be described in more
details.
A. Sugar Coating
Sugar coating was developed primarily from technologies employed in the
confectionery industry, which have been optimized over the years, and are still
widely used today.  Sugar coating processes result in approximately doubling the
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weight of the original tablet core, therefore batch sizes have to be calculated based
on the finished tablet weight after coating.  However, the use of modern spraying
systems allows a dramatic reduction in the final product weight.  Moreover, the
airflow velocity and processing temperature are very critical in achieving a
pharmaceutically elegant finished product [Cole, 1995].
Raw materials used for sugar coating include coating formers, colorants,
flavors, lubricants or glidants or antiadherents, smoothing agents, polishing
agents, and suspension stabilizers.
Processing steps for sugar coating include Sealing (protective coating),
Subcoating, Smoothing, Coloring and Finishing, and Polishing.  In some
products, printing on the high-gloss surface is performed to provide unique
product identification.  Sugar coating layers are built up by repetition of the
processing steps of application, distribution, and drying.  There are three types of
sugar coating techniques used [Bauer et al., 1998]:
i). Plain sugar coating (application of syrup at room temperature)
ii). Two-component coating or lamination process (application of a syrup or
binder solution first in a slight excess amount, and then dusting with a powder
to bind the excess solution)
iii). Hot sugar coating (application of heated syrup)
B. Film Coating
Film coating is defined as a thin and uniform polymer based coat around
20 to 100 µm in thickness applied to the surface of substrates such as tablets,
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granules, powder, capsules, multiparticulates or pellets [Porter, 1995].  Compared
to sugar coating, film coating provides more flexibility to coat a variety of
substrates rather than just compressed tablets [Cole, 1995].
Advantages of Film coating are as follow [Cole, 1995; Porter, 1995]:
- Enhance the elegance and glossy appearance of the dosage form
-  Obtain legible logo and product identification after coating.  Product
information can be engraved on the tablet core
- Improve mechanical integrity and resistance of the dosage form upon
handling and shipping from manufacturing site to patients
- Modify the pharmaceutical function of the dosage form, especially for
enteric coating and modified release coating
-  Increase flexibility in type of formulations to be coated and type of
processing equipment
- Minimal weight increase (about 2-3% of tablet core weight) compared
to weight increase from sugar coating (doubling the weight of tablet
core)
-  Significantly reduced processing time, whereas increased process
efficiency and output
- Prevent dosage forms from dusting
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Typical film coating formulations
Typical film coating formulations usually consist of the following
components:
1. Polymers
Polymers are macromolecules with a high molecular weight range
between 10,000 and several million.  Polymers consist of the number of repeating
units in the structure.  Ideal properties for polymers used in film coating include
solubility in a wide range of solvent systems in order to allow more flexible
formulations, ability to produce films with excellent mechanical properties,
stability against light, oxygen, hydrolysis, low toxicity, and optimum dissolution
in the gastrointestinal tract [Porter, 1995].  Coating polymers can be categorized
into two types: (1) non-functional or conventional film coating polymers, which
can be used as a coating for improving the appearance, improving the handling,
and preventing of the dusting of dosage forms; and (2) functional coating
polymers, which can be used to modify the pharmaceutical function of the dosage
forms, especially for enteric coating and modified release coating.  Characteristics
of concern for polymers used during the coating process including solubility,
solution viscosity, film permeability, mechanical properties (i.e. tensile strength,
elastic modulus, work of failure, strain), and so on.  For the coating application,
the polymer is frequently dissolved in a suitable solvent such as water or a non-
aqueous organic solvent.  However, some water-insoluble polymers are
commercially available as an aqueous dispersion, which permit aqueous film
coating, and are particularly useful for modified release coating applications.
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Based on the method of preparation, polymer dispersions can be classified into
two types: true latexes and pseudolatexes.  Comparison of the two types of
polymer dispersion is shown in Table 1.2.
2. Plasticizers
Plasticizers are low molecular weight organic solvents with high boiling
points.  They are used to alter the physical properties of a polymer (i.e. hard or
brittle) and render it more flexible and softer to function as a film coating
material.  Generally, there are some similar chemical features (i.e. functional
groups) between a polymer and its plasticizer.  The amount of plasticizers used is
normally between 15-35% based on polymer weight.  Plasticizers also have a
significant influence on mechanical properties of the film.  Specifically, they can
reduce cohesive intermolecular forces along the polymer chains, enhance
flexibility by increasing strain or film elongation, and decrease tensile strength
and elastic modulus of the polymer.  Additionally, they influence the permeability
characteristics of the film, especially to water vapor, as well as lowering the glass
transition temperature (Tg) of the polymer to allow a more feasible coating
process.  Therefore, plasticizer efficiency can be measured by the degree of
lowering Tg of that particular type of plasticizer.  Plasticizers also possess solvent
power to insure compatibility with the polymer.  Plasticization time (i.e. mixing
time of plasticizer with polymer) and plasticizer level influence polymer films
[Bodmeier et al., 1997].
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Table 1.2 Comparison of True Latexes and Pseudolatexes [Cole, 1995]
Type True latex Pseudolatex
Description Very fine dispersion of polymer














- Free of monomer
residual and traces
of initiators
Examples Acrylate polymers (Eudragit®









There are three types of plasticizer commonly used in coating processes:
2.1) Polyols (water miscible): Glycerol (glycerin), Propylene glycol
(PG), Polyethylene glycol (PEG 200-6000 grades)
2.2) Organic esters:
-  Water insoluble: Diethyl phthalate (DEP), Dibutyl phthalate (DBP),
Dibutyl sebacate (DBS), Acetyltriethyl citrate (ATEC), Acetyltributyl citrate
(ATBC), Tributyl citrate (TBC)
-  Water miscible: Triethyl citrate (TEC), Triacetin (glyceryl triacetate;
TA)
2.3) Oils/glycerides (water insoluble): Castor oil, Distilled acetylated
monoglycerides (AMG), Fractionated coconut oil
3. Pigments or opacifiers
Pigments or opacifiers are used in film coating to:
- Enable product identification
- Protect the active ingredient against light by optimizing the opacfying
properties of pigments
- Modify the permeability of a film to gases
- Decrease the risk of counterfeiting the product
However, the use of pigments and opacifiers could be omitted from the
formulation if a clear coating was required.
4. Vehicles or solvents
Solvents and vehicles play an important role in carrying the coating
materials to the surface of the product core.  They include water, alcohols,
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ketones, esters, and chlorinated hydrocarbons.  The type of vehicles or solvents
used during the coating process can be used to classify the type of film coating
into (1) organic film coating (non-aqueous film coating), and (2) aqueous film
coating.  These types of coating will be discussed in later sections.  Necessarily,
the solvent has to intimately interact with the selected polymer in order to allow
both film adhesion and mechanical strength to be optimized.
5. Other components
Other components are occasionally used in minor levels in some specific
formulations as processing auxiliary substances or drug release modifiers.
Flavors may be included in some oral formulations to make them more palatable.
Adhesion enhancers (e.g. saccharides such as polydextrose, maltodextrin, and
lactose) are used to increase the adhesion of cellulosic systems to substrate as well
as improve stability towards light for unstable colors [Jordan et al., 1992].
Surfactants or dissolution enhancers (i.e. xanthan gum with Eudragit® NE30D
coated theophylline granules [Li et al., 1989]), as well as pore-forming agents
(e.g. sucrose or sodium chloride with ethylcellulose-coated salicylic acid tablets
[Lindholm and Juslin, 1982]), can be used to enhance the dissolution of the final
dosage forms.  Anti-tacking agents/glidants (e.g. talc, magnesium stearate, kaolin,
glyceryl monostearate) are typically used to reduce sticking during film
formation.  Additionally, some film coatings may contain an active ingredient,
preservative (i.e. sorbic acid), antifoaming agents (i.e. dimethylpolysiloxane),
stabilizing agents, and waxes.
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Types of film coating
There are two major types of film coating: Organic solvent film coating
system and Aqueous film coating system.
B.1) Organic solvent film coating system
An organic solvent film coating system offers the processing advantage of
low heat of vaporization characteristic of the organic solvents.  However, due to
environmental constraints, safety precautions and health-related concerns, the use
of organic-based coatings has decreased recently and the use of aqueous-based
coatings has increased.  Additionally, the introduction of newly developed coating
equipment and the development of new film coating raw materials, which can be
applied in aqueous media as solutions or dispersions, enable a more practical
operation of aqueous-based coating systems. Similarly, some forms of polymer
that were previously used for organic-based systems were developed by
manufacturers into different forms, which allow the formulators to choose a more
suitable form for aqueous-based coatings.
Disadvantages of the organic solvent system [Porter, 1995; Mehta et al.,
1986] include:
- Environmental, flammable and toxicity hazards;
-  Requires flameproof equipment to reduce hazardous working
environment for the operator;
- Residual solvent from coating process;
- Requires solvent recovery systems;
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- High cost process due to the required use of organic solvents and special
safety equipment.
B.2) Aqueous film coating system
Recently, the trend in coating has favored aqueous film coating due to the
high capital outlay in equipment and solvents, limitation placed on chlorinated
hydrocarbons use by regulatory authorities, environmental concerns for pollution,
and development of perforated coating pans and spraying systems, which allow
applications of more difficult coating materials.  There are two major
pharmaceutical applications of aqueous film coating: immediate release and
modified release applications.
B.2.1) Immediate released coatings
Pharmaceutical applications include:
- Mask the unpleasant taste and odor of drug
- Protect the active drug substance from exposure to light, moisture and
atmospheric oxygen
- Enhance the elegance and glossy appearance of the dosage form
- Improve mechanical integrity of the dosage forms upon handling from
manufacturing site to patients
- Prevent dosage forms from dusting
Polymers used for immediate release film coating include cellulose ether
polymers (Table 1.3) and acrylic polymers (methacrylic aminoester copolymer).
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Table 1.3 Cellulose Ethers Used for Immediate Release Coatings





- soluble in both aqueous and
organic solvents
- provides aqueously  clear
soluble films
- colored coating with addition
of pigment possible
- non-tacky nature   easy
processing
- safe to use as a thickener and
emulsifier in the food industry
- 4.0-20.0 %w/w methoxyl





















-soluble in water, insoluble in
organic solvents
- may include some additives
to ensure homogeneous
dispersion of powder in water









- soluble in both aqueous and
alcoholic solvents
- films tend to be tacky and
weak
- currently used in
combination with other
polymers to provide additional
adhesion to the substrate








B.2.2) Modified release film coatings
Modified release coatings can be classified into two different applications:
enteric release and sustained release coatings.  In this research study, only the
sustained release application is focused on.
- Enteric released coatings
This type of film coating provides a delayed release action of drug from a
coated dosage form in the acidic environment of the stomach, but readily releases
the drug once it passes into the more basic pH environment of the upper intestine
(i.e. duodenum).  Enteric release dosage forms avoid side effects (i.e. nausea,
vomiting) caused by the gastric irritation of some active drugs to the gastric
mucosa, as well as prevent the destruction of some drugs by gastric enzymes and
the acidic environment of the gastric fluid.  The USP has specified this type of
dosage form as a “delay-released dosage form”.  For the mechanism of enteric
coating polymers, the polymer remains intact at a low pH, but will undergo
dissolution to allow release of active from the dosage form at a higher pH.
Polymers used for enteric released film coating include cellulose acetate
phthalate (CAP), polyvinyl acetate phthalate (PVAP), shellac, methacrylic acid
copolymers, cellulose acetate trimellitate (CAT), hydroxypropyl methylcellulose
phthalate (HPMCP).
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- Sustained released coatings
Polymers used for sustained release film coating include:
•  Cellulose ethers  (Ethylcellulose, Methylcellulose)
- Ethylcellulose (EC)
The role of EC in pharmaceutical coating will be described in detail in the
following section.
- Methylcellulose (MC) [Schwartz, 1976]
MC is soluble in water.  It is rarely used in film coating for immediate
released applications since there is no commercially available low viscosity grade
product.  USP specified a methoxyl content of 27.5-31.5 %w/w.  MC powder
(Methocel A) is available from The Dow Chemical Company.
•  Methacrylate ester copolymers
This group of polymers is neutral and insoluble over the entire
physiological pH range due to the lack of free carboxylic acid groups caused by
their complete esterification (i.e. pH independent polymer).  However, their
modified release application can be obtained based on their ability to swell and
their permeability to water and dissolved substances.  Some hydrophilic materials
(i.e. soluble cellulose ethers, PEG) are usually incorporated with this polymer to
achieve desirable release profiles.
Some commercially available products include poly(ethylacrylate,
methylmethacrylate) trimethylammonioethylmethacrylate chloride (1:2:0.2, USP
designated type A, Eudragit® RL, Röhm Pharma GmbH, readily permeable),
poly(ethylacrylate, methylmethacrylate) trimethylammonioethylmethacrylate
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chloride (1:2:0.1, USP designated type B, Eudragit® RS, Röhm Pharma GmbH,
poorly permeable), and poly(ethylacrylate, methylmethacrylate) (2:1, Eudragit®
NE, Röhm Pharma GmbH, expandable and permeable).
As can be seen, coatings play a multifunctional role in formulations
depending on the desired properties of the dosage form.  Recent advances in
coating equipment, coating processes, and coating materials have enabled
significant improvements in coating technology.  The type of coating process
chosen depends upon the type of coating that is to be applied, the durability of the
tablet core, stability of the dosage form, and the economics of the process.
However, recent trends in coating technology have favored aqueous film coating
because of its wide application, low environmental concerns, the efficiency of the
process, and the commercial availability of coating materials.  In the following
section, the aqueous film coating system will be described in specific details.
Aqueous Film Coating System
Recently, an aqueous polymeric latex or pseudolatex has been preferable
to use for sustained release or enteric release dosage forms in order to overcome
the undesirable toxicity, residual solvent problems, explosion hazards, and
environmental pollution of organic solvent systems [Mehta and Jones, 1985;
Mehta et al., 1986].
For an aqueous polymeric dispersion, film formation can occur when the
polymer in a wet state is present as a number of discrete particles.  Those particles
come close to each other with the facilitated capillary action of the film of water
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around the particles, which are generated as water evaporates.  Then, they contact,
deform, coalesce, and finally fuse together to form a discrete film.  At the same
time, the water must be removed [Porter, 1989].  Lechmann [Lechmann, 1992]
recommended that the coating temperature or bed temperature during the
application process should be about 10-20°C above the minimum film-forming
temperature (MFT) in order to ensure the optimum condition suitable for film
formation.  MFT is the minimum temperature above which continuous film
formation will occur under specific conditions.  Therefore, the MFT is an
important parameter to determine the appropriate bed temperature of the coating
process.  MFT can be lowered by increasing the level of added plasticizers
[Amighi and Moes, 1996], increasing the plasticization time [Lippold et al., 1990]
or increasing the amount of pore former in some cases [Gunder et al., 1995;
Frohoff-Hulsmann et al., 1999].  MFT is dependent upon the temperature at
which the polymer changes from a hard glassy amorphous state to a softer
rubbery state. This change in state is defined as the glass transition temperature
(Tg) of the polymer.  The coalescence process can be dramatically affected by the
Tg of the polymer.  If the Tg of the polymer is higher than the product bed
temperature generated during the coating process, then the free volume will be too
low [Wicks, 1986] and insufficient viscous flow will occur, which will then allow
complete coalescence of the latex particles.  At the Tg, the polymer chain
segments are increasingly moving, the free volume increases and therefore
increase the flexibility and penetrability of the films [Frohoff-Hulsmann et al.,
1999].  Moreover, the glass transition temperature of such a polymer can be
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lowered by the incorporation of a plasticizer into the polymer solution or
dispersion [Porter, 1989].
Film-coating Process
Fluidized-bed coating process became more popular during the past two
decades for the coating of tablets or pellets.  This was due to the major
improvements of the coating, when comparing to conventional pan coating or
perforated pan coating processes.  Fluidized-bed process can provide a greater
drying efficiency to avoid the formation of liquid bridges between two or more
pellets, and high surface evaporation to avoid solvent penetration into the core.
As a result, an improvement in the smoothness, continuity, and coalescence of the
polymer particles over the surface of the pellets can be obtained.  Bottom sprayed
fluidized-bed with a Wurster column inserted appears to be superior and most
widely used for coating of the pellets (Figure 1.4).  The coating solution is applied
from the bottom at the same time and in the same direction as the flow of the
pellets through the Wurster column.  Therefore, this pattern followed by the
pellets is more regular than the top-spray method, resulting in further
improvements in the physical characteristics and quality of the coating applied.
This process also provides ideal conditions for the completeness coalescence of
the polymer particles, with decreased water penetration into the core of the pellet.
The droplets of the coating solution produced from this method should have a low
viscosity, so when they come into contact with the substrate, they will uniformly
distribute and form a continuous film.  In addition, the evaporation rate of the
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solvent droplets from the surface of the core should be readily fast to prevent
liquid bridging between pellets [Mehta and Jones, 1985].
To achieve the coating purposes as previously described, the film coating
of the dosage forms should be uniform, reproducible, and no physical
imperfections.  Therefore, the coating process as well as processing parameters
used are very critical and should be readily optimized [Mehta and Jones, 1985].
Drug release from pellets is controlled as diffusion through a membrane, which is
obtained from film coating process [Goodhart et al., 1984].
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Figure 1.4: A bottom-spray fluidized-bed coating processing with a Wurster
inserted column [Jones, 1985]
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Film-coating Parameters
Drug release from polymeric film coated dosage forms is strongly
influenced by variables influencing the coalescence of the polymer particles and
hence the film formation process [Harris and Ghebre-Sellassie, 1997].  Process
variables such as coating temperature [Yang and Ghebre-Sellassie, 1990], curing
conditions after the coating process [Goodhart et al., 1984; Ghebre-Sellassie et al.,
1988], type and level of plasticizer [Wheatley and Steuernagel, 1997],
plasticization time [Lippold et al., 1989], type of additives or fillers, nature of the
substrate [Porter, 1989], pH, and effect of surfactant levels [Bodmeier and
Paeratakul, 1991a], must be optimized in order to obtain stable and reproducible
drug release profiles throughout the product’s shelf life.
Cellulose ethers are a major group of polymers used in the film coating
process.  Among cellulose ethers (i.e. cellulose acetate, cellulose acetate butyrate,
cellulose acetate propionate, cellulose acetate phthalate, and ethyl cellulose) that
have been extensively used in a variety of film coating applications, ethylcellulose
is the most widely used [Salib et al., 1976; Porter, 1989; Wheatley and
Steuernagel, 1997].  In this study, role of cellulose ethers and processing
parameters in an aqueous film coating technology were investigated.
Ethylcellulose (EC)
Ethylcellulose (EC) is a nonionic cellulose ether derived from the
polymeric backbone of cellulose.  The molecule has a structure of repeating
anhydroglucose units with three reactive hydroxyl sites.  EC is insoluble in water,
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but miscible with various water-soluble materials.  Therefore, it has been
extensively used in combination with other water-soluble polymers, especially
HPMC or polyethylene glycols (PEG), in order to provide more hydrophilic
nature to the EC film and promote drug diffusion through the pores or channels.
Glass transition temperature (Tg) of pure EC ranging from 128 to135˚C was
reported in the literature [Entwistle and Rowe, 1979; Porter, 1989; Lippold et al.,
1990].  EC provides additional gloss and shine to the tablet surface, as well as
optimizes film toughness to minimize surface imperfections caused by handling.
EC is preferred for modified release coatings because it is odorless, tasteless, and
has a high degree of stability under normal storage conditions, including light and
heat.  The USP specifies an ethoxy content between 44.0-51.0 %w/w.  The water
dispersible form of EC provides significant advantages and makes processing of
water insoluble polymers from an aqueous-based system possible.  The high solid
content and the low viscosity of the aqueous polymeric dispersions make their use
much easier in their applications.  In addition, the high surface area of the
particles significantly reduces the drying time during coating by evaporation of
water inducing the contact and readily coalescence of the particles' boundaries
[Kumar and Banker, 1993; Porter, 1989].
Some commercially available products include:
-  Powder (Aqualon®, Aqualon Division, Hercules Inc.)
It is available in a wide range of viscosity and substitution types for a wide
range of applications.
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- Aqueous dispersion (Aquacoat® ECD (30 %w/w solid content), FMC
Corporation; Surelease®, Colorcon, Inc.)
In this research study, Aquacoat® ECD will be used for controlled release
coating.  Aquacoat® ECD dispersion contains 29-32 %w/w of ethylcellulose
(polymer, N type, 10 cPs), 1.7-3.3 %w/w of cetyl alcohol (stabilizer), and 0.9-1.7
%w/w of sodium lauryl sulfate (stabilizer/emulsifier).  Since the Tg of the EC is
about 135˚C, then a plasticizer is required to assure that the complete coalescence
of the latex particles will occur under the suitable conditions [Porter, 1989].
Aquacoat® ECD formulation is shown below [FMC Corporation, 1996].
Rx Suspension (g) %
Aquacoat® ECD 425.0 80.6
DBS 31.6 19.4
Water 88.0   -
Total 544.6 100.0
The performance of EC coatings obtained from aqueous dispersions may
vary due to the differences in molecular weight of EC used, manufacturing
method, type of additives, and method to incorporate plasticizers [Porter, 1989].
Drug Type
The nature of the drug used as a substrate for film coating was reported as
having an impact on the final product performance.  Solubility of drug as well as
effect of pH on drug solubility can affect the release of the drug from the film
coated dosage forms.  At the same coating level, water-soluble drugs tend to be
released from the EC coated beads (non-pareils) at a faster rate than water
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insoluble drugs.  Additionally, the high molecular weight of the drug may make it
more difficult to diffuse through the membrane [Porter, 1989].
Several techniques have been developed for beads manufacturing.  These
include extrusion/spheronization(marumerization), loading drug onto sugar beads
(nonpareil or Nu-pareil®) from a solution or suspension using fluid bed or pan
coating systems, and loading drug by powder layering using a pan or a
rotogranulator.  Among these techniques, extrusion/spheronization, which the wet
mass of materials is extruded using a suitable extruder and followed by rounding
on a rapidly rotating, roughed plate of the spheronizer, is the most extensively
used for a wide range of drug loading from 0-75%.  This technique may be the
only practical way of achieving pellets with a very high drug loading [Gamlen,
1985; Ku, 1993].  Beads prepared by this method offer several advantages of a
low surface-to-volume ratio, ease of flow, uniform packing, and suitability of
shape for film coating process [Chien, 1985; Rowe, 1985].  Most previous studies
in aqueous polymeric coating were conducted using core beads prepared by
loading the drug onto sugar beads (nonpareil) from a solution or suspension.  The
active drug was distributed only on the surface of the cores.  In this research
study, the extrusion/spheronization technique, which offers more advantages than
other techniques, is used to prepare core beads.  The active drug prepared by this
technique is distributed throughout the matrix beads.
In this coating study, chlorpheniramine maleate (CPM) and theophylline
anhydrous were chosen as the model water-soluble drug and slightly water-
soluble drug, respectively.  The structure of each drug substance is shown in
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Figure 1.5.  Both drugs have been extensively used in several research studies and
they are well characterized in the literatures.  Therefore, in the present study,
preformulation studies on physicochemical properties of both drugs will not be
investigated.
Chlorpheniramine maleate (CPM) is a short-acting antihistamine with
weak sedative properties and a high therapeutic index commonly used in the
treatment of allergies.  The mechanism of action is competitively blocking H1-
receptor sites, thereby preventing the histamine from causing increased capillary
permeability and the formation of tissue edema [Pearlman, 1979].  The onset of
action is 15-30 minutes, effects are maximal within 1-2 hours, and the duration of
action is 4-6 hours [Douglas, 1980].  Drug is slowly absorbed and its absorption is
sensitive to local gastrointestinal conditions, such as water volume, presence of
food, the effect of multiple dosing, and the formulation employed.  The volume of
distribution is between 2.5-5.9 L/kg after IV dosing, and 7.00-7.65 L/kg after oral
dosing.  Serum half-life of drug is about 20 hours in normal adults [Rumore,
1984].
CPM occurs as an odorless, colorless to white, and crystalline solid
[Budavari et al., 1996; Eckhart and McCorkle, 1978].  The maleate salt of
chlorpheniramine is very soluble in mg/ml level at 25°C in water (25%), ethanol,
chloroform, and methanol, but it is slightly soluble in benzene, and ether.  Melting
point is in the range of 130-135 ˚C [Budavari et al., 1996; MDL Information
Systems, 1987].
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CPM is stable at normal temperatures and pressure.  However, contacting
with heat, flames, sparks, other sources of ignition, and with incompatible
materials (i.e. oxidizing materials) should be avoided [MDL Information Systems,
1987].  Stability of CPM has been studied using accelerated heat and light
conditions on solutions of various pH values.  Percent recovery of CPM was in
the range of 95-100% in various pH samples stored at 95°C for 1 week, and in
samples exposed to light for 3 months [Eckhart and McCorkle, 1978].  In another
stability study, CPM tablets were stored in a counting machine, which its intended
use was to save time in an outpatient dispensing operation in a hospital, at
ambient condition (i.e. 23±1 ˚C, 50±10% relative humidity) for 8-12 weeks.  No
difference in the chemical stability assay results, physical appearance,
disintegration times, or dissolution characteristics of the controls and the samples
was reported [Das Gupta and Gupta, 1979].
Theophylline is a xanthine derivative with a variety of therapeutic
activities including diuretic, cardiac stimulant and smooth muscle relaxant.  It is
commonly used as a bronchodilator in the treatment of asthma, emphysema,
bronchitis and other lung disorders [Edelson et al., 1998; Budavari et al., 1996].
During asthma attack, theophylline helps relax the smooth muscles in the
bronchial passages of the lungs, widening the constricted airways and restoring
normal breathing [Edelson et al., 1998].  Drug is generally well absorbed after
oral administration, however, the variation does occur depending upon dosage
form, formulation, and salt form being administered.  Peak plasma levels of
theophylline tablets are varied from 2-4 hours, whereas peak plasma levels of
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sustained release tablets are at 6 hours with a duration of action of 10-12 hours,
dependent on the formulation.  Drug is widely and rapidly distributed into all
tissues with high rates of blood flow and has a volume distribution of 0.3 L/kg.
Serum half-life of drug is varied from patient-to-patient ranging from 2.5-9.5
hours [Cohen, 1975].
Theophylline occurs as a white, odorless, crystalline powder with a bitter
taste [Budavari et al., 1996; MDL Information Systems, 1998; Cohen, 1975].  It
exists in both anhydrous and monohydrate forms.  The monohydrate salt of
theophylline is slightly soluble in water (8.3 mg/ml or 1 g in 120 ml water) and
chloroform (11.6 mg/ml or 1 g in 110 ml chloroform), sparingly soluble in
ethanol (12.5 mg/ml or 1 g in 80 ml ethanol) and ether, and soluble in hot water,
alkali hydroxides, ammonia, dilute hydrochloric acid or nitric acid.  Theophylline
is a weak acidic compound with the proton on the nitrogen in position 7 being
dissociable and high pKa of 8.6 in an aqueous solution.  Additionally,
theophylline is a very weak basic with pKb of 11.5-13.5.  Several basic salts, such
as sodium and potassium salts, have been prepared to enhance the water solubility
of theophylline [Cohen, 1975].  Melting point is in the range of 270-274˚C
[Budavari et al., 1996; MDL Information Systems, 1998].
Theophylline is stable at normal temperatures and pressure.  However,
contacting with heat, flames, sparks, other sources of ignition, and with
incompatible materials (i.e. oxidizing materials) should be avoided [MDL
Information Systems, 1998].  Theophylline solutions are quite stable over the
entire pH range.  However, instability of theophylline in strongly alkaline
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solutions (pH > 12) has been reported.  The decomposition and apparent ring
opening were found after storage for several weeks.  Theophylline solutions are
susceptible to oxidation at position 8.  Due to its low solubility and relative high
pKa, it tends to precipitate from aqueous solutions if the pH drops below 9 unless
present in concentrations less than the water solubility.  Additionally, all acidic
salts are potentially incompatible with theophylline in solution.  Theophylline has
shown to form stable complexes with saccharin, phenobarbital, papaverine,
caffeine, sulfosalicylic acid, benzyl alcohol, and α-, and β-napthalene acetate
[Cohen, 1975].
53
Chlorpheniramine Maleate (C16H19ClN2• C4H4O4, MW 390.86)
Theophylline (C7H8N4O2, MW 180.17)
















Subcoating or Seal Coat
The purpose of applying the seal coat to the substrate prior to application
of controlled release coating is to retard the release of the drug, especially with
highly water soluble drugs, and the rate-controlling membrane is derived from an
aqueous latex coating system.  Seal coats can be used to reduce the brittleness of
the drug layer and thus reducing abrasion in early stages of coating application,
seal off surface irregularities of substrate, prevent the prematrure dissolution of
drug by water in the coating dispersion, and reduce porosity of the substrate that
may affect film formation process [Porter, 1989].  To eliminate the drug migration
into the polymer film during curing or storage, an intermediate seal coat may be
used to separate the drug core from the polymer coating.  A thin layer of HPMC,
of which drug is not soluble, was applied to ibruprofen core beads prior to
Aquacoat® application to eliminate the diffusion of the drug to the bead surface
through the EC coating [Bodmeier and Paeratakul, 1994].
Plasticization
For aqueous EC coating, added plasticizers are necessary to reduce the
glass transition temperature of EC polymer, improve the mechanical properties
and enable the formation of tough, flexible films without cracks.  Generally,
aqueous EC dispersion requires the addition of 20-30 %w/w plasticizer based on
EC polymer weight.  The type and amount of plasticizer used during film coating
to increase the flexibility of the coatings and facilitate coalescence of the coatings
produced from aqueous latex systems is very critical.  The appropriate plasticizer
and amount used can help improve the barrier properties to drug release of the EC
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film, resulting in a reduction in drug release rate [Porter, 1989; Saettone et al.,
1995].  When increasing the amount of plasticizer in the coating, the drug release
rate tended to be decreased due to the plasticizer, which altered the water
permeability of the coating.  This evidence was observed in the case of
theophylline beads coated with EC dispersion plasticized with AMG (Myvacet®9-
40) or DEP or DBS [Saettone et al, 1995].  However, this trend was not always
true in some other studies [Chang et al., 1989; Ho and Suryakusuma, 1988].
Goodhart showed that 24-40 %w/w (based on film former) of plasticizer,
TEC or DBS, with at least 30 minutes plasticization time, was necessary to soften
the latex particles, promote film coalescence, and finally, retard the release of
phenylpropanolamine HCl from the EC-Eudragit E-30D (6:4 ratio) coated beads
[Goodhart et al., 1984].
Generally, when a high amount of plasticizer (higher than 30 %w/w) is
used in any aqueous coating formulations, especially acrylic polymers, tackiness
or sticking of films is likely to occur and antitacking agents, such as talc or glycerl
monostearate (GMS), are recommended.  Tackiness increases with increasing
plasticizer concentration, especially at the higher curing temperatures, due to the
softening of the polymer.  In the case of Aquacoat®, films are easy to separate
from each other and it has the lowest tackiness [Wesseling et al., 1999a].
Therefore, antitacking agents may not be necessary for an Aquacoat® coating
system.
From an evaluation of the physical properties of a plasticized film cast
from ethanol solution, at least 20 %w/w DBS and 20 %w/w AMG were found to
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be the most efficient plasticizers for EC in terms of mechanical property (i.e. low
elastic modulus, high elasticity) and thermal property (i.e. low Tg values)
[Hyppola et al., 1996].
Plasticization time is the time elapsed between the addition of plasticizer
to the latex and coating process.  This is due to the distribution of plasticizers
between aqueous and polymer phases, which is time dependent.  Plasticization
time was found to have an influence on the properties of polymer films [Lippold
et al., 1989; Bodmeier et al., 1997].  The water insoluble plasticizers (i.e. DBS
and DBP) required a longer time to reach the maximum concentration in the EC
dispersion than the water-soluble plasticizers (i.e. DEP, TEC).  The distribution
between polymer and aqueous phases readily occurred when the more water-
soluble plasticizers are mixed with the aqueous dispersion.  Aqueous solubilities
at 20˚C of 10% DBS and 10% TEC are 0.01% and 6.90%, respectively.
Additionally, aqueous solubility of the plasticizers also affects the concentration
gradient between aqueous and polymer phases [Frohoff-Hulsmann et al., 1999a].
Curing Condition
During coating of solid dosage forms with an aqueous dispersion,
especially Aquacoat® dispersion, coalescence of the colloidal polymer particles
into a homogeneous film is often incomplete.  This is due to the bed temperature
used (about 40˚C or 10-20˚C above MFT), which is not sufficient enough to
complete film coalescence.  Therefore, it is recommended to cure the coated
products after the coating process in order to overcome this problem.  Curing or
further gradual coalescence is a thermal treatment or expose the coated products
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to elevated temperatures above the glass transition temperature of the polymeric
material to accelerate the film formation process and to avoid aging problems of
the coated products [Ghebre-Sellassie et al., 1988; Lippold et al., 1989; Gilligan
and Li Wan Po, 1991; Bodmeier and Paeratakul, 1991a; Wesseling and Bodmeier,
1999b].  However, the curing step was shown to have no influence on the drug
release from beads coated with another EC dispersion, Surelease®, or an organic
EC solution.  This may be due to the differences in coating composition and
preparation between Aquacoat® ECD and Surelease® and the differences in film
formation mechanism [Shah et al., 1994; Wesseling and Bodmeier, 1999b].
Typically, the curing step results in a reduction of drug release when
compared to drug release from uncured dosage forms [Lippold et al., 1989;
Gilligan and Li Wan Po, 1991; Bodmeier and Paeratakul, 1991a; Schmidt and
Niemann, 1993; Hutchings et al., 1994a; Bodmeier and Paeratakul, 1994; Guma
et al., 1997; Amighi and Moes, 1997; Sakr et al., 1998; Frohoff-Hulsmann et al.,
1999a].  Goodhart et al. observed a faster drug release rate from coated pellets
cured at 45˚C for 48 hours, whereas a slower drug release was observed from
pellets cured for an additional 96 hours at 65˚C.  Explanation of this effect was
that when the drying temperature was decreased, the hardness of the polymer
particles was increased resulting in resistance to deformation of the film and
incomplete film formation.  At a higher temperature of 65˚C, a more
homogeneous film with lower diffusivity was produced.  Also, additional drying
at a higher temperature promoted further gradual coalescence and further
decreased in the drug release rate [Goodhart et al., 1984].  Gilligan and Li Wan Po
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showed that the curing at 60˚C for at least 1 hour after coating was necessary to
ensure that the EC-TEC coated Nu-pareil® beads of dextrometrophan
hydrobromide containing HPMC produced consistency of release rates with no
aging effects.  It was necessary to coat the pellets at a temperature sufficient to
promote further gradual coalescence and to include a post spray drying period into
the coating procedure [Gilligan and Li Wan Po, 1991].  Bodmeier and Paeratakul
observed that a limiting drug release pattern was approached from CPM-loaded
nonpareil beads coated with EC pseudolatexes after curing the beads for 1 hour at
60˚C [Bodmeier and Paeratakul, 1991a].
In contrast, some studies found that some curing conditions may result in
an increase of drug release when compared to drug release from uncured dosage
forms.  Sakr et al. reported that the release of theophylline from the granules
coated with EC dispersion (Aquacoat®) plasticized with 30% DBS was influenced
by oven-curing temperatures and times and the length of storage.  The immediate
drug release profile was obtained from the coated granules without exposure to
any curing conditions after coating.  At 70˚C curing temperature, the curing times
of 70 and 260 minutes had no significant effects in drug release pattern.  No
significant differences in amount of drug release from coated granules cured at
room temperature for 1 year and from coated granules cured at 45˚C for 5 minute
were found.  However, the theophylline release was slightly increased when the
granules were cured at 45˚C for longer times of 10, 35, and 70 minutes or cured at
a higher temperature of 70˚C for 10 minute [Sakr et al., 1998].  In another case of
ibruprofen, a drug with a high affinity with the EC coating, an increase in drug
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release was observed after the curing step due to diffusion of the drug into the
coating.  Therefore, an intermediate seal coat, HPMC, was used to reduce the
diffusion of the drug into the EC coating [Bodmeier and Paeratakul, 1994].
Hutchings et al. found that when 30% DBS was employed as a plasticizer in the
coating, propranolol hydrochloride release was faster when coated beads were
exposed to higher curing time and temperatures.  This result may be due to the
migration of the DBS to the surface of the barrier coating or the higher solubility
of drug DBS at the rigorous conditions, or the sticking and picking of the coating
layer from adjacent beads at a high temperature.  Whereas when 25% TBC was
employed as a plasticizer in the coating, propranolol hydrochloride release was
slower when coated beads were exposed to higher curing time and temperatures.
This may be correlated with findings for the free films of Aquacoat® prepared
with TBC, which showed greater elongation after exposure to higher curing
temperatures [Hutchings, 1994a; Hutchings, 1994b].
Frohoff-Hulsmann et al. showed that when the amount of plasticizer
increased from 9% to 20%, the curing temperature, which was necessary to reach
a constant and low release rate, decreased.  The temperatures used to cure the
coated beads for 1 hour in the study were 70, 80, 90, and 100˚C.  The amount and
type of plasticizer used in the formulation can influence the film formation, and
adequate curing time and temperature.  The content of HPMC as a pore former in
the coating had no effects on the optimum curing conditions [Frohoff-Hulsmann
et al., 1999a].  Curing time required to obtain complete coalescence was less
pronounced when plasticizer level in the film was increased.  This was due to the
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fact that the high amount of plasticizer drastically reduced the thermal properties
of the polymer, such as the Tg and the MFT, and permitted the complete
coalescence of latex particles during coating process [Bodmeier and Paeratakul,
1994; Amighi and Moes, 1996].  For instance, no curing step was necessary to
obtain good film formation for CPM, a drug with low affinity for EC coating,
coated beads when more than 25% TEC was added to EC dispersions.  However,
a curing step was required to stabilize the film when intermediate plasticizer
levels between 15-25% were used [Bodmeier and Paeratakul, 1994].
The curing rates of coated beads are higher with higher storage
temperature.  Also, curing temperature has a more dramatic effect than curing
time.  This is due to the enhancement of the polymer chain mobility and the free
volume values at high temperatures, which accelerate the coalescence of the latex
particles [Wicks, 1986; Bodmeier and Paeratakul, 1991a; Hutchings et al., 1994a;
Amighi and Moes, 1996].  However, attention must be paid to undesirable
alterations of film and/or core properties, which are likely to occur when extreme
storage conditions are adopted [Amighi and Moes, 1997].  Porter suggested that
curing might not always be necessary since curing conditions (from 1-144 hours
at 60˚C) had no significant influence on chlorpheniramine maleate release from
beads coated with 10% of EC aqueous dispersion (Surelease®) [Porter, 1989].  In
order to avoid unpredictable release profiles, it was not recommended to store the
coated products at a temperature higher than 40˚C since it may cause a softening,
hardening or leaking of the plasticizer of the coatings, or a stability problem of the
active drug [Ghebre-Sellassie  et al., 1987].
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The conflicting information suggests that a further investigation of the
influence of curing conditions on drug release is needed to obtain a better
understanding.  Additionally, optimum curing conditions for EC film have not
been well characterized in the literature.
Water Soluble Additives
In some coated dosage forms including tablets and pellets, the release rate
of the active drug from the dosage form is considered to be extremely slow.  This
incident was also seen for the release rate of pellets coated with Aquacoat® ECD
containing only a plasticizer [Lippold et al., 1989; Gunder et al., 1995; Harris and
Ghebre-Sellassie, 1997].  Therefore, it is very important to increase the release
rate of the drug substances in order to ensure that they are sufficiently fast
absorbed during passage through the gastrointestinal tract.  The most effective
method of enhancing the release rate of the active drug is to incorporate some
pore forming agents in the release-controlling membranes [Kallstrand and Ekman,
1983; Ghebre-Sellassie et al., 1987; Bodmeier and Paeratakul, 1990; Bodmeier
and Paeratakul, 1991b; Gunder et al., 1995].  Pore forming agents are water-
soluble additives that are incorporated into a sustained release coating formulation
to increase the release rate of the drug.  Water-soluble cellulose ethers, such as
MC and HPMC, have been widely used as pore forming agents.  The use of MC
as an additive in combination with EC for preparation of rapidly disintegrating
tablets of the organic film coated aspirin crystals was reported in the literature.
The release rate of aspirin crystals was dependent on the ratio of both cellulose
ethers.  Specifically, the release rate was increased when the amount of MC was
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increased in the ratio due to higher solubility rate of MC [Coletta and Rubin,
1964].  The combination of HPMC and EC was also used as a model for the study
of time-release cast films in an organic solvent system.  A variety of release
patterns was obtained by changing the proportions of EC and HPMC in the cast
film.  Solute, yellow dye, transport occurred through channels formed by the
dispersed HPMC within the film.  The formation of two types of channels or
pores to permit transport of solute was governed by two factors.  First factor was
the hydration and dissolution of the HPMC, resulting in leaving pores in the film.
The second factor was the hydrated HPMC, which retained in the film as a
barrier, required the diffusion of the solute through the gel layer, resulting in
reduction of the transport rate.  However, the observed transport rate of solute was
a function of the balance of the film thickness and HPMC concentration [Shah
and Sheth, 1972].  Similarly, release rates of different drug types were enhanced
by the addition of a hydrophilic polymer (HPC (75-100 cPs) or PEG 4000) to the
EC casted film in the organic system.  Enhancement coefficients of each system
(i.e. EC-PEG or EC-HPC) were different due to the different mechanisms of
hydrophilic polymer action [Donbrow and Samuelov, 1980].  In another EC-PEG
organic coating system, the release of the active terbutaline sulfate increased as
the amount of HPC in the coating solution increased.  It was suggested that the
formation of pores were increased in the coating layer as the amount of HPC
increased [Umprayn et al., 1999].  Lindstedt et al. showed that the permeability of
EC film was increased by incorporating HPMC (0-24%) in the film composition.
Drug, potassium chloride (KCl), release from tablets coated with mixtures of EC
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and up to 24% HPMC was controlled by osmotic pumping and drug diffusion
mechanisms.  At low HPMC content, a minor amount of HPMC was leached and
no pores were formed.  In contrast, at high HPMC content (24%), the formation
of pores was caused by the leaching of the water-soluble HPMC [Lindstedt et al.,
1989; Lindstedt et al., 1991].  However, another study reported that HPMC may
have a limited degree of miscibility with EC; it may be incompatible at some level
[Sakellariou et al., 1987].  Porter reported the effect of incorporation of the water-
soluble MC polymer (15 cPs) into EC dispersion (Surelease®) on release of
chlorpheniramine maleate from EC coated beads at 10% coating level.  The
amount of MC investigated was from 0-10 %w/w in dry film.  For the control (no
MC was added), extent of CPM released was longer than 12 hours.  When more
than 6 %w/w of MC was incorporated, CPM was released at a faster rate and
shorter extent of less than 6 hours [Porter, 1989].  The effect of an addition of 0-
12 %w/w HPMC on the release of dextromethorphan hydrobromide from aqueous
EC coated non-pareil pellets was investigated.  Numerous pores were present in
the polymer film coating after dissolution.  Post-coating condition was shown to
be an important factor to ensure consistency of release rates from pellets
containing 0-12 %w/w of HPMC [Gilligan and Li Wan Po, 1991].  Gunder et al.
showed the effect of levels of the low-viscosity HPMC (Pharmacoat® 603,
viscosity 3 cPs at 20˚C) incorporated into aqueous EC dispersion (Aquacoat®
ECD) on the release of different drug type from coated pellets.  During the first 2
hours of the release process, diffusion pellets contained water-filled pores in the
release-controlling membrane after extraction of the HPMC.  At the high levels of
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HPMC (25-40%) used in the formulations, these pores closed irreversibly due to
pore fusion if the release in an acidic medium occurred above the MFT.  As a
result, the release rate of drug was as slow as if it was from the control
formulation (without HPMC).  In contrast, in alkaline medium, the pore fusion
did not occur due to ionized carboxylic groups of EC in alkaline environment
[Gunder et al., 1995].  Recently, the release mechanisms of theophylline pellets
coated with an aqueous EC dispersion (Aquacoat® ECD) containing different
plasticizers and a pore former, HPMC (Pharmacoat® 603, viscosity 3 cPs at 20˚C),
have been described.  Release mechanism of theophylline from coated pellets was
dependent on the aqueous solubility of the plasticizers as well as the ionic
strength of the release medium.  Additionally, the release mechanisms depended
on the glass transition temperature of the EC and on the migration of the
plasticizers and the pore former [Frohoff-Hulsmann et al., 1999a].  The properties
of sprayed films prepared from the same combination of the coating were also
investigated in order to obtain a better understanding of the drug release
mechanisms of the coated pellets [Frohoff-Hulsmann et al., 1999b].  In addition to
water-soluble polymers, some low molecular weight additives such as sucrose and
surfactants (i.e. polysorbate 20) were also incorporated into EC organic-solvent
based solutions.  The macroporous membrane was created and release rate of
drugs were increased [Lindholm et al., 1982; Lindholm, 1986a; Lindholm et al.,
1986b].  In a slab model system, prepared by spraying an ethanolic solution of EC
and acetaminophen on to flat tablet surfaces in a spray box, the addition of xylitol
(25-75% by weight of EC), as a pore former, enhanced the release rate of
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acetaminophen [van Bommel et al., 1989].  For the aqueous coating system,
microporous osmotic pumps have been utilized in tablet coating applications.
Bodmeier and Paeratakul showed that theophylline or KCl release from tablets
coated with an aqueous acrylic latex (poly(ethylacrylate methylmethancrylate))
containing a dispersed pore former (60-80 %w/w) with pH-dependent solubility
characteristics, dibasic calcium phosphate, was a function of pore former level
and the membrane thickness, but was independent of the pH of the dissolution
medium and the degree of agitation.  Drug release increased with increasing the
pore former level and drug was released via diffusion through pores created after
dissolution of the calcium salt [Bodmeier and Paeratakul, 1990; Bodmeier and
Paeratakul, 1991b].  Additionally, urea was also used as a pore former in different
studies because of its small, readily water soluble, and uncharged molecule.  The
addition of urea (30-85 %w/w of Aquacoat ECD solids) to plasticized EC latex
(Aquacoat ECD) resulted in the formation of the microporous latex coatings,
when urea was eluted from the EC coatings.  Therefore, the release of KCl or
diltiazem HCl from coated osmotic tablets was enhanced.  However, plasticizer
type and level, and coating thickness also had some impacts on the release pattern
of drugs from osmotic devices [Appel and Zentner, 1991].
In another matrix system, d-mannitol or bovine serum albumin (BSA) was
also used as a pore former in biomaterials, polyurethane matrices (BioSpan®),
containing hirudin.  When the weight fraction of mannitol increased from 20-
40%, the release rate and the total amount of hirudin released from the matrix
were enhanced.  More hirudin was released when d-mannitol was used as a pore
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former than BSA.  Moreover, large particle size of both pore formers enhanced
the release rate and the total amount of hirudin release [Kim et al., 1998].
As can be seen from the above literature review, the use of a variety of
hydrophilic additives to modify the release of a slightly water-soluble drug from




In general, the overall objectives of this research were to investigate the
use of cellulose ether polymers to formulate different pharmaceutical oral dosage
forms, and to control the release of active ingredient from the specific oral
delivery system over an extended period of time.  Specifically, this research
included the use of cellulose ethers to control the release of active drug from the
following systems: 1). Single matrix tablet and 2). Multiparticulate dosage form.
Formulations and processing parameters were optimized in order to achieve the
desirable amount of drug release from each delivery system investigated.  The
study was divided into two major sections; the detailed research objectives of
each system were as follows:
1.3.1 Single Unit System (Matrix Tablets)
Primary objectives
The primary objectives of this research system were to evaluate the
different processing parameters and develop two stable, oral controlled release
formulations of matrix tablets containing different molecular weight types
(nominal viscosities) of HPMC, but both formulations had the same in vitro drug
release.  These two formulations, which were equivalent in vitro, were tested for
bioequivalence during in vivo clinical study.
This research study was divided into four major parts to support the
primary goal of this research.
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1.3.1.1 Preformulation Studies for Alprazolam
Supporting objectives:
•  To investigate the physiochemical properties of alprazolam, which is intended
to be used as a model drug substance in the matrix tablet formulations.  These
properties included drug solubility, thermal property, particle size and particle
size distribution, surface morphology, and crystallinity,
•  To develop analytical methods, including ultraviolet spectroscopy and
chromatographic analysis, for alprazolam quantitation.
1.3.1.2 Drug Recovery from Hydrophilic Matrix Tablets
Supporting objectives:
•  To develop an analytical method for the recovery of the lipophilic drug from
controlled release matrix tablets containing HPMC.
•  To investigate the influence of formulation composition, such as HPMC
molecular weight type and excipient type, on drug recovery.
1.3.1.3 Investigation of Formulation Parameters on Drug Release
a). Screening Study and Formulation Development
Supporting objectives:
•  To perform a screening study to determine optimum parameters, such as tablet
size, amount of drug loading, polymer levels, in order to obtain sustained
release profiles.
•  To develop a blending method for tablet manufacturing in order to obtain
uniform distribution of low dose drug within a single dosage unit.
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•  To investigate the influence of excipient type and level on the release of the
alprazolam formulated in controlled release tablets containing HPMC.
•  To determine the influence of excipient type on the release mechanism of
alprazolam from matrix tablets.
•  To investigate formulations containing varying molecular weight types
(nominal viscosity types) of HPMC polymer (i.e. HPMC K4MP and HPMC
K100LVP), based on screening study.
•  To investigate the influence of dissolution media on alprazolam release from
matrix tablets.
b). Formulation and Characterization
Supporting objectives:
•  To determine if oral controlled release tablet formulations containing varying
molecular weight types (nominal viscosity) of HPMC polymer have an
equivalent in vitro performance, when formulated with a lipophilic drug
(alprazolam).
•  To obtain a better understanding of the importance of influence of molecular
weight type (nominal viscosity) of HPMC on in vitro product performance.
•  To physically characterize the tablet formulations developed in terms of
weight and hardness distributions, content uniformity and in vitro drug
release.
•  To statistically compare the dissolution profiles of the formulations developed
using the similarity factor (f2 factor).
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•  To investigate the stability of alprazolam in the tablet formulations developed,
based on the dissolution profiles and similarity factor.
1.3.1.4 In Vivo Clinical Study
Supporting objectives:
•  To investigate if two similar controlled release formulations of a lipophilic
drug (alprazolam) having the same in vitro drug release, but containing
different molecular weight types (nominal viscosities), are bioequivalent.
•  To compare the pharmacokinetics and pharmacodynamics of alprazolam from
two oral controlled release tablet formulations containing different molecular
weight types (nominal viscosities) of HPMC polymer.
•  To examine the effect of food on in vivo drug release from these HPMC
matrix tablets.
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1.3.2 Multiparticulate System (Film-Coated Beads)
Influence of processing parameters on drug release from cellulose ether coated
matrix bead formulations.
Primary objective
The primary objective of this research was to investigate the influence of
processing parameters including drug type, plasticization time and level, the
incorporation of a water-soluble additive, and curing conditions on drug release
from ethylcellulose coated matrix bead formulations.
This research study was divided into three major parts to support the
primary goal of this research.
1.3.2.1 Curing Conditions
Supporting objectives:
•  To optimize the curing conditions of ethylcellulose coated beads in order to
obtain sustained release profiles for a water-soluble model drug and a slightly
water-soluble model drug.
•  To determine the influence of curing time and temperature for ethylcellulose
films on drug release from matrix bead formulations.
•  To determine the optimum curing conditions needed for completing film
coalescence of matrix beads without disrupting film integrity.
•  To investigate the influence of drug type, coating level, and subcoating




•  To investigate the influence of plasticizer type (i.e. water miscible and water
insoluble) and mixing time (plasticization time) on drug release from the
ethylcellulose coated matrix beads containing either a water-soluble model
drug or a slightly water-soluble model drug.
•  To investigate the influence of drug type and coating level on the
plasticization of the ethylcellulose coated matrix beads.
1.3.2.3 Water Soluble Additives
Supporting objectives:
•  To investigate the influence of hydrophilic water-soluble additives on the
release of a slightly water-insoluble drug from ethylcellulose coated beads.
•  To obtain a better understanding of using water-soluble additives and their





2.1.1 Single Unit System (Matrix Tablets)
The following materials were used during preformulation studies of
alprazolam: Alprazolam USP (ALP; Controlled substance DEA Schedule IV;
Spectrum Quality Products, Gardena, CA, USA); potassium chloride (KCl, EM
Science, Gibbstown, NJ, USA); 1 N hydrochloric acid solution (Spectrum Quality
Products, Gardena, CA, USA); tribasic sodium phosphate (Na3PO4.12H2O, EM
Science, Gibbstown, NJ, USA); Sulfuric Acid (H2SO4, EM Science, Gibbstown,
NJ, USA); potassium phosphate monobasic (KH2PO4, EM Science, Gibbstown,
NJ, USA); sodium hydroxide (NaOH, EM Science, Gibbstown, NJ, USA);
phosphoric acid (H3PO4, EM Science, Gibbstown, NJ, USA); Polyoxyethylene
sorbitan monooleate (Tween 80, Crillet® 4 NF; Croda Inc., Parsippany, NJ, USA)
was used to disperse the drug particle during particle size study.
The following materials were used for the preparation of powder blends
and matrix tablets in drug recovery and formulation studies: Alprazolam USP
(ALP; Controlled substance DEA Schedule IV; Spectrum Quality Products,
Gardena, CA, USA); hydroxypropyl methylcellulose USP (HPMC substitution
type 2208, Methocel K100 Premium LVCR EP (K100LVP, 22.8% methoxyl
content, 8.7% hydroxypropyl content, and 107 cPs apparent viscosity as a 2%
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aqueous solution) or Methocel K4M Premium CR (K4MP, 22.6% methoxyl
content, 9.6% hydroxypropyl content, and 4126 cPs apparent viscosity as a 2%
aqueous solution), The Dow Chemical Company, Midland, MI, USA);
microcrystalline cellulose N.F. (MCC; Avicel PH 200, FMC Corporation,
Philadelphia, PA, USA); lactose monohydrate N.F. (LAC; Modified Spray-dried,
Foremost Farms USA, Baraboo, WI, USA); dicalcium phosphate dihydrate (DCP;
Di-Tab, Rhodia North America, Chicago Heights, IL, USA); dicalcium phosphate
anhydrous (DCA; A-Tab, Rhodia North America, Chicago Heights, IL, USA);
sucrose (SUC; DiPac, Domino Sugar, Baltimore, MD, USA); dextrose (DEX;
Emdex, Penwest Pharmaceuticals Company, Patterson, NY, USA); calcium
sulfate dihydrate (CSD; Compactrol, Penwest Pharmaceuticals Company,
Patterson, NY, USA); silicon dioxide (Cab-O-Sil M5P, Cabot Corporation,
Tuscola, IL, USA); and magnesium stearate USP/N.F. (Spectrum Quality
Products, Gardena, CA, USA).
The following packaging components were used for the stability study of
the tablet formulations, 1-gram Silica Gel Pak (Desiccare, Inc., Richland, MS,
USA); 60 cc and 250 cc high density polyethylene (HDPE) wide-mouth white
bottles and polypropylene (PP) cap (Foamed polyethylene (PE) and pressure
sensitive liner (Berlin Packaging, Arlington Hgts, IL, USA).
For HPLC analysis, the chemicals used were analytical reagent grade.
HPLC grade acetonitrile, tetrahydrofuran (distilled; THF), monobasic potassium
phosphate, and sodium hydroxide were purchased from EM Science (Gibbstown,
NJ, USA).  Alprazolam USP reference standard was purchased from U.S.
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Pharmacopoeia (Rockville, MD, USA).  Whatman 0.45 µm (47 mm diameter)
nylon membrane filters (Whatman International Ltd., Maidstone, England) and
GHP 0.45 µm (GHP Acrodisc 13 mm, Pall Gelman Laboratory, Ann Arbor, MI,
USA) syringe filters were used to filter mobile phase and samples, respectively.
Water was purified with a Milli-Q UV Plus system (Millipore, Molsheim,
France).
For the dissolution study of the matrix tablets, 1 N hydrochloric acid
(HCl) solution (J. T. Baker, Phillipsburg, NJ, USA) and purified water were used
for preparation of 0.1 N HCl solution.  For USP buffer pH 6.0 preparation,
potassium phosphate monobasic (KH2PO4, EM Science, Gibbstown, NJ, USA),
sodium hydroxide (NaOH, EM Science, Gibbstown, NJ, USA), and purified water
were used.  The 10 µm filters (Vankel Technologies Group, Cary, NC, USA)
were used to filter all samples collected during dissolution tests.
2.1.2 Multiparticulate System (Film-Coated Beads)
The following materials were used for the preparation of uncoated matrix
beads: Chlorpheniramine maleate (CPM, Spectrum Quality Products, Gardena,
CA, USA), Theophylline anhydrous USP (Spectrum Quality Products, Gardena,
CA, USA), microcrystalline cellulose N.F. (MCC; Avicel PH 101, FMC
Corporation, Philadelphia, PA, USA), and purified water.  A 30 %w/w aqueous
dispersion of ethylcellulose (Aquacoat® ECD, FMC Corporation, Philadelphia,
PA, USA) and hydroxypropyl methylcellulose USP (HPMC substitution type
2910, Methocel E5P, The Dow Chemical Company, Midland, MI, USA) were
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used as coating materials.  Different types of water miscible and water insoluble
plasticizers including polyethylene glycol 400 (PEG 400, Carbowax®, Fisher
Scientific, Fair Lawn, NJ, USA), triethyl citrate PG/NF (TEC, Citroflex 2,
Morflex Inc., Greensboro, NC, USA); dibutyl sebacate NF (DBS, Morflex Inc.,
Greensboro, NC, USA); acetylated monoglycerides (AMG, Myvacet 9-45,
Eastman Chemical Co., Kingsport, TN, USA) were used during the coating
process.  In some formulations, the pore forming agents included hydroxypropyl
methylcellulose (HPMC substitution type 2910, Methocel E5P, The Dow
Chemical Company, Midland, MI, USA); polyethylene glycol 8000 (PEG 8000),
sucrose, or mannitol (Spectrum Quality Products, Gardena, CA, USA) was added
to the coating dispersion.
For dissolution studies of the film-coated beads, monobasic potassium
phosphate, sodium hydroxide (EM Science, Gibbstown, NJ, USA), phosphoric
acid (EM Science, Gibbstown, NJ, USA), and purified water were used to prepare
dissolution media.  The 10 µm filters (Vankel Technologies Group, Cary, NC,
USA) were used to filter all samples collected during the dissolution tests.
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2.2 METHODS
2.2.1 Single Unit System (Matrix Tablets)
2.2.1.1 Preformulation Studies for ALP
Determination of ALP Solubility
Solubility study of the active drug, ALP, was investigated in different
media as follows:
1). Purified water
2). 0.05 M Sulfuric Acid (H2SO4)
3). 0.1 N hydrochloric Acid (HCl), pH 1.1 (dissolution medium for ALP tablets)
4). Buffer pH 1.2 (Simulated Gastric Fluid, SGF)
5). USP buffer pH 2.0
6). Buffer pH 5.0
7). Buffer pH 6.8 (Simulated Intestinal Fluid, SIF)
8). USP buffer pH 8.0
An excess amount of ALP powder was added to each scintillation glass
vial containing 10 ml of each medium.  Each vial was mechanically stirred,
sonicated, and then continuously shaken at 37±0.5˚C using a laboratory shaker
(Lab-Line® Orbit Environ-shaker, Lab-line Instruments, Inc., Melrose Park, IL) to
facilitate saturated drug dissolution.  The amount of ALP in the solution after
equilibrating for 1 day and 2 days was determined by ultraviolet spectroscopy
described in a later section.  The samples were prepared for UV analysis by
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filtering them through a 0.45 mm GHP syringe filter (GHP Acrodisc 13 mm).
Appropriate dilutions were made with each medium prior to analysis.
Finally, solubility results in each medium after 1 and 2 days equilibration
were compared to ensure the equilibrium saturated solubility of ALP at 37±0.5˚C.
Thermal Analysis
Thermal properties of ALP powder were evaluated by Differential
Scanning Calorimetry (DSC) using a Modulated Differential Scanning
Calorimeter (Model DSC 2920; TA Instruments, New Castle, DE, USA).  The
standard DSC (heat flow as a function of temperature) was chosen.  The scan rate
was 10˚C/minute in a dynamic nitrogen environment between 50˚C and 300˚C.
The sample weighed about 2-4 mg and was contained in closed aluminum pans.
Duplicate determinations were carried out for each sample.
To investigate if ALP had undergone the recrystallization process,
repeated heating and cooling processes were used.  The sample was heated from
50˚C to 300˚C at the scan rate of 10˚C/minute, cooling from 300˚C down to 50˚C
at the scan rate of 5˚C/minute, heating from 50˚C to 300˚C at the scan rate of
10˚C/minute, cooling from 300˚C down to 50˚C at the scan rate of 20˚C/minute,
and then heating from 50˚C to 300˚C at the scan rate of 10˚C/minute.
Particle Size and Particle Size Distribution Study (Laser Light Scattering)
Particle size distribution of ALP was determined using a Shimadzu
SALD1100 laser diffraction type particle size analyzer (Shimadzu Scientific
Instrument Inc., Columbia, MD, USA).  The laser operates at a wavelength of 780
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nm with an output of 3 mW.  Particle size distribution data consists of volume
percent distribution, light energy distribution, cumulative volume distribution, and
differential distribution.  Particle size distribution curves were plotted between
percent cumulative undersized and particle size of ALP.  Two replicate samples
were dispersed in 0.02% Tween 80 immediately prior to analysis, agitated to
ensure a uniform dispersion by using a mechanical stirrer and ultrasonic wave
bath, and were read in duplicate.
Scanning Electron Microscopy (SEM)
Scanning electron microscopy was used to examine the particle size,
surface morphology and crystal shape of ALP powder.  Drug powder was
mounted on brass SEM stages using 3M double sided tape and was then coated
with gold-palladium for 60 seconds under an argon atmosphere using a Pelco®
Model 3 Sputter Coater (TED Pella, Inc., Tusin, CA, USA) in a high vacuum
evaporator equipped with an omni-rotary stage.  Samples were examined with a
Jeol scanning electron microscope (Model JSM-35C, Jeol USA, Inc., Peabody,
MA, USA) or Hitachi S-4500 field emission scanning electron microscope
(Hitachi Instruments Inc., Irvine, CA, USA) at 4.0 kV.  The scanning electron
micrographs were taken by a Polaroid® 545 Land Camera with 4" x 5" exposure
film.
Powder X-ray Diffractometry
The ALP powder samples were packed in the X-ray holder from the top
prior to analysis. X-ray diffraction patterns were obtained with a Philips vertical
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scanning diffractometer (Phillips Vertical Scanning Diffractometer, Type
PW1729; Philips Electronic Instruments, Mount Vernon, NY, USA) and Philips
data acquisition software (Type APD3520) over a 2-theta range of 5˚ to 50˚
(where theta is the scattering angle) with a step size of 0.05˚ 2-theta.  The analysis
was carried out at room temperature under ambient conditions.  Duplicate




The UV spectroscopic method for ALP quantitation used in this study was
modified from an assay method of ALP in 0.05 M sulfuric acid (H2SO4) solution
developed by Acikkol et al [Acikkol et al., 1991].  This method was modified to
determine the amount of ALP in each medium used during the solubility study
and the amount of drug release from a matrix tablet into a dissolution medium
during the dissolution study.  The amount of drug was quantified by ultraviolet
spectroscopy (Hewlett Packard Diode Array Spectrophotometer, Model 8452A,
with 1-cm quartz cell) at the maximum wavelength of ALP.
For standard curve preparation, a 0.05 M H2SO4 solution was used as a
diluent for determination of ALP in each medium during the solubility study;
whereas a 0.1 N hydrochloric acid (HCl) solution was used as a diluent for
determination of drug release in a dissolution medium during the dissolution
study.  For standard curve preparation, about 0.01 g of ALP powder was weighed
into a 100 ml-volumetric flask.  About 80 ml of an appropriate diluent was added
to dissolve the drug.  The stock solution was sonicated for 15 minutes to ensure
complete dissolution of all drug particles before adjusting to a final volume with
an appropriate diluent.  Final concentration of stock solution was about 0.1
mg/ml.  The stock solution was then diluted with a diluent to concentrations in the
range of 0.001–0.020 mg/ml.  A calibration curve was prepared by plotting the
absorbance values of each standard against the concentration of each standard.
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Finally, the quantity of ALP was calculated from the regression equation of the
calibration curve.  Linear correlation over the concentration range of 0.001–0.020
mg/ml for ALP should be close to 1 (r2 = 1).
For sample preparation, an appropriate dilution of each sample was made
with an appropriate diluent such that the final concentration was within the linear
portion of the standard curve for ALP prior to analysis.
Chromatographic Analysis
The reverse-phase HPLC method used to determine the amount of ALP in
the powder blends and pulverized matrix tablets was a modification from the
assay method of ALP Tablets listed in USP 24/NF 19 monograph [United States
Pharmacopeial Convention, 1999].  The chromatographic system (Shimadzu,
Columbia, MD, USA) consisted of a system controller (Model SCL-10A-VP), a
PDA detector (Model SPD-M10A VP, deuterium lamp), a chromatographic data
control and acquisition system (Class-VP software version 4.2), pumps (Model
LC-10AT VP), and an autoinjector (SIL-10A). A Luna 5µ C8(2) (5 µm, 100 x 4.6
mm, Phenomenex, Torrance, CA, USA), USP packing type L7, column and a
security guard cartridge C8 (4 x 3.0 mm, Phenomenex, Torrance, CA, USA) were
used.
The mobile phase was composed of a mixture of 35.34 mM phosphate
buffer (pH 6.0±0.1), acetonitrile and tetrahydrofuran in a ratio of 68:28:4 (v/v/v).
The 35.34 mM phosphate buffer solution was prepared by dissolving monobasic
potassium phosphate in purified water, and then adjusting the pH to 6.0±0.1 with
5.3 M sodium hydroxide solution.  Prior to use, the mobile phase was filtered
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through a 0.45 µm nylon membrane filter (Whatman, 47 mm diameter), and
degassed with vacuum and sonication for 10 minutes.  The flow rate of the mobile
phase was 2 ml/min (isocratic) and the injection volume was 20 µl.  The
absorbance was monitored at 222 nm.  The run time was 10 min.  A calibration
curve was prepared by dissolving ALP USP reference standard with the diluent
(purified water-acetonitrile, 50:50, v/v), and the stock solution was diluted to
concentrations in the range of 0.005 to 0.06 mg/ml.  Replicate standards were
injected to ensure repeatability prior to sample analysis.  Integration of
chromatographic peaks was performed using the default values of 3500 and 0.75
for peak threshold and peak width, respectively.  Peaks were integrated using a
tangential skim or valley-to-valley method.  System suitability criteria were
established: the correlation coefficient (r2) of the calibration curve, not less than
0.998; relative standard deviation (RSD) of five replicate injections, ≤ 2.0%;
number of theoretical plates, > 500 plates/column; and the peak asymmetry, ≤ 1.5
[United States Pharmacopeial Convention, 1999].  A check standard of known
concentration was inserted between every five samples.  All samples were filtered
through 0.45 µm GHP syringe filters (GHP Acrodisc 13 mm) into HPLC vials.
2.2.1.2 Drug Recovery from Hydrophilic Matrix Tablets
Sample Preparation Methods
Each sample contained placebo powder and a known amount of ALP.  A
mixture of HPMC polymer (either Methocel K4MP or K100LVP),
microcrystalline cellulose, other excipient(s), silicon dioxide, and magnesium
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stearate was prepared by geometric dilution in a V-blender.  Either ALP powder
or an aliquot of stock solution containing a known amount of ALP was added to
an aliquot of the placebo powder blend.  Two sample preparation methods (I and
II) were investigated to determine ALP recovery.  Each sample listed in Table 2.1
was prepared in replicates of three using sample preparation method indicated
below.
Sample Preparation Method I
Acetonitrile (ACN) alone was used as the extraction solvent.  After final
volume adjustment, each sample was filtered through a 0.45 µm GHP syringe
filter (GHP Acrodisc 13 mm) into a glass vial.  Finally, the drug content was
determined by HPLC.  The samples investigated (A to J) using method I and
orders of addition are described in Table 2.1.  The quantitative composition of
each placebo powder (A to J) is listed in Table 2.2.
Sample Preparation Method II
The composition of placebo powder blend used for sample K preparation
and analyzed using method II is described in Table 2.2.  A physical blend of
placebo powder blend and ALP powder were blended and transferred to a 1-L
volumetric flask.  To the physical blend, 170 ml of hot water (~ 90˚C) was added
with stirring to disperse the physical blend before addition of 330 ml of cold water
(~ 5˚C).  The slurry was stirred in an ice bath at 2˚C for 3 hours to dissolve the
HPMC gel.  Then, about 450 ml of ACN was added and stirring was continued
for 4 hours at 25˚C.  The sample was adjusted to final volume and then 50 %v/v
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ACN mixture was obtained.  Finally, the mixture was filtered through a 0.45 µm
GHP syringe filter (GHP Acrodisc 13 mm) into a glass vial for HPLC analysis.
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Placebo powder blend1, add ACN, add
ALP Stock Solution, mix and adjust to
volume.
B powder 100 % ACN
(22˚C)
Placebo powder blend1, add ACN, sonicate
for 30 min., add ALP Powder, sonicate for
30 min., mix and adjust to volume.
C powder 100 % ACN
(22˚C)
ALP Powder, add ACN, sonicate for 30
min., add Placebo powder blend1, mix and
adjust to volume.
D powder 100 % ACN
(22˚C)
Placebo powder blend1, add ALP Powder,
add ACN, sonicate for 30 min., mix and
adjust to volume.
E powder 100 % cold
ACN
(5˚C)
Placebo powder blend1, add ALP Powder,
add cold ACN, sonicate for 30 min., stir at
25˚C for 12 hrs, mix and adjust to volume.
F powder 100 % cold
ACN
(5˚C)
ALP Powder, add cold ACN, sonicate for
30 min, add Placebo powder blend1, stir at
25˚C for 12 hrs, mix and adjust to volume.
G powder 100 % cold
ACN
(5˚C)
Placebo powder blend1, add cold ACN,
sonicate for 30 min., add ALP Powder,
sonicate for 30 min., stir at 25˚C for 12 hrs,
mix and adjust to volume.
H powder 100 % cold
ACN
(-10˚C)
Placebo powder blend1, add ALP Powder,
add cold ACN, sonicate for 30 min., stir at







Placebo powder blend1, add ALP Stock
Solution, add ACN (-10˚C), sonicate for 30
min., stir overnight at 25˚C, mix and
adjust to volume.
J powder 100 % cold
ACN
(-20˚C)
Placebo powder blend1, add ALP Powder,
add ACN (-20˚C), stir at -17˚C for 2 hrs,
mix and adjust to volume.
1 Placebo powder contained 23 %w/w of HPMC-K4MP, 20 %w/w of microcrystalline cellulose,
56 %w/w of dicalcium phosphate dihydrate, 0.5 %w/w of silicon dioxide, and 0.5 %w/w of
magnesium stearate.
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Other Excipients in Tablet
Formulation






microcrystalline cellulose (20 %w/w),
silicon dioxide (0.5 %w/w),







microcrystalline cellulose (20 %w/w),
silicon dioxide (0.5 %w/w),





microcrystalline cellulose (20 %w/w),
silicon dioxide (0.5 %w/w),





microcrystalline cellulose (20 %w/w),
silicon dioxide (0.5 %w/w),







microcrystalline cellulose (20 %w/w),
silicon dioxide (0.5 %w/w),







microcrystalline cellulose (20 %w/w),
silicon dioxide (0.5 %w/w),
magnesium stearate (0.5 %w/w)
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Influence of molecular weight type (nominal viscosity) of HPMC on ALP
recovery
The two different molecular weight types of HPMC polymer (Methocel
K100 having an apparent viscosity of 107 cPs and Methocel K4MP having an
apparent viscosity of 4126 cPs) were incorporated into the placebo powder blends
(Table 2.2 - samples K and L).  Sample K contained the high molecular weight
polymer (23 %w/w of HPMC K4MP), whereas sample L contained the low
molecular weight polymer (40 %w/w of HPMC K100LVP).  Both samples K and
L were prepared by using sample preparation method II as described in the
previous section.
Influence of excipient type on ALP recovery
The water-soluble excipients investigated include sucrose and dextrose.
The water insoluble excipients investigated include anhydrous dicalcium
phosphate and calcium sulfate dihydrate.  The composition of the placebo powder
blends used to prepare samples M-P are shown in Table 2.2.  All samples were
prepared by using sample preparation method II as described in the previous
section.
Determination of drug content in a matrix tablet
Matrix tablet preparation:
Two hydrophilic matrix tablet formulations containing either HPMC
K4MP or K100LVP polymer were prepared for a 300-gram batch size.  Batch
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composition in percent weight by weight is shown in Table 2.3.  All ingredients
were blended using a geometric dilution technique in a V-blender.  Matrix tablet
preparation will be described in detail in the following section.  Tablets weighing
400 mg were prepared by direct compression using standard tablet tooling
(concave, 11 mm diameter) and tablet press (Stokes Dual Pressure Press Model
B2, Serial No. B59671, F.J. Stokes Machine Company, Philadelphia, PA, USA).
Tablet size, shape and hardness were identical for both formulations.
Content uniformity assay of matrix tablets
A content uniformity assay of ground individual tablets and a composite
assay of 10 ground tablets from each formulation were determined using sample
preparation method II.  ALP content in the matrix tablet(s) was quantified by
HPLC.
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2.2.1.3 Investigation of Formulation Parameters on Drug Release
In order to develop a 14- to 16-hour sustained release matrix tablet
formulation, the influence on ALP release of the parameters including tablet size,
drug loading, polymer level, polymer molecular weight type, excipient type and
level, and dissolution medium, were investigated.  A screening formulation study
was carried out in order to select the optimum tablet size, drug loading, and
polymer level.  Influence of excipient, polymer molecular weight type, and
dissolution medium on drug release was investigated during formulation
development.
Screening Study
Each tablet formulation was prepared in a 300-gram batch size. General
formulation compositions and levels are shown in Table 2.4.  Powder blend was
prepared by geometric dilution in a V-blender.  A blending method was
developed to obtain uniformity of the dosage form, especially for low dosing
level.  The blending procedure is described in detail in the next section.
Tablet Size
Hydrophilic matrix tablet formulations contained ALP as a model drug, a
hydrophilic polymer (HPMC K4MP), an excipient (microcrystalline cellulose
(Avicel PH 200) or lactose monohydrate), and a lubricant (magnesium stearate).
Three different sizes of tooling (8, 9, and 11 mm diameter, concave
tooling) were then used to prepare the matrix tablets.  Tablet weight was 120, 240,
and 400 mg for 8, 9, and 11 mm diameter tooling, respectively.  Tablets were
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compressed to the hardness range between 10-14 kg for 8 and 9 mm diameter
tooling, and to the hardness range between 6.5-9.5 kg for 11 mm diameter tooling.
A dissolution study of each tablet size from the formulations developed was
performed at least in triplicate for screening purpose in order to obtain a product
with 14- to 16-hour sustained release period.
Drug Loading
Hydrophilic matrix tablet formulations contained ALP, HPMC K4MP or
HPMC K100LVP, microcrystalline cellulose (Avicel PH 200), magnesium
stearate, and the tablet weight was adjusted with dicalcium phosphate.
Two levels of drug ALP were used to prepare 11-mm diameter tablets
with hardness range between 6.5-9.5 kg.  Either 5-mg dose (1.25 %w/w) or 10-mg
dose (2.50 %w/w) of ALP was contained in a 400-mg tablet.
Polymer Level
Hydrophilic matrix tablet formulations contained 2.5 %w/w ALP, HPMC
K4MP, microcrystalline cellulose (Avicel PH 200), silicon dioxide, magnesium
stearate, and the tablet weight was adjusted to 400 mg with lactose.
Different levels of HPMC polymer (30-65 %w/w) were used to prepare
11-mm diameter tablets with hardness range between 6.5-9.5 kg.
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Alprazolam 1.25 - 2.50
HPMC K100LVP or K4MP 30.00 - 65.00
Microcrystalline cellulose (PH200)   0.00 - 20.00







A hydrophilic matrix tablet formulation was developed to contain ALP,
HPMC K4MP polymer, a swelling excipient (microcrystalline cellulose, Avicel
PH 200), a glidant (silicon dioxide), a lubricant (magnesium stearate), and other
excipients.  Each formulation was prepared for a 300-gram batch size. The
composition of each tablet formulation is shown in Table 2.5.  The excipient type
was varied and included water soluble excipients (LAC, SUC, DEX) and/or water
insoluble excipients (DCP, DCA, CSD).  Method of preparation is described in
detail in the next section.
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2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5
HPMC K4MP 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0
Microcrystalline
cellulose (MCC)
20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0
Silicon dioxide 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
Magnesium
stearate








- 9.1 18.3 27.4 36.5 - - - -
Sucrose (SUC) - - - - - 36.5 - - -




- - - - - - - 36.5 -
Calcium sulfate
dihydrate (CSD)
- - - - - - - - 36.5
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
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HPMC Molecular Weight Type (Nominal Viscosity)
As can be seen in Table 2.6, a hydrophilic matrix tablet formulation was
developed to contain ALP as a model drug, an insoluble swelling excipient
(microcrystalline cellulose, Avicel PH 200), a soluble excipient (lactose
monohydrate), a hydrophilic polymer (HPMC), a glidant (silicon dioxide), and a
lubricant (magnesium stearate).  The two different molecular weight types of
HPMC polymer (Methocel K4MP or Methocel K100LVP) were substituted into
the matrix tablet formulation to make the two formulations to be tested for
equivalence in vitro.  The level of HPMC polymer in each formulation was varied
from 30-45 %w/w in order to accommodate the similar dissolution profiles.
Method of preparation is described in detail in the next section.
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(10 mg/400 mg tablet)
2.50
HPMC K100LVP or K4MP 30.00-45.00






Controlled Release Tablet Preparation
The components were combined geometrically and mixed using a rotating
V-blender.  The blending method for a low level of drug loading (2.5 mg/120 mg
tablet or 5 mg/240 mg tablet, 2.08 %w/w; 10 mg/400 mg tablet, 2.5 %w/w) was
developed.  The following section describes the blending method in detail for
preparation of the tablets for the HPMC molecular weight type study.  A similar
preparation method was also applied to other formulations investigated.
However, a different hardness range was varied for each size of tooling used.
Either 8 or 9 mm diameter tooling was used to prepare tablets with hardness range
between 10-14 kg, whereas 11 mm diameter tooling was used to prepare tablets
with hardness range between 6.5-9.5 kg.  Figure 2.1 shows the schematic of
matrix tablet preparations.
Preparation of Active direct compression blend
1). Sieve all ingredients through No.40 mesh screen to deaggregate the particles.
2). Weigh out each ingredient according to batch charge for 300-g batch size (750
tablets).
3). Add ALP USP and Silicon Dioxide into a V-blender (1.2 L. volume) and mix
for 10 minutes.
4). Add about 1/3 the amount of Microcrystalline Cellulose N.F. into the V-
blender from step 3) and mix for 10 minutes.
5). Add another 1/3 the amount of Microcrystalline Cellulose N.F. into the V-
blender from step 4) and mix for 10 minutes.
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6). Add the last portion (1/3) of Microcrystalline Cellulose N.F. into the V-
blender from step 5) and mix for another 10 minutes.
7). Add about 1/2 the amount of Lactose Monohydrate N.F. into the V-blender
from step 6) and mix for 10 minutes.
8). Add the last portion (1/2) of Lactose Monohydrate N.F. into the V-blender
from step 7) and mix for another 10 minutes.
9). Add HPMC K100LVP or K4MP into the V-blender from step 8), mix for 10
minutes, carefully remove the powder blend from the V-blender, pass
through a No.40 mesh screen, and transfer back into the V-blender.
10). Mix for 10 minutes, remove the powder blend from the V-blender, pass
through a No.40 mesh screen, and transfer back into the V-blender.
11). Add 1.5 g of Magnesium Stearate USP/N.F. into the V-blender, and mix for
5 minutes.
12). Label contents “Active Direct Compression Blend-Formulation __”.
Compression
13). Transfer the active direct compression blend from step 12) to the hopper of
the tablet machine.
14). Compress the active direct compression blend using concave, 11 mm
diameter tablet tooling into a tablet weighing 400 mg±5%  (380–420 mg
weight variation) with a target hardness of 8 kg (acceptable range 6.5–9.5
kg).
Tablet press: Stokes Dual Pressure Press Model B2 (F.J. Stokes Machine
Company, Philadelphia, PA)
100
Hardness Tester: Heberlein Type WTP-3 (Fab. Nr. 1082, Heberlein & Co
AG).
15). Sample 3 tablets approximately every 50 tablets, confirm weight and
hardness to meet the specification in step 14).  Adjustment of the tablet press
is allowed during compression process in order to obtain tablets with above
specifications.  Approximately, a tablet yield of 200-300 tablets is needed.
After process is complete, tablets, active direct compression blend and waste
are collected in separate container.
16). Randomly confirm weight of 20 tablets and hardness of 10 tablets from the
entire batch.
17). Package tablets into HDPE bottles with PP caps and desiccant to protect from
light and moisture.  Label “Formulation ____” on the bottle.
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Figure 2.1 Schematic of matrix tablet preparation
40




1/2 of Excipient1/2 of Excipient
HPMC
10 min





400 mg Matrix tablets
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Characterization of Matrix Tablets
Each tablet formulation was characterized as follows:
Weight and hardness variations
The weight of 20 tablets and the hardness of 10 tablets (Heberlein
Hardness Tester Type WTP-3, Fab. Nr. 1082, Heberlein & Co AG) were
determined on tablets sampled randomly across the lot.
The acceptable average tablet weight was 380-420 mg (400 mg target) for
the tablet weight and the average tablet hardness was 6.5-9.5 kg (8 kg target).
Content Uniformity Assay
A content uniformity assay of 10 tablets from each formulation was
performed using an extraction method developed in the previous section.  The
extraction method comprised using hot water to swell the HPMC polymer,
followed by the addition of cold water to completely dissolve HPMC, and then
adding acetonitrile to dissolve the ALP.  The content uniformity assay procedure
is described in detail as follows:
1). Individually weigh each of the 10 tablets and record actual weight.
2). Grind each tablet in a glass mortar and pestle.
3). Transfer tablet powder blend onto a weighing paper.
4). Transfer powder from a paper into a 250-ml volumetric flask.
5). Carefully rinse all powder with 42 ml of hot water (~90˚C).  Put the magnetic
stir bar into the flask, and stir to wet and swell the polymer.
6). Rinse with another 83 ml of cold water (~5˚C).  Stir to dissolve the polymer in
an ice bath for about 3 hours.
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7). Add acetonitrile (ACN) up to the neck of the flask.  Keep stirring for another
4 hours or until the solution temperature reaches room temperature.
8). Remove the stir bar and adjust volume to the mark with acetonitrile.  Mix
well.
Caution: When ACN is added, sample needs to be shaken or stirred for 1–2
minutes because of volume contraction between ACN and water.
9). Filter sample through 0.45 um GHP syringe filter into a glass vial for HPLC
assay.  ALP was quantified using a validated HPLC method as previously
described.
The acceptance criteria was 90–110% of label claim and %RSD < 6%.
Composite Assay
A composite assay of 10 tablets from each formulation was performed
using an extraction method developed in the previous section. The content
uniformity assay procedure is described in details as follows:
1). Weigh 10 tablets together and record actual weight.
2). Grind tablets in a glass mortar and pestle.
3). Transfer tablet powder blend onto a weighing paper.
4). Transfer powder from paper into a 2-L volumetric flask.
5). Carefully rinse all powder with 336 ml of hot water (~90˚C).  Put the
magnetic stir bar into the flask, and stir to wet and swell the polymer.
6). Rinse with another 664 ml of cold water (~5˚C).  Stir to dissolve the polymer
in an ice bath for about 3 hours.
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7). Add acetonitrile up to the neck of the flask.  Keep stirring for another 4 hours
or until the solution temperature reaches room temperature.
8). Remove the stir bar and adjust volume to the mark with acetonitrile.  Mix
well.
Caution: When ACN is added, sample needs to be shaken or stirred for 1–2
minutes because of volume contraction between ACN and water.
9). Filter sample through 0.45 um GHP syringe filter into a glass vial for HPLC
assay. ALP was quantified using a validated HPLC method as previously
described.
The acceptance criteria was 90–110% of label claim.
In Vitro Dissolution study and Dissolution Profiles Comparison
The dissolution test of ALP controlled release tablets was modified from
Test 4, Official monograph of Procainamide hydrochloride extended release
tablets [United States Pharmacopeial Convention, 1999].  For each tablet
formulation, a dissolution test of six tablet samples were conducted at 37˚C using
USP Apparatus 2 (paddle) and a rotation speed of 50 RPM.  The dissolution
medium consisted of 900 ml of 0.1 N HCl solution (pH = 1.1).  The 0.1 N HCl
solution was prepared from the dilution of 1 N HCl solution with purified water.
The final pH of the solution was between 1.05-1.15.  A 4-ml sample was taken
from the medium at 1, 2, 4, 6, 8, 10, 12, 14, and 16 hours.  At the end of
dissolution study, the actual drug content in each vessel was confirmed by
breaking the rest of gel matrix into small parts and then stirring at a rotating speed
of 120 rpm for about an hour.  Each sample was filtered through a 10 µm filter
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prior to analysis.  The amount of drug release was determined by UV
spectroscopy as previously described in the preformulation section 2.2.1.1.
For HPMC MW type study, specification of ALP release from final tablet
formulations should be:
Time (hr) % ALP Released
   2 Less than 45%
   4 45 – 65%
   8 75 – 90%
  12 Greater than 90%
To compare the influence of dissolution media on the ALP release from
the matrix tablets, USP buffer pH 6.0 or purified water was used as a dissolution
medium instead of 0.1 N HCl solution (pH 1.1).  Drug release from same tablet
formulation was compared in each medium.
•  Statistical Comparison of Dissolution Profiles
Dissolution profiles were constructed and the similarity factor (f2 factor) was
used to compare the dissolution profile of each formulation.  This model is most
suitable for dissolution profile comparison when three to four or more dissolution
time points are available.  The similarity factor (f2) is a logarithmic reciprocal
square root transformation of the sum of squared error and is a measurement of
the similarity in the percent dissolution between the two curves.  The following
equation defines a similarity factor (f2):

























where f2 is the similarity factor, log is logarithm to base 10, P is number of
sampling time points, ∑ is the summation of over all time points, µti is the
dissolution measurement (in mean percent labeled amount) at time point t of the
first batch (test batch) profile, µri is the dissolution measurement (in mean percent
labeled amount) at time point t of the second batch (reference batch) profile.  Two
dissolution profiles should be conducted under exactly the same conditions and
the sampling time points are identical.  The f2 values are sensitive to the number
of dissolution time points.  Therefore, only one point past the plateau of the
dissolution profiles or only the time point after 85% dissolution of both batches
was recommended for use to calculate the similarity factor.  This was due to the
inclusion of 'P' for the late time points of the profiles into the formula, which can
insure a high f2 value and leads to bias in the similarity assessment [FDA, 1997a;
FDA, 1995b; Shah et al., 1998; Shah et al., 1999].
The following criteria of f2 limit were used to define different average
distances between two dissolution profiles at multiple time points by appropriate
substitution in f2 equation above [Shah et al., 1998].







If f2 value calculated from the equation is 45, this indicated that two
dissolution profiles are about 15% average difference at all key time points.  If the
f2 value is close to 100, the two profiles are nearly identical.  In general, the FDA
standard of an f2 between 50-100 (≤ 10% average difference) indicates similarity
or equivalence between two dissolution profiles [FDA, 1995a; FDA, 1997a; Shah
et al., 1998; Shah et al., 1999; Moore and Flanner, 1996].
Stability Study of Matrix Tablets
Final tablet formulations for in vivo clinical study were placed on stability
using the recommended ICH guidelines.  The tablets were packaged in HDPE
bottles with PP cap (foamed PE and pressure sensitive liner), and stored at
25±2°C, 60±5% relative humidity for 3, 6, and 12 months and at 40±2°C, 75±5%
relative humidity for 1, 2, 3, and 6 months).  The results from dissolution testing
were statistically evaluated for differences using similarity factor as described in
the previous section.
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2.2.1.4 In Vivo Clinical Study
The in vivo clinical study in human subjects was performed in
collaboration with Robert L. Talbert, Pharm.D., Division Head and SmithKline
Professor, Department of Clinical Pharmacy, University of Texas Health Science
Center at San Antonio.
The principal determinations for bioequivalence for the probe drugs used
in testing various polymers were area-under-the-curve (AUC), maximal
concentration (Cmax), and time of maximal concentration (Tmax).  The current
FDA guidelines for bioequivalence are that two formulations whose rate and
extent of absorption differ by  -20% to +25% or less are generally considered
bioequivalent.  This is based on the concept that a difference of -20% to +25%
would not lead to change in therapy for a patient.  To verify that the -20%/+25%
rule for bioequivalence was satisfied, the student paired t-test was used to
compare the log transformed data of the AUC, Cmax, and Tmax obtained from
the bioequivalence study.  It was estimated that 10 subjects must be randomized
to detect a +/- 20% difference in AUC with 95% confidence.  FDA guideline
recommended that 12 persons be tested in crossover design for evaluation of
inter-subject bioequivalence.  Given that our estimates were based on a small
population and the recommendation from the FDA, 15 subjects were screened
with the goal of obtaining 10-12 completers.  The testing protocol was approved




The clinical bioequivalence testing was conducted as a randomized, open-
label, four-way crossover design.  The study site was the General Clinical
Research Center (GCRC) at the South Texas Veterans Health Care System in San
Antonio, TX (VA medical center).  Two developed ALP tablet formulations
containing different molecular weight types of HPMC polymer (i.e. HPMC-
K4MP (polymer A) and HPMC-K100LVP (polymer B)) were used during the
study.  Each formulation (K4M-42 or K100LV-27 formulations) was tested in the
fed and fasted state.  The randomization scheme was shown in Table 2.7.
Randomization was controlled through a computerized randomization
procedure.  After obtaining written informed consent, 15 normal volunteers were
screened using medical and medication history, physical examination and routine
clinical laboratory tests including Chem-20 including hepatic enzymes, ß-HCG in
females, and CBC with platelet count.  The entire sampling period was 72 hours
since the median half-life (t1/2) of ALP is about 12 hours and to ensure adequate
characterization of the AUC, sampling needs to cover approximately 5 half-lives.
ALP 10 mg matrix tablets were given in the fasted state after the initial baseline
blood sample of 10 ml (time=0 hr.) for determination of plasma ALP
concentration was taken.  The sampling schedule for subsequent blood samples
was 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours.  Samples obtained at
48 and 72 hours were done in an outpatient setting.  The total number of samples
to be obtained was 14 (140 ml of blood).  The pharmacodynamic effects of
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controlled release ALP was monitored using subject rated sedation on visual
analogue scale (VAS) for wakefulness, observer rated sedation, and symbol digit
matching test (SDMT, see Appendix A).  Clinical evaluation using these scales
was performed at each schedule blood draw.  For subjects randomized to receive
ALP tablet with food, a standardized meal was served from the GCRC kitchen
and all subjects received the meal at the same time and each meal had the same
content of calories and fat.  Subjects randomized to receive ALP tablet in the
fasted state were required to have not eaten for eight hours prior to administration
and for two hours after administration of the study medication.
Samples were obtained through a saline-lock intravenous catheter (SL-
IV).  Other procedures, which were not done in the course of normal medical care
for a healthy patient, include the baseline physical exam, initial laboratory
screening (Chem-20, LFT, ß-HCG in females, and CBC as stated above), ALP
administration, overnight admission to GCRC, returning to the GCRC for 48 and
72 hour sampling and administration of previously mentioned sedation and
SDMT rating scales.
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Table 2.7 Randomization Scheme for Bioequivalence Study





Note: Polymer A = HPMC-K4MP; Polymer B = HPMC-K100LVP
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Since ALP is a legend (prescription) drug product and it causes
drowsiness and sleep, the volunteers must be studied in a controlled environment
and observed until the drug effects have subsided.  A physician was available on
call for the first 1-3 hours after dosing to insure that any adverse effects of ALP
were managed appropriately.  The most common and expected side effect was
drowsiness.  Other side effects, which may occur in about 1 in 10 persons,
includes fatigue, dizziness, headache, nausea, vomiting, and memory loss.  It is
unlikely that any of these side effects will persist after 24 hours.
Subjects included English-speaking, healthy, non-pregnant, non-nursing
persons aged 18-65 years of age.  Patients with abnormal values on initial
laboratory screening or positive pregnancy test were excluded.  Patients with
know hypersensitivity to ALP or any benzodiazepine were excluded.  All female
subjects of childbearing potential were instructed to use birth control while taking
part in the study and to inform the investigators if at anytime they thought they
were pregnant.  Subjects were recruited through flyers posted on the grounds of
the University of Texas Health Science Center at San Antonio campus (See
Appendix B for example of patient recruitment flyers).  Consent was obtained
after subject candidates contacted the primary investigator and were deemed
eligible for enrollment (See Appendix C for example of consent forms).  All
copies of informed consent were kept in the Clinical Pharmacy office in
McDermontt Room 3.414.
This study had no therapeutic intent.  There were no known or expected
benefits or risks that occurred in non-English-speaking subjects.  The study was
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not powered to detect any potential unknown differences and no evaluation of
therapeutic endpoints was planned.  It was unlikely that the dissolution profiles of
the two ALP tablets tested were affected by any ethnic influences in and all
English-speaking population.
All study subject's medical information was kept confidential.  If the
results of the study are published in a scientific journal or book, study subjects
will not be identified in any way.
Sample Analysis
After each 10-ml blood sample collection, plasma was immediately
separated and frozen until the assay.
ALP plasma concentrations were quantitated using a validated reverse
phase HPLC method with UV detection, developed by Y. W. Francis Lam,
Pharm.D., Associate Professor of Pharmacology and Medicine, University of
Texas Health Science Center at San Antonio.
An Ultrasphere C18 column was used for analysis.  Column temperature
was maintained at 30˚C.  The mobile phase was composed of a mixture of 50 mM
phosphate buffer (pH 4.0) and acetonitrile in a ratio of 70:30 (v/v).  The flow rate
of the mobile phase was 1 ml/min (isocratic) and the injection volume was 25 µl.
The absorbance was monitored at 221 nm.  Nitrazepam was used as an internal
standard.  The linearity was obtained with ALP concentration ranging from 5-250
ng/ml.  The correlation coefficient (r2) of the calibration curve should not be less
than 0.994.  The sensitivity of the assay method was 2 ng/ml.
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2.2.2 Multiparticulate System (Film-Coated Beads)
Influence of processing parameters on drug release from cellulose ether coated
matrix bead formulations.
2.2.2.1 Uncoated Matrix Bead Preparation
A 300-g matrix bead formulation of a highly water soluble drug,
chlorpheniramine maleate (CPM), or a slightly water soluble drug, theophylline
anhydrous, were prepared by mixing the active drug with microcrystalline
cellulose in a V-blender for 20 minutes.  Matrix bead formulations are shown in
Table 2.8.  The wet mass of the powder blend was prepared in a Kitchen Aid
Mixer (Model KSM90, Kitchen Aid, Inc, St. Joseph, MI), operated at a low speed,
by slow addition of purified water (binder), and then the blend was passed
through the extruder  (Benchtop Granulator, Model no. 5666, LCI Corporation,
Charlotte, NC, USA), operated at a constant extruding speed of 50 rpm and fitted
with a 1.2-mm screen.  The extrudate was immediately spheronized (Spheronizer,
Caleva, Model 120, GEI Processing, Towaco, NJ, USA) at a rotational speed of
1000 rpm for the optimum residence time needed to produce uniform spherical
particles.  The beads were rotated in the spheronizer for 5 to 8 minutes.  Wet
beads sized between 14 and 18 mesh were collected, dried for at least 18 hours in
the oven at 40˚C and then beads sized between 16 and 20 mesh were collected for
the coating experiments.  The wet beads that were out of the specified particle
size range were recycled into the extruder and spheronizer in order to obtain a
high yield of uncoated beads.
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Table 2.8 Uncoated Matrix Bead Formulation







15 45 - -
Theophylline
anhydrous




85 255 60 180
Purified Water*
(ml)
85 255 82 246
Total Batch Size 100 300 100 300
Note: * Purified water is removed after drying the core beads in the oven.
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2.2.2.2 Coated Matrix Bead Preparation
The 30 %w/w ethylcellulose dispersion (Aquacoat®ECD, FMC
Corporation, Newark, DE) was moderately mixed prior to addition of the water-
miscible plasticizer (triethyl citrate (TEC)) or the water-insoluble plasticizer
(dibutyl sebacate (DBS), or distilled acetylated monoglycerides (AMG, Myvacet
9-45)) at a level of 24-30 %w/w based on dry polymer weight.  The plasticizer
was incorporated into the EC dispersion for either a 2- or 24-hour plasticization
time using a mechanical stirrer.
In some coating formulations for CPM beads, a subcoating solution was
applied prior to the application of the EC dispersion.  The subcoating solution
consisted of 7.5 %w/w HPMC E5 plasticized with 2 %w/w (based on polymer
weight) of PEG 400 for 2 hours.  Then, it was applied to the uncoated matrix
beads at a 2% coating level.
In some coating formulations for theophylline beads, after plasticization, a
solution of water-soluble additive (HPMC E5, PEG 8000, sucrose, or mannitol)
was added to the coating dispersion upon mixing at 5-20% w/w (based on dry
polymer weight) level and mixed for another 15 minutes.  Then, purified water
was added and continuously mixed for another 10 minutes at a moderate mixing
speed to obtain a final dispersion of 15-20% total solids.
A 250-300 g batch of 16–20 mesh drug-loaded matrix beads were then
coated with the mixed dispersion in a fluid bed coater with a Wurster insert
(Strea-1, Aeromatic AG, Aeromatic Inc., Towaco, NJ, USA) at the optimum
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spraying time and rate in order to obtain 5-21% theoretical coating levels for
Theophylline beads and 15-36% theoretical coating levels for CPM beads.  The
following parameters were used:
Inlet air temperature: 45-50˚C
Outlet air temperature: 38-42˚C
Nozzle size: 1.2 mm
Atomization pressure: 1.3 bar
Spray rate: 2.4 g/min
Preheating time: 15 min
Postdrying time: 15 min at 60˚C
Spray time: 2–4 hours
The inlet air temperature was adjusted to maintain the outlet air
temperature of 38-42˚C, which was about 10˚C above the minimum film forming
temperature of the EC-plasticizer dispersion.
After spraying, beads were rotated in the coater column maintaining bed
temperature (post column drying temperature) for an additional 15 minutes at
60˚C to avoid sticking problems.  The film coated beads with different coating
levels were oven-cured at 40˚C, 60˚C or 80˚C for up to 72 hours.  The schematic
of the film-coated beads preparation is summarized in Figure 2.2.
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Figure 2.2 Film coated beads preparation






Dry at 40˚C for 18 hrs
Size (16-20 Mesh Size)
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2.2.2.3 Characterization of Matrix Beads
In Vitro Release Studies
In vitro dissolution study was performed at least in triplicate.  For CPM
coated beads, the in vitro release studies were carried out according to Test 1
method for determination of drug release from Chlorpheniramine Maleate
Extended-Release Capsules specified in USP 24/NF 19 [United States
Pharmacopeial Convention, 1999].  The dissolution profiles of the uncoated and
coated beads were determined using USP Apparatus 1 (basket) (Vankel VK 6010
and Vanderkamp VK 650 A with an autosampling unit, Vankel VK 800) operated
at 100 rpm in 500 ml purified water at 37±0.5˚C.  Dissolution samples of 4 ml
were collected at 1.5, 3, 6, 8, and 10 hours.  For actual drug content in each
vessel, the last dissolution sample was collected after vigorously stir with a
medium shear mixer (Polytron Silverson type mixer; Brinkmann Instruments,
Wettburg, NY, USA) at a mid-range speed for 30 seconds.  Each sample was
filtered through a 10 µm filter prior to analysis.
For theophylline coated beads, the in vitro release studies were carried out
according to Test 5 method for determination of drug release from Theophylline
Extended-Release Capsules specified in USP 24/NF 19 [United States
Pharmacopeial Convention, 1999].  The dissolution profiles of the uncoated and
coated beads were determined using USP Apparatus 2 (paddle) (Vankel VK 6010
and Vanderkamp VK 650 A with an autosampling unit, Vankel VK 800) operated
at 50 rpm in 900 ml pH 3.0±0.05 phosphate buffer for the first 3.5 hours, followed
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by the addition of 5.3 M sodium hydroxide to adjust to a pH of 7.4±0.05 at
37±0.5˚C for the remaining 6.5 hours.  Dissolution samples of 4 ml were collected
at 1, 3.5, 5, 7, and 10 hours.  For actual drug content in each vessel, the last
dissolution sample was collected after vigorously stir with a medium shear mixer
(Polytron Silverson type mixer) at a middle speed for 30 seconds.  Each sample
was filtered through a 10 µm filter prior to analysis.
Ultraviolet Spectroscopy
Drug assay was conducted using an ultraviolet spectrophotometer at a
wavelength of 262 nm for CPM quantitation and at a wavelength of 272-274 nm
for theophylline quantitation (Hewlett Packard Diode Array Spectrophotometer,
Model 8452A, with 1-cm quartz cell).
For standard curve preparation of CPM, about 0.1 g of CPM powder was
weighed into a 100 ml-volumetric flask.  About 80 ml of purified water was
added to dissolve the drug.  The stock solution was sonicated for 5 minutes to
ensure complete dissolution of all drug particles before adjusting to a final volume
with purified water.  Final concentration of stock solution was about 1 mg/ml.
The stock solution was then diluted with purified water to concentrations in the
range of 0.02–0.09 mg/ml.
For standard curve preparation of theophylline, about 0.05 g of
theophylline powder was weighed into two 100 ml-volumetric flasks.  Two
standard curves of theophylline were prepared for quantitaion of drug in acidic
medium (buffer pH 3.0±0.05) and in basic medium (buffer pH 7.4±0.05).  About
80 ml of an appropriate diluent (dissolution medium) was added to dissolve the
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drug.  Each stock solution was sonicated for 15 minutes to ensure complete
dissolution of all drug particles before adjusting to a final volume with an
appropriate diluent.  Final concentration of each stock solution was about 0.5
mg/ml.  Each stock solution was then diluted with its diluent to concentrations in
the range of 0.005–0.02 mg/ml.
For both drug substances, each calibration curve was prepared by plotting
the absorbance values of each standard against the concentration of each standard.
Finally, the quantity of drug was calculated from the regression equation of the
calibration curve.  Linear correlation over the concentration range prepared
should be close to 1 (r2 = 1).
For sample preparation, an appropriate dilution of each sample was made
with a diluent (dissolution medium) such that the final concentration was within
the linear portion of the standard curve for the drug prior to analysis.
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Scanning Electron Microscopy (SEM)
Scanning electron microscopy was used to examine the surface
morphology of the beads.  Beads were mounted on brass SEM stages using 3M
double sided tape and were then coated with gold-palladium for 60 seconds under
an argon atmosphere using a Pelco® Model 3 Sputter Coater (TED Pella, Inc.,
Tusin, CA, USA) in a high vacuum evaporator equipped with an omni-rotary
stage.  Samples were examined with a Jeol scanning electron microscope (Model
JSM-35C, Jeol USA, Inc., Peabody, MA, USA) or Hitachi S-4500 field emission
scanning electron microscope (Hitachi Instruments Inc., Irvine, CA, USA) at 4.0
kV.  The scanning electron micrographs were taken by a Polaroid® 545 Land




3.1 SINGLE UNIT SYSTEM (MATRIX TABLETS)
3.1.1 Preformulation Studies for ALP
Determination of ALP Solubility
Drug solubility, especially for poorly water soluble or insoluble drugs,
such as ALP, is an important factor during formulation studies.  Solubility studies
of ALP in different media were performed by shaking the vials containing an
excess amount of ALP in different media at 37±0.5˚C.  The amount of ALP in
each medium after equilibrating for 1 or 2 days was determined by UV
spectrophotometry.  As shown in Table 3.1 for the comparison of solubility
results from day 1 and day 2, the solubility values of ALP from both days in each
medium are not significantly different, indicating equilibrium saturated solubility
condition.  An approximate aqueous solubility of ALP at 37±0.5˚C was 44 µg/ml
(1 part of ALP per 22727 parts of water), indicating water-insoluble drug [United
States Pharmacopeial Convention, 1999].  ALP is more soluble in acidic media
with an apparent pKa value close to 3.50 [Laihanen et al., 1996a].  The solubility
of ALP is also pH dependent.  As can be seen from Table 3.1, ALP has a higher
solubility in an acidic pH solution (i.e. about 14 mg/ml in 0.1 N HCl solution,
about 21 mg/ml in 0.05 M H2SO4) than in a basic pH solution or alkaline media
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(i.e. about 40 µg/ml in buffer pH 5.0, 6.8, and 8.0 (SIF)).  Similarly, solubility
results determined at 25±1˚C of different crystal modifications at pH 1.6 and pH
5.0 were 8-10 mg/ml and 0.1 mg/ml, respectively [Laihanen et al., 1996a].
During dissolution studies conducted on the dosage forms, sink conditions
are an important experimental parameter that must be controlled.  Sink conditions
are approximated when the saturation volume is five to ten times higher than the
test volume.  Therefore, the saturated drug solubility (Csat) is much higher than
drug concentration in the medium at any given time (Csol), Csat >> Csol.  For low
solubility drugs, a specified dosage level may be close to the saturation point in
the dissolution medium such that the sink conditions cannot be attained.
Therefore, accurate dissolution profiles are difficult to obtain [Hanson, 1990].  In
this research study, dissolution studies of ALP tablets were carried out in 0.1 N
HCl solution (pH 1.1), where ALP has a higher solubility and the sink conditions
for ALP release occur.  In contrast, dissolution of ALP in purified water or
alkaline media did not occur under sink conditions due to its low solubility.
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Table 3.1 ALP Solubility at 37±0.5˚C
Solubility of ALP (mg/ml)Medium
Day 1 Day 2
Purified water 0.044 0.045
0.05 M H2SO4 20.641 21.547
0.1 N HCl Solution (pH 1.1) 14.544 14.038
Buffer pH 1.2 (SGF) 12.227 11.141
USP buffer pH 2.0 1.968 2.191
Buffer pH 5.0 0.042 0.038
Buffer pH 6.8 (SIF) 0.045 0.041
USP buffer pH 8.0 0.038 0.045
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Thermal Analysis
The DSC results presented in Figure 3.1 demonstrated a sharp
endothermic peak for ALP at 232-233˚C, which corresponded to its melting point.
The melting point reported for ALP is 228-229˚C [Budavari et al., 1996].  This
also indicated the crystalline nature of the drug.  In addition, no peaks were found
during repeated heating and cooling processes (except the peak during the first
heating cycle, which corresponded to the melting point) indicating an irreversible
melting process and that the drug has not undergone a recrystallization process
(Figure 3.2).
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Figure 3.1 Endothermic peak of ALP during the melting process
Figure 3.2 Thermographic pattern of ALP during the heating and cooling
processes
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Particle Size and Particle Size Distribution Study (Laser Light Scattering)
Figure 3.3 shows particle size distribution curves plotted between percent
cumulative undersized and the particle size of ALP in microns (µm).  Average
particle size (cumulative 50 percent undersized) of ALP is in the range of 8-9 µm.
Scanning Electron Microscopy (SEM)
A SEM technique was used to examine qualitatively the particle size as
well as the surface morphology and crystal shape of the drug particles.  SEM
micrographs of ALP powder in Figure 3.4 shows an irregular crystalline structure.
The average particle size was in the range of 2-5 µm, which is slightly smaller
than the average particle size determined by the laser light scattering technique.
Additionally, ALP particles tended to be agglomerated.
Powder X-ray Diffractometry
Figure 3.5 shows the plot of number of counts plotted on the y-axis versus
the 2-theta range of 5° to 50° plotted on the x-axis.  X-ray powder diffraction
patterns of both ALP samples displayed multiple peaks.  This indicated the
crystalline characteristics of the drug, similar to the previous results obtained from
DSC and SEM.
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Figure 3.4 Scanning electron micrographs of ALP powder
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Figure 3.5 X-ray diffractometry pattern of ALP powder







The UV spectroscopic method for the quantitation of ALP in each solvent
used during the solubility study and the amount of drug released from a matrix
tablet into a dissolution medium during the dissolution study was modified from
the method described in the literature [Acikkol et al., 1991].  For the
determination of ALP dissolved in each medium during the solubility study, 0.05
M H2SO4 was used as a diluent for standard curve preparation.  For the
determination of ALP in each dissolution sample, 0.1 N HCl solution was used as
a diluent for standard curve preparation.  The maximum wavelength of ALP in
each diluent was determined to be 264 nm, where ALP had maximum absorbance.
Typical UV standard curves in the range of 0.001-0.020 mg/ml of ALP are shown
in Figure 3.6.  The linearity of the standard curve was excellent with a correlation
coefficient (r2) of 0.999.  The precision of the UV method was determined by
measuring the absorbance of the same working standard in replicates of five,
which had an RSD of less than 1%.
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Figure 3.6 Typical UV standard curves of ALP in each diluent: a) 0.05 M
H2SO4 solution; b) 0.1 N HCl solution.
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A reverse-phase HPLC method was developed for quantification of the
highly lipophilic model drug substance, ALP, contained in matrix tablet
formulations.  System suitability was performed according to generally accepted
laboratory practices to ensure that the HPLC system and recovery procedure were
capable of providing accurate and precise data [Synder et al., 1997].  The
wavelength of 222 nm was selected because ALP had a maximum absorbance at
this level.  No interference between any of the components of the powder blend
and ALP were found at this wavelength.  A typical HPLC chromatogram is shown
in Figure 3.7.  The number of theoretical plates (N) was about 3,000
plates/column and the peak asymmetry was approximately 1.1.  The retention
time of ALP was about 4.2 minutes.  The sample diluent (50 %ACN in water) and
sample placebo blend showed no interferences in the region of interest, and
excellent method specificity was demonstrated.  The linearity of the calibration
curve in the range of 0.005-0.060 mg/ml was excellent with a correlation
coefficient (r2) of 0.999.  The precision of the chromatographic method was
determined by making five replicate injections of a working standard solution.
The precision was excellent as indicated by the low magnitude of the RSD
(0.9%).  Therefore, the system suitability specifications were met.
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3.1.2 Drug Recovery from Hydrophilic Matrix Tablets [Williams III et al.,
2001]
Sample Preparation Methods
Different solvents and sample preparation methods were investigated in
order to recover the lipophilic drug, ALP, from pulverized HPMC matrix tablets
or matrix powder blends.  Two studies were conducted in order to determine the
percent drug recovery from the same powder blend formulation (Tables 2.1 and
2.2).  The first study was focused on finding an extraction solvent, which would
dissolve ALP and not dissolve the hydrophilic HPMC polymer.  Acetonitrile was
selected as an extraction solvent in sample preparation method I because it has a
high solubilizing power for ALP, it is a component of the mobile phase, and it is a
poor solvent for HPMC as determined in the study.  Sample preparation method II
was focused on finding a cosolvent system, which would dissolve both ALP and
HPMC polymer.  Acetonitrile was the solvent selected to dissolve ALP, whereas
water was selected as the solvent to dissolve HPMC polymer.
Sample Preparation Method I
Using ACN alone as the extraction solvent, samples A and B were
prepared using the same sample preparation method, but differing in the method
of incorporating ALP.  For sample A, ALP was dissolved in ACN and then added
as a solution, whereas ALP powder was used in sample B. The percent recoveries
of ALP from samples A and B were 100.54±1.83% and 86.81±2.45%,
respectively (Table 3.2).  Similar to sample B, drug recoveries from samples C
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and D using ALP powder and different orders of addition were low, 95.11±1 80%
and 91.59±2.38%, respectively (Table 3.2).  This was because the gelation rate of
the HPMC polymer was faster than the dissolution rate of ALP powder in the
extraction solvent, ACN.  HPMC was poorly soluble in ACN, but gelled upon
exposure to ACN.  Therefore, drug was entrapped within the swelling gel layers
of HPMC polymer before it could be completely dissolved.  Also, ACN, at
temperatures of –20˚C to 5˚C, was used as the extraction solvent for samples E-J
(Table 2.1).  These methods were performed in order to minimize the solubility of
HPMC in ACN at the low temperatures and increase drug recovery.  Drug
recoveries from samples prepared from ALP powder were significantly low (p <
0.05; except for sample I), and ranged from 90–96% (Table 3.2), regardless of the
sample preparation method used and the order of addition of drug and placebo
powder blend containing HPMC (samples E, F, G, H, and J, Table 2.1).
However, sample I prepared from the ALP stock solution using cold ACN at -
10˚C as a solvent was 99.10±1.53%, which was similar to the recovery found for
sample A using ACN at 22˚C as a solvent (Tables 2.1 and 3.2).  Therefore, the
solvent temperature did not improve the recovery of ALP.  Some drug particles
were entrapped within the gel layers of HPMC before complete dissolution in the
extraction solvent.  The results indicated that it is necessary to dissolve HPMC
prior to dissolving the drug substance in order to prevent entrapment of drug
particles and incomplete dissolution as the HPMC swells and gels upon contact
with ACN.  Therefore, sample preparation method II was investigated to identify
a cosolvent system capable of dissolving both drug and polymer.
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Sample Preparation Method II
In sample preparation method II, ACN was used as the extraction solvent
for ALP, and water was used as the solvent for HPMC.  Water was a poor solvent
for ALP because the aqueous equilibrium solubility at 37˚C was 44 µg/ml (1 part
of ALP per 22727 parts of water) as determined in the preformulation section
3.1.1.  Therefore, stronger solvents were still necessary to enhance the dissolution
of ALP.  Recovery of ALP from sample K that was prepared by swelling HPMC
in hot water (~ 90˚C) and dissolving HPMC in cold water (~ 5˚C) prior to
extraction of the drug in ACN at 22˚C was 100.52±2.41%, even though drug
powder was used in the preparation (Table 3.2).  Once the HPMC polymer was
completely dissolved in the aqueous solution, its gelling and hydrating properties
did not influence drug dissolution.  This method was shown to achieve complete
recovery of ALP from matrix placebo blends.  This method was employed for
investigating formulation compositions (samples K, L, M, N, O, and P) as
discussed in the following section.
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Sample Preparation Method I: Acetonitrile Alone
A
(K4MP)
0.02000 0.02011 100.54 ± 1.83
B
(K4MP)
0.04960 0.04306 86.81 ± 2.45
C
(K4MP)
0.05040 0.04793 95.11 ± 1.80
D
(K4MP)
0.04970 0.04552 91.59 ± 2.38
E
(K4MP)
0.05200 0.04997 96.09 ± 1.49
F
(K4MP)
0.05260 0.05036 95.74 ± 1.08
G
(K4MP)
0.05040 0.04835 95.94 ± 1.55
H
(K4MP)
0.05550 0.05272 94.99 ± 2.34
I
(K4MP)
0.04000 0.03964 99.10 ± 1.53
J
(K4MP)
0.05450 0.04939 90.62 ± 1.13
Sample Preparation Method II: Acetonitrile/Water
K
(K4MP)
0.05030 0.05056 100.52 ± 2.41
L
(K100LVP)
0.05010 0.05090 101.60 ± 1.59
140
Influence of molecular weight type (viscosity grade) of HPMC on ALP recovery
Table 3.2 shows the percent ALP recoveries from samples K and L
prepared from placebo blends containing different grades of HPMC polymer
(100.52±2.41% and 101.60±1.59%, respectively).  Sample K contained high
molecular weight (high nominal viscosity) type of HPMC (Methocel K4MP, 4126
cPs apparent viscosity as a 2% aqueous solution) and sample L contained low
molecular weight (low nominal viscosity) type of HPMC (Methocel K100LVP,
107 cPs apparent viscosity as a 2% aqueous solution).  Both HPMC types possess
similar degree of methoxyl substitution (19-24% methoxyl), hydroxypropyl
substitution (7-12% hydroxypropoxyl), and similar gelation rates.  However, they
are different in terms of degree of polymerization resulting in different molecular
weight, which is reflected in the viscosity of an aqueous solution [The Dow
Chemical Company, 2000].  Although sample K contained HPMC with a
molecular weight or nominal viscosity about 40 times greater than sample L, the
percent drug recoveries were similar at about 100% using sample preparation
method II.  This indicated that the molecular weight type or nominal viscosity of
the polymer did not influence the dissolution of the lipophilic drug using sample
preparation method II because HPMC was completely dissolved before ALP.
Influence of excipient type on ALP recovery
The results shown in Table 3.3 describe the influence of excipient type on
the recovery of ALP from matrix powder blends using sample preparation method
II.  The percent recovery of ALP from samples containing water-soluble
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excipients, sucrose and dextrose, was 100.26±1.92% and 97.60±0.79%,
respectively.  Similar results were obtained for samples containing water
insoluble excipients, dicalcium phosphate anhydrous and calcium sulfate
dihydrate (98.90±1.36% and 102.68±2.03%, respectively).  The chromatogram
shown in Figure 3.7 is characteristic of the chromatogram obtained for each of the
investigated excipients.  The results indicated that the excipients comprising the
matrix tablet formulations did not influence the recovery of ALP.
Sample preparation method II allowed for complete recovery of ALP from
matrix powder blends containing HPMC and different types of tableting
excipients.
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Table 3.3 ALP Recovery from Powder Blends Containing Different Types of











M Sucrose 0.05070 0.05083 100.26 ± 1.92








0.05020 0.05155 102.68 ± 2.03
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Determination of drug content in a matrix tablet
Sample preparation method II was used to determine the content
uniformity and composite assay of two lots of tablets.  Two tablet formulations
containing different grades of HPMC (K4MP or K100LVP) and lactose
monohydrate as the excipient (Table 2.3) were tested.  For content uniformity
results of each tablet formulation, the mean ALP level of 10 tablets for
formulation Q (K4MP) and formulation R (K100LVP) was 101.90±3.41% (3.35
%RSD) and 98.80±2.16% (2.18 %RSD) of label claim.  For both formulations,
the ALP content in each tablet was uniform as indicated by the low magnitude of
the RSD.  The results obtained for the composite assay of 10 tablets from
formulations Q and R were 99.35±2.06% and 97.98±1.92%, respectively.
Therefore, the results from the drug content uniformity indicated that sample
preparation method II achieved complete recovery of ALP from the tablets.
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3.1.3 Investigation of Formulation Parameters on Drug Release
The main goal for this formulation study was to develop two oral
controlled release formulations of matrix tablets, which were equivalent in their in
vitro dissolution profiles.  These formulations were intended for in vivo clinical
studies.
Screening Study
A screening study was carried out in order to optimize the basic
formulation parameters and obtain matrix tablets that could sustain the release of
ALP between 14 and 16 hours.  The basic formulation parameters including tablet
size, drug loading, and polymer level were optimized.  General formulation
compositions and levels are shown in Table 2.4.  In vitro  dissolution studies and
similarity factor assessments were used as tools during formulation development.
Tablet Size
Two different tooling diameters with the same concave shape were used to
prepare matrix tablets using the same blend formulation.  Tablets with 8-mm
diameter had a smaller surface area when compared to tablets with 9-mm
diameter.  As can be seen from Figure 3.8, the larger diameter tablet (larger
surface area) had a lower degree of drug release at each time-point.  This is due to
the hydrated gel layer of the larger diameter tablet, which has a larger surface area
to sustain the release of the drug.  In addition, drug release from the larger tablet
is extended beyond 8 hours and prolonged to more than 12 hours, whereas the
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drug release from the smaller diameter tablet approaches 100% at 7 hours.  The
dissolution profiles shown in Figure 3.8 display an average difference greater than
20% (f2 = 31).  Similar results are shown in Figure 3.9 for another formulation
containing MCC.  The dissolution profiles in Figure 3.9 also display an average
difference greater than 20% (f2 = 27).  Different excipients in each formulation
(MCC or LAC) did not have an impact on the drug release.  However, both
formulations required a large amount of the very fine powder of HPMC K4MP
(65 %w/w) in order to achieve sustained release.  This high amount of HPMC
K4MP has limited flow properties during the direct compression process for tablet
manufacturing.  Therefore, tablet size or tooling diameter was increased to 11 mm
and the HPMC level was reduced in the following studies in order to optimize
between the flowability of the formulation and the sustained release profiles.
Figure 3.10 shows the sustained release profile obtained from 11-mm diameter
tablets.  Even though the amount of HPMC K4MP in the formulation was only 37
%w/w, drug release was delayed up to 12 hours.  Therefore, tablet size can
influence both amount and extent of drug release from a matrix tablet as well as
the amount of HPMC necessary in the formulation to maintain a sustained release
profile.  Generally, a high level of HPMC is necessary for smaller tablets to obtain
a desirable sustained release profile.  When tablet size is increased, resulting in an
increased surface area for drug release, the amount of drug release is slower due
to the change in the surface area and the amount of initial gel formation.
Additionally, when the tablet size was increased, the amount of HPMC necessary
for sustaining the drug release could be significantly reduced.  Flowability of the
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blend can also be improved by decreased amounts of fine particle HPMC and
increased amounts of flowable excipients to replace a portion of HPMC, such as
spray-dried lactose or other directly compressible fillers [Alderman, 1984].
However, opposite results were r ported for promethazine HCl matrix
tablets containing 25 mg of drug, 120 mg of HPMC K15M and 0.75% of
magnesium stearate.  Tablets were compressed to the same weight, same
formulation and same flat-faced shape, but differed in tablet size or diameter.
When tablet diameter was increased from 0.25 to 0.375 or 0.5 inches, resulting in
an increased tablet surface area, the square root of time release rate was increased
from 4.13 to 4.61 or 5.99% min-1/2, respectively [Ford et al., 1987].  These
different results may be due to differences between the active drugs used in the
hydrophilic matrix systems such as their aqueous solubility and release
mechanism.
From results previously described, an 11-mm concave tooling was
selected for use throughout the formulation development.  The target tablet weight
was 400 mg.
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Figure 3.8 Effect of tablet size on ALP release from a matrix tablet (2.08 %w/w
ALP, 65 %w/w, HPMC K4MP, 0.5 %w/w Mg stearate, lactose qs.)
Figure 3.9 Effect of tablet size on ALP release from a matrix tablet (2.08 %w/w
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Figure 3.10 Drug release profile of ALP matrix tablet (2.5 %w/w ALP, 37 %w/w
HPMC K4MP, 20 %w/w MCC, 0.5 %w/w Mg stearate, 0.5 %w/w
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Drug Loading
For multiple dosing of ALP tablets, the commercial product, Xanax
(Pharmacia & Upjohn Company, Kalamazoo, MI), is available in 0.25, 0.5, 1, 2,
and 4 mg strengths.  In order to prepare a sustained release product with a 14 to
16 hour release period, a higher dose of ALP was loaded into a single matrix
tablet.  The maximum recommended daily human dose of ALP is 10 mg
[Pharmacia & Upjohn Company, 2000].  Therefore, two levels of ALP (i.e. 5 or
10 mg) were loaded into each tablet intended for a single daily dose.  However,
either 5 or 10 mg ALP was only 1.25 or 2.50 %w/w, respectively, when compared
to a total tablet weight of 400 mg.  Content uniformity of each tablet prepared by
direct compression was such a challenge.  If the active drug, ALP, was not
distributed evenly between tablets, it may potentially cause adverse reactions or
overdose symptoms in patients.  In this study, the blending method to achieve
good content uniformity was also developed and described in a following section.
In this section, the effect of different drug loadings on the amount of drug
release was evaluated.  As can be seen from Figures 3.11 and 3.12, the amount of
drug loading has no effect on the release of ALP from a matrix tablet.
Specifically, dissolution profiles obtained from tablets containing HPMC K4MP
and either 5 or 10 mg drug loading were similar with a similarity factor of 90
(only 2% average difference, Figure 3.11).  This may due to both levels of drug
loading were extremely low (1.25 or 2.50 %w/w), when compared to a total tablet
weight of 400 mg.  Similarly, dissolution profiles obtained from tablets containing
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HPMC K100LVP and either 5 or 10 mg drug loading were similar with a
similarity factor of 71 (5% average difference, Figure 3.12). Dose dumping was
not observed from tablets containing either 5 or 10 mg ALP.  Therefore, a higher
drug loading of 10 mg was used during formulation development because
uniformity of the dosage form would be more feasible.
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Figure 3.11 Influence of drug loading on drug release from matrix tablets
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Figure 3.12 Influence of drug loading on drug release from matrix tablets (40
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Polymer Level
Figure 3.13 shows the influence of HPMC polymer level on the ALP
release from matrix tablets.  As described in several studies, polymer
concentration is the most important factor to control drug release from a matrix
tablet.  When the polymer level in the formulation increases, the amount and
extent of drug release will be decreased [Ford, 1985a; Ford, 1985b; Shah et al.,
1993; Xu and Sunada, 1995; Velasco et al., 1999; Helena Amaral et al., 2001].
This is due to an increase in polymer concentration resulting in an increased
viscosity of the gel as well as the formation of a gel layer with a longer diffusional
path.  As a result, a decrease in the effective diffusion coefficient of the drug and
a reduction in the drug release rate were obtained [Velasco et al., 1999].
When comparing dissolution profiles in Figure 3.13, the formulation
containing 33 %w/w of polymer was 5% and 15% average difference from the
formulations containing 35 %w/w (f2 = 67) and 40 %w/w (f2 = 41) of polymer,
respectively.  About 10% average difference (f2 = 48) was found when comparing
formulations containing 35 and 40 %w/w of polymer.  Additionally, at least 30
%w/w of HPMC K4MP is necessary within the tablet formulation in order to
prepare product with at least 12-hour release.  However, excipients used in the
formulation, the HPMC molecular weight type, and other factors may have some
influence on the amount of drug release as described in the following sections.
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Figure 3.13 Influence of HPMC K4MP level on drug release from matrix tablet
(2.5 %w/w ALP, 20 %w/w MCC, 0.5 %w/w Mg stearate, 0.5 %w/w














The following study was carried out in order to investigate the influence of
excipient, polymer molecular weight type, and dissolution media on drug release.
These parameters were optimized in order to obtain matrix tablets that could
sustain the release of ALP between 14 and 16 hours.  In vitro  dissolution studies
and similarity factor assessments were used as tools during formulation
development.
Excipient Type [Williams III et al., 2001]
Physical Characterization of ALP Matrix Tablets
As seen in Table 2.5, each tablet formulation contained equivalent
amounts of ALP (10 mg/400 mg tablet), HPMC K4MP hydrophilic polymer (160
mg/tablet), MCC, silicon dioxide and magnesium stearate, and other excipient(s)
investigated (146 mg/tab).  The type of excipient (formulations A, E, F, G, H, I)
was varied from formulation-to-formulation.  Formulations A to E were prepared
using different levels of LAC and DCP.  Table 3.4 shows the physical
characterization of tablets from each formulation.  The percent weight variation of
tablets randomly sampled from each formulation was less than 2%, and tablet
hardness was in a narrow range of 6.80-8.10 kg.  Tablet potency determined from


























































































































































































































































































































































Figure 3.14 shows the dissolution profiles of tablet formulations A, F, and
G containing the water-soluble excipients (36.5 %w/w), LAC, SUC and DEX,
respectively.  A comparison of the similarity factor and percent average
difference, referring to the similarity between the formulations, is shown in Table
3.5.  The similarity factor (f2) is used to quantitate agreement between two
dissolution profiles.  If the f2 value is close to 100, the two profiles are nearly
identical.  In general, the FDA standard of f2 between 50-100 (≤ 10% average
difference) indicates similarity between two dissolution profiles [Shah et al.,
1998; Shah et al., 1999; Moore and Flanner, 1996].  Dissolution profiles of
formulation A (LAC) and formulation F (SUC) showed only a 2% difference (f2 =
88).  Although the release of ALP from tablets containing DEX (formulation G)
was slightly faster than that from tablets containing SUC (formulation F) or LAC
(formulation A), the dissolution profile of tablets containing DEX (formulation G)
was similar to those of LAC (formulation A) and SUC (formulation F), having a
f2 value of 62 and 58 (10% difference), respectively (Table 3.5).  The amount of
drug release from formulations containing these soluble excipients reached 90%
within 12-14 hours.  Similar results from the previous study were reported for the
release of either slightly soluble theophylline (8.33 mg/ml in water) or soluble
naproxen sodium (196.7 mg/ml in water) from tablets containing LAC, SUC, or
DEX (50-65 %w/w).  In addition, no significant difference in those release
profiles was found for the tablets containing either HPMC K4M or HPMC E4M
[The Dow Chemical Company, 2000].  Despite the differences in drug solubility
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between ALP, theophylline and naproxen sodium, similar release profiles were
reported.  Similar release results obtained due to the relatively high amount of the
soluble excipient in these tablet formulations (36.5-65 %w/w) that led to the
formation of the hydrated gel layers with high drug permeability.
Drug release profiles of tablets containing the water insoluble excipient
(36.5 %w/w), DCP (formulation E), DCA (formulation H), and CSD (formulation
I) are shown in Figure 3.14.  The f2 values calculated for the formulations
containing insoluble excipients (E vs. H, H vs. I, and E vs. I) also showed a 5-
10% average difference (Table 3.5).  The amount of drug release from those
formulations was only 75-85% within 12-14 hours and the release extended
beyond 16 hours.
Figure 3.14 also shows the release profiles from formulations containing
the soluble excipients, LAC (formulation A), and DEX (formulation G),
compared to those from formulations containing insoluble excipients, DCP
(formulation E), DCA (formulation H), and CSD (formulation I).  The percent
average difference, based on f2 values, between dissolution profiles of
formulations containing a soluble excipient compared to formulations containing
an insoluble excipient was in the range of 15-20%, indicating dissimilarities in the
profiles (Table 3.5).  The formulations containing insoluble excipients, especially
the DCP formulation, released the active drug at a slower rate and to a lesser
extent than those containing a soluble excipient.  The hydrated gel layer was more
permeable for drug release when a soluble excipient was contained in the
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formulation [The Dow Chemical Company, 2000; Hirschorn and Kornblum,
1971].
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Figure 3.14 Comparison of dissolution profiles of ALP matrix tablet
















Table 3.5 Summary of f2 Similarity Factor Comparison of the Tablet
Formulations Investigated
ComparisonNumber
Reference formulation Test formulation
f2 % Average
difference1
1 A (LAC:DCP, 100:0) B (LAC:DCP, 75:25) 67 5
2 A (LAC:DCP, 100:0) C (LAC:DCP, 50:50) 71 5
3 A (LAC:DCP, 100:0) D (LAC:DCP, 25:75) 70 5
4 A (LAC:DCP, 100:0) E (LAC:DCP, 0:100) 44 15
5 A (LAC:DCP, 100:0) F (SUC) 88 2
6 A (LAC:DCP, 100:0) G (DEX) 62 10
7 A (LAC:DCP, 100:0) H (DCA) 54 10
8 A (LAC:DCP, 100:0) I (CSD) 54 10
9 B (LAC:DCP, 75:25) C (LAC:DCP, 50:50) 57 10
10 B (LAC:DCP, 75:25) D (LAC:DCP, 25:75) 58 10
11 B (LAC:DCP, 75:25) E (LAC:DCP, 0:100) 38 20
12 B (LAC:DCP, 75:25) F (SUC) 63 10
13 B (LAC:DCP, 75:25) G (DEX) 76 5
14 B (LAC:DCP, 75:25) H (DCA) 45 15
15 B (LAC:DCP, 75:25) I (CSD) 46 15
16 C (LAC:DCP, 50:50) D (LAC:DCP, 25:75) 94 2
17 C (LAC:DCP, 50:50) E (LAC:DCP, 0:100) 48 15
18 C (LAC:DCP, 50:50) F (SUC) 79 5
19 C (LAC:DCP, 50:50) G (DEX) 52 10
20 C (LAC:DCP, 50:50) H (DCA) 61 10
21 C (LAC:DCP, 50:50) I (CSD) 59 10
22 D (LAC:DCP, 25:75) E (LAC:DCP, 0:100) 47 15
23 D (LAC:DCP, 25:75) F (SUC) 78 5
24 D (LAC:DCP, 25:75) G (DEX) 52 10
25 D (LAC:DCP, 25:75) H (DCA) 60 10
26 D (LAC:DCP, 25:75) I (CSD) 58 10
27 E (LAC:DCP, 0:100) F (SUC) 46 15
28 E (LAC:DCP, 0:100) G (DEX) 36 20
29 E (LAC:DCP, 0:100) H (DCA) 63 10
30 E (LAC:DCP, 0:100) I (CSD) 66 5
31 F (SUC) G (DEX) 58 10
32 F (SUC) H (DCA) 57 10
33 F (SUC) I (CSD) 56 10
34 G (DEX) H (DCA) 43 15
35 G (DEX) I (CSD) 43 15
36 H (DCA) I (CSD) 82 5
Note: 1 % Average difference refers to the similarity between the test formulation to the reference formulation with
an average difference of specified percentage based on the criteria (the average differences of 2%, 5%, 10%,
15%, and 20% correspond to f2 limit of 83, 65, 50, 41, 35, respectively).
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The use of LAC and DCP in the tablet formulation produced drug release
profiles of intermediate duration (Figure 3.15).  There were slight differences in
release profiles for formulations containing LAC at levels of 100%, 75%, 50%,
and 25% of the excipient investigated (36.5 %w/w of the total formulation;
formulations A, B, C, and D, respectively).  In terms of f2 value, formulations
containing LAC at levels greater than 25% of 36.5 %w/w excipient (formulations
A, B, C, and D) were similar (5% average difference between the two profiles
comparison).  The release profile from tablet formulations containing no LAC
(formulation E) was different from those containing LAC (formulations A, B, C,
and D), with an f2 indicating a 15-20% average difference.  As can been seen in
Figure 3.15, the LAC level was less important compared to whether or not LAC
was used in the formulation.  Only when the DCP level was sufficiently high
(36.5 %w/w) in the tablet formulations (formulation E) was the release rate and
extent decreased.  This was due to the incorporation of LAC, which increased the
interspace volume and porosity of the matrix and resulted in faster diffusion of
drug from the matrix, and an increased rate of erosion of the matrix tablet [The
Dow Chemical Company, 2000; Tahara et al., 1995].
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Figure 3.15 Dissolution profiles of ALP matrix tablet formulations containing
binary mixtures of water-soluble lactose (LAC) and water-insoluble















Mathematical Modeling of Drug Release Profiles
The most common approach to determine the drug release mechanism of
matrix tablets is to fit the well-known equations of Hixson-Crowell [Hixson and
Crowell, 1931] and Peppas [Peppas, 1985; Peppas and Ritger, 1987a; Peppas and
Ritger, 1987b].  Different mathematical models of ALP release from a tablet are
proposed in order to describe the release mechanism based on the release data
obtained from the formulations investigated.
•  Hixson-Crowell cube root kinetics equation
In the case of dissolution of a drug with poor aqueous solubility like ALP,
dissolution occurs mainly after the erosion process resulting in release of drug
particles from the matrix tablet, as represented by the Hixson-Crowell cube root
kinetics equation [Tahara et al., 1995; Hixson and Crowell, 1931] illustrated in
Equation 1,
where Wd is dry weight of tablet at the designated time after immersion in
the medium, Wi is the initial dry weight of tablet, t is time, and k1 is the erosion
rate constant for the tablet.  From Equation 1, when drug dissolution from
particles is considerably slower than tablet erosion, dissolution profiles of the
drug (Qd) is more accurately represented by Equation 2,















where Qd is amount of drug dissolved at time t, A is the total amount of
drug present in the matrix, t is time, and k2 is the apparent rate constant for the
drug dissolution.  When Equation 2 was plotted for each formulation, as shown in
Figure 3.16, a linear relationship was obtained from each formulation indicating
that the dissolution of ALP occurred predominantly after release of the solid drug
particles from the tablets, regardless of the excipient type used in the tablets.
Table 3.6 shows the linear regression results of fitting the drug release data from
each formulation to the Hixson-Crowell cube root kinetics equation (Equation 2).
The linear regression coefficient (r2) of all formulations investigated ranged from
0.994 to 0.999 and indicated best fit of the release data according to the Hixson-
Crowell cube root kinetics equation (Equation 2).  The apparent rate constant for
ALP dissolution (k2) ranged from 0.030 to 0.052 hr
-1.  This indicated the
difference in dissolution rate of ALP from tablets containing different types of
excipient.  The rate of ALP dissolution from tablets containing water-soluble
excipient (LAC (formulation A-D), SUC (formulation F), DEX (formulation G);
0.038-0.052 hr-1), was faster than the dissolution rate of ALP from tablets
containing water-insoluble excipient (DCP (formulation E), DCA (formulation
H), CSD (formulation I); 0.030-0.034 hr-1).  The hydrated gel layers were more
permeable for ALP release when the tablets contained soluble excipients,
resulting in faster rates of dissolution.  Tahara et al. reported similar results for the

















release of poorly water soluble drug, U-78875 (0.08 mg/ml in pH 6.8 medium),
from a tablet containing a different substitution type of HPMC (HPMC 2910, 50
cPs) and lactose [Tahara et al., 1995].  This indicated that drug release mechanism
depends primarily on drug solubility, regardless of the HPMC substitution type or
excipient type used in the tablets.  From the dissolution release rate constants (k2)
obtained from the slope of the plots in Table 3.6, tablets containing soluble
excipients, such as LAC, SUC or DEX (formulations A, B, C, D, F, and G) had
faster release rates when compared to the release rates of tablets containing
insoluble excipients, such as DCP, DCA or CSD (formulations E, H, and I).
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Figure 3.16 Plot of ALP released as a function of time according to Hixson-
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Table 3.6 Results of Linear Regression for ALP Release Fitted to Hixson-




A 0.038 0.994 0.947
B 0.052 0.995 0.982
C 0.042 0.999 0.981
D 0.044 0.997 0.986
E 0.030 0.995 0.979
F 0.040 0.998 0.959
G 0.046 0.997 0.945
H 0.034 0.998 0.973
I 0.031 0.995 0.960
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Peppas’ equation
Peppas' transport equation has been developed to allow for the influences
of hydration and swelling on drug release.  Based on Peppas’equation, Korsmeyer
et al. derived a simple relationship, which may be used to describe drug release
from polymeric systems in which release deviates from Fickian diffusion as
expressed in Equation 3 [Peppas, 1985; Peppas and Ritger, 1987a; Peppas and
Ritger, 1987b; Korsemeyer et al., 1983].  Equation 4 was used to investigate the
ALP release kinetics from tablet formulations containing different types of
excipients:
where Mt/ M∞ is the fraction of drug release, t is the release time, k is a
constant incorporating structural and geometric characteristics of the controlled
release device, and n is the diffusional release exponent indicative of the
mechanism of drug release for drug dissolution.  To characterize the release
mechanism, the dissolution data (Mt/ ∞ < 0.6, first 4-6 hours of release) were
evaluated according to Equation 4 [Peppas, 1985; Peppas and Ritger, 1987a;
Peppas and Ritger, 1987b; Korsemeyer et al., 1983].  Figure 3.17 shows a plot of
the log fraction of drug dissolved as a function of time for each formulation.  The
linear regression results are given in Table 3.7.  The linear regression coefficient
(r2) of all formulations investigated ranged from 0.986 to 0.999 and indicated best















fit of the release data according to Equation 4.  According to Peppas and
Korsmeyer [Peppas, 1985; Peppas and Ritger, 1987a; Peppas and Ritger, 1987b;
Korsemeyer et al., 1983], the value of the diffusional exponent, n, determined
from the slope of all formulations containing different types of excipients ranged
from 0.67 to 0.85, indicating a non-Fickian (anomalous) release behavior of ALP
from the matrix tablet controlled by a combination of diffusion and
macromolecular chain relaxation mechanisms.  The slight difference in the
diffusional release exponent value (n) may be due to the different types of
excipients used in the tablet formulations, however all n values indicated the same
type of release mechanism of ALP from the matrix tablet.  Skoug et al. reported
that the release of ALP from sustained release tablets (no formulation
compositions were described) demonstrated a significant increase in n from about
0.65 to 0.74 for tablets containing 0.5 mg and 3 mg of the active, respectively.
The mechanism of release for both 0.5 and 3 mg tablets was classified as
anomalous diffusion, similar to the results reported in this study [Skoug et al.,
1993].  Therefore, neither the amount of drug loading, nor the formulation
composition, had an influence on the ALP release mechanism for the formulations
investigated.  Additionally, similar release kinetics (n = 0.69) were obtained for
the release of the practically water insoluble drug, atenolol, from a matrix tablet
containing HPMC K100LV, HPMC K4M, lactose, povidone and magnesium
stearate [Eyjolfsson, 1999].  Therefore, differences in molecular weight
distribution of HPMC polymers, as well as excipient type and level used in the
tablet formulations, have less impact on the drug release mechanism.
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Figure 3.17 Plot of Fraction of ALP dissolved as a function of the logarithm of
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Table 3.7 Results of Linear Regression for ALP Release Fitted to Peppas’
Equation (Equation 4)
Formulation Slope, n r2 k
A 0.677 0.998 0.206
B 0.691 0.999 0.211
C 0.784 0.996 0.163
D 0.723 0.999 0.172
E 0.852 0.986 0.113
F 0.688 0.996 0.197
G 0.675 0.994 0.232
H 0.680 0.999 0.164
I 0.678 0.999 0.168
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HPMC Molecular Weight Type (Viscosity Grade)
During screening studies of ALP controlled release matrix tablets, the
influence of molecular weight type (viscosity grade) of HPMC polymer on the
amount of ALP release was investigated.  As shown in Figure 3.18, the amount of
ALP release from a tablet formulation containing a low molecular weight type
HPMC, HPMC-K100LVP, was faster than the amount of ALP release from a
similar tablet formulation containing a high molecular weight type HPMC,
HPMC-K4MP.  Additionally, the release of the drug from tablets containing
HPMC-K4MP was extended beyond 10 hours; whereas the release of the drug
from tablets containing HPMC-K100LVP approached 100% at 10 hours.  Both
release profiles are an approximate 15 %average difference with an f2 factor of 41.
Even though both HPMC types possess a similar degree of methoxyl substitution
and hydroxypropyl substitution and similar gelation rates, they are different in
terms of their degree of polymerization resulting in different molecular weights,
which is reflected in the viscosity of an aqueous solution.  Specifically, HPMC-
K4MP has a molecular weight or nominal viscosity about 40 times greater than
HPMC-K100LVP [The Dow Chemical Company, 2000].
Similar to ALP tablets investigated in this study, promethazine HCl tablets
containing a low viscosity grade polymer, HPMC-K100, had a faster dissolution
rate than tablets containing a higher viscosity grade polymers, such as HPMC-
K4M, HPMC-K15M, HPMC-K100M, at a constant HPMC:drug ratio.  However,
the high viscosity grade polymers, HPMC-K4M, HPMC-K15M, and HPMC-
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K100M, showed similar release rates despite the variation in their molecular size.
This may due to a higher apparent diffusion coefficient of HPMC-K100 to the
drug substance [Ford et al., 1985a; Ford et al., 1985b].  Even though both active
drugs, ALP and promethazine HCl, are different in terms of their aqueous
solubilities, the release patterns that resulted from different molecular weight
types of HPMC used in the tablets are similar.  Generally, tablets containing a low
molecular weight type HPMC have a faster drug release rate and a shorter release
period than tablets containing a high molecular weight type HPMC.
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Figure 3.18 Influence of HPMC molecular weight type (viscosity grade) on drug
release from matrix tablets (1.25 %w/w ALP, 40 %w/w HPMC, 20
%w/w MCC, 0.5 %w/w Mg stearate, 0.5 %w/w silicon dioxide,












From formulations previously shown in Table 2.6, the varying levels of
HPMC K4MP or HPMC K100LVP ranged from 30-45 %w/w were used to
develop and optimize the two controlled-release tablet formulations.  They had
similar in vitro dissolution profiles and were intended for an in vivo clinical study.
Finally, two tablet formulations containing different HPMC molecular
weight types (i.e. formulations K100LV-27 and K4M-42) were developed.  Tablet
size, shape and hardness were identical for both formulations.  The compositions
of each tablet formulation in %w/w and in 300-gram batch sizes (750 tablets) are
shown in Table 3.8.  Manufacturing procedures were previously described in
section 2.2.1.3 and Figure 2.1.  Following the successful pilot scale production of
a 300-gram batch size, the clinical batch using the same batch size for each tablet
formulation (i.e. formulation K4M-42-lot M0009 and formulation K100LV-27-lot
M0010) was prepared according to cGMP at the Veteran's Administration
Cooperative Studies Program, Clinical Research Pharmacy Coordinating Center,
Albuquerque, NM.  Both clinical batches were tested for initial product release
prior to conducting the in vivo clinical study.
As can be seen from Table 3.8, a higher amount of HPMC (45 %w/w) is
necessary for tablets containing low molecular weight type or low viscosity grade,
HPMC K100LVP, in order to obtain identical release profiles with tablets
containing high molecular weight type or high viscosity grade HPMC, HPMC
K4MP (37 %w/w).  Tablet release profiles are shown within the tablet
characterization section (Figure 3.19).
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Ingredient %w/w grams in 300 grams
Alprazolam
(10 mg/400 mg tablet), 99.7% potency
2.5075 7.5225
HPMC K100LVP 45.0000 135.0000
Microcrystalline cellulose (PH200) 20.0000 60.0000
Lactose, Fast-Flo 31.4925 94.4775
Silicon dioxide 0.5000 1.5000




Ingredient %w/w grams in 300 grams
Alprazolam
(10 mg/400 mg tablet), 99.7% potency
2.5075 7.5225
HPMC K4MP 37.0000 111.0000
Microcrystalline cellulose (PH200) 20.0000 60.0000
Lactose, Fast-Flo 39.4925 118.4775
Silicon dioxide 0.5000 1.5000
Mg stearate 0.5000 1.5000
Total 100.0000 300.0000
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Characterization of Matrix Tablets
Tablets from the two clinical batches containing different molecular
weight types of HPMC (formulations K100LV-27 and K4M-42) were
characterized in terms of weight and hardness variations, content uniformity,
batch composite, and in vitro dissolution.
Table 3.9 displays the physical characterization of tablets from each
clinical batch.  The percent weight variation of 20 tablets randomly sampled from
each batch was less than 1%, which indicated flowable properties of the powder
blend during the direct compression process.  The average tablet hardness was
6.46 kg for the K4M-42 formulation (lot M0009) and 6.13 for the K100LV-27
formulation (lot M0010).
Table 3.10 summarizes the initial product release results of tablets from
both tablet formulations prepared for the clinical study.  Tablet potency of each
formulation determined by the previously developed content uniformity assay of
10 tablets, was 101.67% (3.59 %RSD) and 94.82% (4.55 %RSD) of label claim
for the K4M-42 (lot M0009) and K100LV-27 (lot M0010) formulations,
respectively.  Both formulations prepared using the previously developed
blending method showed a uniformity of ALP content in each tablet as indicated
by the low magnitude of the RSD.
The extent of drug release in 0.1 N HCl solution (pH 1.1) from each tablet
formulation, at a specific time point, is shown in Table 3.10.  The release profiles
for both tablet formulations are shown in Figure 3.19.  The f2 factor calculation
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for the dissolution profile comparison of formulations K4M-42 (lot M0009) and
K100LV-27 (lot 0010) are shown in Table 3.11.  A high f2 factor of 91 (2
%average difference) was obtained, indicating that e two profiles were nearly
identical.  According to FDA guidelines for f2 factor previously described in
section 2.2.1.3, an f2 factor between 50-100 (≤ 10% average difference) indicates
similarity or equivalence between two dissolution profiles [FDA, 1995a; FDA,
1997a; Shah et al., 1998; Shah et al., 1999; Moore and Flanner, 1996].  Therefore,
the two clinical batches containing different molecular weight types of HPMC
polymer were in vitro equivalent.
After reviewing the initial release results of both clinical batches shown in
Table 3.10, all results were within the release specifications listed in section
2.2.1.3.
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Table 3.9 Summary of Tablet Weight and Hardness Variations of ALP Matrix
Tablet Formulations Containing Different Molecular Weight Type
HPMC
Formulation
Tablet No. Weight (mg) Hardness (kg) Weight (mg) Hardness (kg)
n=20 n=20 n=20 n=20
1 397 7.40 398 6.25
2 399 6.60 401 5.75
3 400 6.40 396 6.80
4 398 6.00 402 7.25
5 406 6.30 403 5.50
6 402 6.10 397 6.25
7 406 6.60 396 6.20
8 403 6.60 397 5.30
9 403 6.80 396 6.30
10 400 7.60 397 4.90
11 402 6.60 399 7.10
12 406 6.20 398 5.90
13 400 5.50 394 6.20
14 398 5.80 400 6.50
15 398 7.10 394 5.25
16 399 7.00 398 5.30
17 399 6.25 403 7.60
18 404 7.20 394 6.00
19 398 5.70 394 6.00
20 398 5.50 397 6.25
Average 400.80 6 .46 397.70 6 .13
S D 2 .98 0 .61 2 .89 0 .70
%RSD 0 .74 9 .37 0 .73 11 .42
K4M-42 (M0009) K100LV-27 (M0010)
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Table 3.10 Summary of Initial Product Release Results for the Clinical Study of
ALP Matrix Tablets Containing Different Molecular Weight Type
HPMC
Formulation K4M-42 K100LV-27
Clinical Lot No. M0009 M0010
Manufacturing date 6/6/00 6/7/00
HPMC Type K4MP K100LVP
HPMC Level 37 45
Hardness (kg) 6.46 6.13
Avr. Tablet Weight (mg) 400.80 397.70
% Wt variation 0.20 0.58
Tablet potency (% Label) 101.67 (3.59 %RSD) 94.82 (4.55 %RSD)
Dissolution Time (hr) % Released (± SD)
(Based on label claim)
0 0.00 ± 0.00 0.00 ± 0.00
1 24.81 ± 2.75 24.14 ± 2.11
2 38.22 ± 2.83 38.01 ± 3.64
4 58.03 ± 4.22 58.35 ± 5.94
6 72.47 ± 4.99 72.92 ± 4.09
8 82.93 ± 4.75 84.31 ± 3.40
10 91.42 ± 4.06 93.69 ± 3.60
12 97.06 ± 3.21 99.51 ± 2.74
14 102.06 ± 3.47 102.65 ± 1.54
16 102.78 ± 1.41 102.95 ± 2.05
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Figure 3.19 Similar release profiles (f2 factor = 91, 2 %average difference) of
ALP matrix tablets obtained from formulations containing different
HPMC levels and different molecular weight types of HPMC (2.5
%w/w ALP, 20 %w/w MCC, 0.5 %w/w Mg stearate, 0.5 %w/w
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K100LV-27 (45 %w/w HPMC K100LVP)
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Table 3.11 Similarity Factor (f2) for Dissolution Profile Comparison of
Formulations K4M-42 and K100LV-27
Reference batch: K100LV-27 (45 %w/w HPMC K100LVP, lot M0010)
Test batch: K4M-42 (37 %w/w HPMC K4MP, lot M0009)
Formula Time
(hr)






1 24.14 24.81 0.4426
2 38.01 38.22 0.0469
4 58.35 58.03 0.0992
6 72.92 72.47 0.2044
8 84.31 82.93 1.8985
10 93.69 91.42 5.1317
P (number of time points) 6
∑ (µti-µri )2 7.8232
[1+(1/P)x∑ (µti-µri )2]-1/2 0.6588
f2=50xlog{[1+(1/P)x∑ (µti-µri )2]-1/2}x100} 91*
Note: * The similarity between the test batch to the reference batch with an average difference of
2% based on the criteria [Shah et al., 1998].
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Dissolution Medium
Drug release analysis of ALP matrix tablets was carried out in 0.1 HCl
solution with an acidic pH of 1.1 at 37±0.5˚C such that sink conditions were met.
Drug solubility in this medium, as obtained from preformulation studies in section
3.1.1 was approximately 14 mg/ml (Csat).  The maximum drug concentrations
(Csol) in 900 ml dissolution medium were 0.0056 mg/ml and 0.0111 mg/ml for
tablets containing 5 and 10 mg active, respectively.  In this case, Csat was 1260 to
2500 times higher than Csol.  In contrast, dissolution of ALP tablets in alkaline
medium was not under sink conditions, due to its inherently low saturated
solubility of ALP.  For example, drug solubility in simulated intestinal fluid (SIF)
pH 6.8 obtained during preformulation studies in section 3.1.1 was approximately
0.04 mg/ml (Csat).  The maximum drug concentrations (Csol) in 900 ml dissolution
medium are were 0.0056 mg/ml and 0.0111 mg/ml for tablets containing 5 and 10
mg active, respectively.  Because of this, Csat was only 3 to 7 times higher than
Csol.
To investigate the influence of dissolution media on the release of ALP
from the matrix tablets, USP buffer pH 6.0 or purified water was used as a
dissolution medium rather than 0.1 N HCl solution (pH 1.1).  Drug release
profiles of the same tablet formulation in different media were compared.  Figures
3.20 and 3.21 show the release profiles of K4M-42 and K100LV-27 formulations
in acidic medium (0.1 N HCl solution) and basic medium (USP buffer pH 6.0).
The extent of ALP release from both tablet formulations in USP buffer pH 6.0 is
significantly lower than the extent of drug release from both formulations in 0.1 N
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HCl solution.  Additionally, the extent of drug release in buffer pH 6.0 is
incomplete and less than 50% at 12 hours, which is due to the dissolution of ALP
from the tablets in buffer pH 6.0 did not occur under sink conditions.  This also
indicates that no dose dumping of ALP occurred at both acidic and basic pH
conditions, which may confirm the safety for oral administration of ALP tablets
during the in vivo clinical study.  Similarly, dissolution profiles of another ALP
tablet formulation developed during the screening study, which were conducted in
both 0.1 N HCl and purified water, are shown in Figure 3.22.  The rate and extent
of ALP release from the matrix tablets in purified water was significantly lower
and incomplete, which was due to a decrease in drug solubility and loss of sink
conditions.
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Figure 3.20 Effect of dissolution medium on ALP release from a matrix tablet
(2.5 %w/w ALP, 37 %w/w HPMC K4MP, 20 %w/w MCC, 0.5
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Figure 3.21 Effect of dissolution medium on ALP release from a matrix tablet
(2.5 %w/w ALP, 45 %w/w HPMC K100LVP, 20 %w/w MCC, 0.5
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Figure 3.22 Effect of dissolution medium on ALP release from a matrix tablet
(2.5 %w/w ALP, 40 %w/w of HPMC K100LVP, 20 %w/w MCC,
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Stability Study of Matrix Tablets
Two clinical tablet formulations containing different molecular weight
types of HPMC, HPMC K4M-42 (lot M0009) and K100LV-27 (lot M0010), were
packaged in HDPE bottles with PP cap (foamed PE and pressure sensitive liner),
and stored under different stability conditions, according to recommended ICH
guidelines.  At the conclusion of each stability condition, tablets from each
formulation were tested for in vitro dissolution and statistically evaluated for
differences using the similarity factor as previously defined.  Additionally, a
composite assay of 10 tablets and a HPLC analysis were conducted to determine
the potency of the tablets and to investigate any possible degradation of ALP
during storage.  Stability studies were carried out to ensure the stability and safety
of the tablet dosage forms during clinical study such that the tablets remained
stable for at least one stability period following the completion of the clinical
study, as mandated by clinical study requirements.
Table 3.12 summarizes the dissolution results of the two formulations at
different storage conditions.  Dissolution profiles at each stability condition are
shown in Figure 3.23.  In comparison to initial dissolution results, the dissolution
results from each storage condition are well within the initial release specification.
At each storage condition, dissolution profiles of the two clinical formulations
were similar or equivalent with an f2 actor ranging from 68-91 (only 2-5
%average difference, Table 3.13).
Dissolution profiles of K100LV-27 and K4M-42 formulations at different
storage conditions, compared with the initial storage condition (time zero), are
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shown in Figures 3.24 and 3.25, respectively.  For each tablet formulation, the f2
factor was calculated by a comparison of the dissolution profiles at each storage
condition with the control at the initial condition.  Results of f2 factor ranging
from 76-95 (2-5 %average difference) are shown in Table 3.14.  Therefore, in
vitro dissolution profiles of both tablet formulations remain unchanged for at least
6 months at 40˚C/75% relative humidity and 12 months at 25˚C/65% relative
humidity.
In addition to the dissolution profiles, tablet potency results for all stability
conditions as shown in Table 3.13 were within 90-110% of label claim.  No
degradation peaks were observed during HPLC analysis of tablets from all storage
conditions.  Table 3.15 shows the average tablet hardness of both formulations at
different storage conditions compared to initial results obtained following tablet
manufacturing.  Results indicate that tablets tend to become slightly softer (lower
hardness) when expose to a high temperature and humidity condition (i.e.
40˚C/75%RH).  At the 25˚C/60%RH storage condition, average tablet hardness
remained unchanged for at least 12 months.  Tablets stored at 40˚C/75%RH
condition may absorb some moisture from the environment and become softer
over time.  However, no swelling or hydration was observed from tablets stored at
different storage conditions.
Overall, results from the stability studies indicated that tablets from both
formulations were physically and chemically stable for at least 6 months at
40˚C/75%RH and 12 months at 25˚C/65%RH.  Both tablet batches manufactured
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under cGMP were within specification and could be released for in vivo clinical
study.
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Table 3.12 Summary of Dissolution Study of Two ALP Matrix Tablet
Formulations Containing Different Molecular Weight Types of
HPMC at Different Storage Conditions
Formulation K4M-42 (Lot M0009)
Formulation K100LV-27 (Lot M0010)
Time (hour)
Assay date 6/14/00 SD 7/20/00 SD 8/14/00 SD 9/15/00 SD 12/21/00 SD 9/16/00 SD 12/24/00 SD 5/10/01 SD
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
1 24.14 2.11 23.62 2.38 22.63 3.39 25.81 2.90 22.06 2.40 24.32 5.43 25.81 1.53 22.60 2.99
2 38.01 3.64 38.76 4.63 37.42 4.96 40.97 3.15 35.68 3.06 35.45 0.47 38.57 2.80 36.21 3.78
4 58.35 5.94 59.33 5.25 56.82 5.13 60.06 3.42 55.90 3.93 55.05 0.65 57.53 4.56 55.47 1.68
6 72.92 4.09 74.44 4.36 70.85 4.35 73.58 3.42 70.53 3.62 70.34 0.57 72.19 5.11 70.00 2.15
8 84.31 3.40 86.23 3.31 81.56 3.53 84.48 2.44 82.09 2.46 82.16 0.71 83.08 5.21 83.41 6.83
1 0 93.69 3.60 95.89 3.35 89.92 2.67 92.18 1.45 90.05 1.67 91.87 0.74 91.21 4.52 90.64 2.52
1 2 99.51 2.74 101.74 1.83 95.54 2.54 98.17 0.78 95.76 0.86 98.68 1.19 97.27 3.10 97.66 2.44
1 4 102.65 1.54 104.84 1.60 97.88 2.68 100.56 0.44 98.81 1.03 101.99 1.73 100.39 2.24 102.37 2.35
1 6 102.95 2.05 105.79 1.26 98.60 3.43 101.27 0.71 99.85 1.24 103.64 2.01 101.30 2.23 103.95 2.13
40 C, 3 mo. 25 C, 3 mo.40 C, 6 mo. 25 C, 12 mo.
K100LV-27 (Lot M0010)
Init ial 40 C , 1 mo. 40 C, 2 mo. 25 C, 6 mo.
Time (hour)
Assay date 6/13/00 SD 7/14/00 SD 8/13/00 SD 9/14/00 SD 12/22/00 SD 9/17/00 SD 12/23/00 SD 5/11/01 SD
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
1 24.81 2.75 22.79 0.27 20.88 1.12 23.53 2.29 22.28 2.55 26.42 2.66 23.90 2.04 22.03 2.30
2 38.22 2.83 36.65 0.35 35.22 3.02 36.11 3.58 35.35 3.54 40.25 3.78 38.09 3.11 40.10 3.20
4 58.03 4.22 59.32 0.47 54.05 4.68 56.95 6.26 55.48 5.52 60.08 5.61 59.08 4.96 60.06 4.96
6 72.47 4.99 71.79 0.53 68.26 5.05 68.46 6.37 69.69 6.23 74.39 6.04 73.52 5.05 75.43 5.45
8 82.93 4.75 81.72 0.58 79.06 5.87 79.11 6.38 80.16 6.13 86.37 5.29 83.25 4.75 86.82 5.46
1 0 91.42 4.06 90.41 0.63 87.90 5.51 88.77 6.03 87.99 5.39 93.79 5.95 90.74 4.08 95.12 5.11
1 2 97.06 3.21 95.92 0.66 92.46 3.80 94.97 4.92 93.27 4.47 98.84 4.34 95.65 3.44 100.47 4.25
1 4 102.06 3.47 100.39 0.68 96.60 3.05 99.03 4.22 96.43 3.58 102.67 3.57 98.64 2.67 104.31 3.69
1 6 102.78 1.41 103.19 0.70 99.61 2.77 102.62 3.40 99.13 2.40 105.24 3.30 100.90 1.74 106.77 3.30
40 C, 6 mo. 25 C, 6 mo.Init ial 40 C , 1 mo. 25 C, 3 mo. 25 C, 12 mo.
K4M-42 (Lot M0009)
40 C, 2 mo. 40 C, 3 mo.
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Figure 3.23 Dissolution profiles of two ALP matrix tablet formulations
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Table 3.13 Stability Study of ALP Matrix Tablet Formulations Containing
different Molecular Weight Type of HPMC
K100LV-27 (Lot M0010)
Description Tablet potency  (% Label)
40 ˚C/75 %RH 25 ˚C/60 %RH
Initial 1 mo. 2 mo. 3 mo. 6 mo. 3 mo. 6 mo. 12 mo.
Content
uniformity 94.82 n/a n/a n/a n/a n/a n/a n/a
Composite assay
of 10 tablets 101.04 100.11 100.35 101.10 103.57 100.15 102.75 100.21
Similarity factor
(f2)* 91 78 80 68 90 68 91 70
% Average
difference 2 5 5 5 2 5 2 5
K4M-42 (Lot M0009)
Description Tablet potency  (% Label)
40 ˚C/75 %RH 25 ˚C/60 %RH
Initial 1 mo. 2 mo. 3 mo. 6 mo. 3 mo. 6 mo. 12 mo.
Content
uniformity 101.67 n/a n/a n/a n/a n/a n/a n/a
Composite assay
of 10 tablets 105.58 105.56 101.35 102.14 102.58 102.01 103.15 105.09
Similarity factor
(f2)* 91 78 80 68 90 68 91 70
% Average
difference 2 5 5 5 2 5 2 5
Note: * Calculated based on percent label claim between K4M-42 and K100LV-27 formulations at
the same stability condition.
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Figure 3.24 Dissolution profiles of ALP matrix tablets at different storage
condition (formulation K100LV-27: 2.5 %w/w ALP, 45 %w/w
HPMC K100LVP, 20 %w/w MCC, 0.5 %w/w Mg stearate, 0.5
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Figure 3.25 Dissolution profiles of ALP matrix tablets at different storage
condition (formulation K4M-42: 2.5 %w/w ALP, 37 %w/w HPMC
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Table 3.14 Similarity Factor (f2) of ALP Matrix Tablet Dissolution Profiles






f2 factor % Avr.
difference
f2 factor % Avr.
difference
40 ˚C/75 %RH, 3 mo. 77 5 85 2
40 ˚C/75 %RH, 6 mo. 76 5 78 5
25 ˚C/60 %RH, 6 mo. 95 2 88 2
25 ˚C/60 %RH, 12 mo. 76 5 80 5
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Table 3.15 Tablet Hardness of ALP Matrix Tablets at Different Stability
Conditions
Formulation Stability Condition Hardness (kg)
Avr ± SD
K100LV-27 (Lot M0010) Initial 6.13 ± 0.70
12 mo., 25 C/60%RH 6.16 ± 1.03
12 mo., 40 C/75%RH 5.36 ± 0.86
K4M-42 (Lot M0009) Initial 6.46 ± 0.61
12 mo., 25 C/60%RH 6.15 ± 0.36
12 mo., 40 C/75%RH 4.58 ± 0.62
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3.1.4 In Vivo Clinical Study
The in vivo clinical study in human subjects was completed in
collaboration with Robert L. Talbert, Pharm.D. and his colleagues at GCRC, VA
hospital, San Antonio, according to the testing protocol, previously approved by
the Institutional Review Board (IRB) of the University of Texas Health Science
Center.
Ten healthy volunteers participated throughout the study.  The gender
ratio of male:female subjects was 6:4.  The range of age was 18-58 years old with
an average age of 33.5±12.9 years old.  The average body weight of the subjects
was 83.4±11.9 kg.
A validated reverse-phase HPLC method was previously developed for
quantification of ALP in plasma samples collected throughout the sampling
schedule.  Figures 3.26 and 3.27 displays the HPLC chromatograms of a control
sample and a blood sample collected from a subject, respectively.  Sharp peaks
with good separations are shown in each chromatogram.  The linearity of the
calibration curve was excellent with a correlation coefficient (r2) of no less than
0.994.
The assessments of the data collected throughout the study can be
separated into two parts: Pharmacokinetics and Pharmacodynamics.
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Figure 3.26 HPLC chromatogram of a control sample
201
Figure 3.27 HPLC chromatogram of a blood sample collected from a subject
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Pharmacokinetic Assessments
As shown in Figure 3.19, equivalent in vitro dissolution profiles were
obtained from tablets containing different MW types (nominal viscosities) of
HPMC (Initial dissolution: f2 = 91, 2 %average difference).  Additionally, In vitro
dissolution profiles of both tablet formulations remained unchanged for at least 6
months at 40°C/75%RH and 12 months at 25°C/60%RH (f2 = 67-91, 2-5
%average difference).  This indicated that both tablet formulations stored at
ambient conditions at the study site remained stable throughout the time period
required for in vivo clinical study.
Figure 3.28 shows the plots of the mean plasma concentrations of ALP in
each tablet formulation over time at different dosing conditions (i.e. fasted and fed
states).  For all conditions investigated, the mean plasma concentration of ALP
(Cp) rapidly increased after an oral administration and then reached the maximum
concentration (Cmax).  Peak plasma concentrations at all conditions occurred 9 to
17.8 hours after oral administration, for all subjects.  After reaching the peak
plasma concentrations (Cmax), the Cp of ALP gradually declined, which
corresponded to the drug elimination phase.  From Figure 3.28, the absorption of
ALP was delayed for 3 hours (3 hour lag period), when ALP tablets were taken
during the fed state, with the presence of a high fat diet (i.e. 1000 kcal, 50% fat)
within the stomach.  This was similar to results reported in prior research.  Drug
absorption was delayed when ALP was taken after a fed state than a fasted state,
but total absorption remained unchanged.  High fat diets may have a potential for
drug-food interactions and may alter drug absorption [United States
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Pharmacopeial Convention, 1999; FDA, 1996; Greenblatt and Wright, 1993;
Charman, 2000].
Table 3.16 summarizes the pharmacokinetic parameters, including
AUC0-∞, Tmax and Cmax, of both tablet formulations in fasted and fed states.  For
each parameter, the plots of both tablet formulations containing different
molecular weight type polymers in fasted and fed states were compared in Figures
3.29, 3.30, and 3.31.  The wide range for Tmax from 9.0-17.8 hours was obtained
from all conditions investigated.  This may due to the small subject size used in
the study.  However, overall results indicated that the AUC0-∞, Tmax, and Cmax
were insignificantly different between two tablet formulations containing different
MW types (nominal viscosities) of HPMC (HPMC-K4MP and HPMC-K100LVP)
in the fed and fasted states.  Therefore, MW types of HPMC did not influence in
vitro or in vivo performance of controlled release tablets.
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Figure 3.28 Plots of mean plasma concentrations over time of different
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Table 3.16 Pharmacokinetic Parameters in Fasted and Fe States of ALP in
Matrix Tablet Formulations Containing Different Molecular Weight
Types of HPMC Polymer (i.e. HPMC-K4MP and HPMC-K100LVP)
State Fasted Fed
Parameters K4MP K100LVP K4MP K100LVP
AUC0-∞
(ng/ml.hr)
2625 2678 2590 2683
P-Value 0.82 0.90
Tmax (hr) 17.8 9.6 9.0 9.2
P-Value 0.2 0.5
Cmax (ng/ml) 56.2 69.4 80.4 82.9
P-value 0.28 0.66
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Figure 3.29 AUC0-∞ (ng/ml.hr) in fasted and fed states of ALP in Matrix Tablet
Formulations Containing Different Molecular Weight Types of






















Figure 3.30 Tmax (hr) in fasted and fed states of ALP in Matrix Tablet
Formulations Containing Different Molecular Weight Types of






















Figure 3.31 Cmax (ng/ml) in fasted and fed states of ALP in Matrix Tablet
Formulations Containing Different Molecular Weight Types of




































Pharmacodynamic assessments obtained from each blood sample included
Visual Analog Scale (VAS) for wakefulness and Symbol Digital Matching Test
(SDMT), which is matching time over 90 seconds where different forms were
used for each time period,.  For SDMT, the symbol digit substitution test assessed
concentration and psychomotor speed, where the number correct in 90 seconds
was recorded (See Appendix A for SDMT worksheet used during the study).
Pharmacodynamic assessments during fasted and fed states are shown in
Figures 3.32a and 3.32b, respectively.  During the fasted state, although the
formulation containing HPMC-K100LVP polymer produced slightly greater
sedation at 4 hours, but the difference was not statistically significant.  The Tmax
for effect was slightly earlier with the formulation containing HPMC-K4MP
polymer (3 vs. 4 hours).  Large SD in SDMT scores was seen for both
formulations containing different MW types of HPMC polymer from hour 1
through hour 12.  Additionally, at hour 4, the SD was approximately 2/3 of the
mean value (24.2±16.5).  The rate of recovery was similar between the two
formulations containing different MW types of HPMC polymer.
During the fed state, no significant differences were observed in onset,
peak effect or duration for sedation rating when compared the formulation
containing HPMC-K4MP with the formulation containing HPMC-K100LVP.
The presence of a high fat meal (i.e. 1000 kcal, 50% fat) delayed the absorption of
ALP and lengthened the time of maximal sedation, based on the SDMT scores,
compared with the fasted state.
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Figure 3.32 Mean SDMT scores for HPMC-K4MP and HPMC-K100LVP
polymers in a) fasted state and b) fed state





































Figure 3.33 displays the reverse relationship between SDMT scores and the mean
plasma concentrations of ALP (Cp).  The Cp of ALP rapidly increased after oral
administration and then reached the maximum concentration (Cmax) at Tmax of 9
hours (for subject 2).  The SDMT scores decreased dramatically, when the Cp of
ALP approached the Cmax.  This was due to high degree of sedation that
occurred during first 9 hours following oral administration.  After 9 hours, the Cp
of ALP gradually decreased, while the SDMT scores of the subject were
improved due to less degree of sedation.  In other words, time-dependent effects
occurred during the oral administration of ALP tablets.  Specifically, less sedation
at the same or greater plasma concentrations later in time was observed.
Figure 3.34 shows the counter-clockwise hysteresis that was apparent in
both fasted and fed states.  This also indicated that acute tolerance occurred.
Additionally, a lag phase for onset of sedation was observed in the fed state.
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Figure 3.33 Relationship between SDMT scores and plasma concentration of
































Figure 3.34 Counter-clockwise hysteresis of the formulation containing HPMC-
K100LVP polymer (K100LV-27 formulation) in fasted and fed
states

























3.2 MULTIPARTICULATE SYSTEM (FILM-COATED BEADS)
Influence of processing parameters on drug release from cellulose ether
coated matrix bead formulations.
3.2.1 Uncoated Matrix Beads
Uncoated matrix beads of CPM and theophylline were prepared by an
extrusion/spheronization technique using purified water as a binder.  Dried beads
sized between 16 and 20 mesh were collected for further coating.  Dissolution of
each active drug from uncoated beads was determined using the appropriate
media as previously described in section 2.2.2, to ensure an immediate release
pattern.  As is shown in Figure 3.35, the release profile of each uncoated bead
formulation displays an immediate release behavior.  Specifically, the release of
CPM from uncoated beads in purified water was nearly 100% within the first 20
minutes, whereas the release of theophylline from uncoated beads in buffer pH
3.0 was nearly 100% within 60 minutes.  However, the release of theophylline
from uncoated beads was slower than the release of CPM, even though the matrix
beads contained the same excipient, microcrystalline cellulose.  This was due to
the differences in physical properties between active drug substances, such as
their aqueous solubilities as well as the level of drug loading within each type of
bead formulation (i.e. 15% CPM loading and 40% theophylline loading).
Uncoated matrix beads prepared with microcrystalline cellulose displayed a
strong physical structure that did not easily break or became damaged during
fluidized bed coating.
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3.2.2 Coated Matrix Beads
Uncoated beads of each drug type were utilized for different coating
studies.  The influence of processing parameters, including curing conditions,
plasticization, and the incorporation of a water-soluble additive, on drug release
from EC coated matrix bead formulations was investigated.  Dissolution study,
dissolution profile comparisons using similarity factor (f2), and SEM were used as
tools during this investigation.
This research study was divided into three sections in order to investigate
the impact of each processing parameter used during EC coating on drug release
from the matrix beads.
3.2.2.1 Curing Conditions
Following the coating process, EC coated beads containing either a water-
soluble drug, CPM, or a slightly water-soluble drug, theophylline, were oven-
cured at different temperatures (40˚C, 60˚C, or 80˚C) for up to 72 hours in order
to determine the optimum conditions for complete film coalescence and to
stabilize the amount of drug release.  Bead samples were taken at different curing
times and analyzed using dissolution studies.  Generally, the curing process
results in a reduction of drug release when compared to drug release from uncured
dosage forms [Lippold et al., 1989; Gilligan and Li Wan Po, 1991; Bodmeier and
Paeratakul, 1991a; Schmidt and Niemann, 1993; Hutchings et al., 1994a;
Bodmeier and Paeratakul, 1994; Guma et al., 1997; Amighi and Moes, 1997; Sakr
et al., 1998; Frohoff-Hulsmann et al., 1999a].
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For CPM coated beads, a higher percent weight gain or coating level, up
to 36%, is necessary to achieve sustained release, because of its high aqueous
solubility.  Figure 3.36 shows the effect of different curing times at 60˚C on the
amount of CPM release from beads coated with an EC dispersion (35%
theoretical coating level), plasticized with 30%w/w water miscible plasticizer,
TEC, for 2 hours.  The rate of CPM release was slower when coated beads were
exposed to 60˚C for at least 2 hours.  However, the slowest rate of drug release
was obtained from coated beads cured for 12 hours at 60˚C, indicating more
complete film coalescence at this condition.  When comparing dissolution profiles
of coated beads cured for 2 and 12 hours at 60˚C, the amount of CPM release was
significantly reduced for the samples cured for 12 hours with an f2 of 27 (greater
than 20% average difference between both profiles).  Interestingly, coated beads
cured for 18 hours at 60˚C showed slightly higher drug release when compared to
coated beads cured for 12 hours at the same temperature.  Similar results obtained
from beads cured for various times at 80˚C are shown in Figure 3.37.  The slowest
drug release rate was obtained from coated beads cured for 1 hour at 80˚C.
However, the amount of CPM release tended to increase when coated beads were
exposed to a longer curing time of 12 hours.  When comparing the dissolution
profiles of coated beads cured at 60˚C and 80˚C for 12 hours in Figure 3.38, the
curing temperature of 80˚C was more efficient for film coalescence, resulting in a
reduction in the amount of drug release from the coated beads.  When a higher
curing temperature used, the time to achieve complete film formation is shorter
because the high temperature facilitates the coalescence of the film.  In other
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words, the curing rates of coated beads are higher with higher storage
temperatures.  Figure 3.39 shows the influence of the coating levels on the
amount of CPM release from the same coated beads formulation cured at 80˚C for
2 hours.  As expected, the amount of CPM release was reduced when the higher
coating level was applied to the uncoated beads.  The theoretical coating level of
24% was sufficient to obtain a sustained release profile of CPM coated beads.
However, this only applies when coated beads are cured at 80˚C for 2 hours.
When an efficient curing condition is used (80˚C for 2 hours in this case), the
amount of coating solution and time can be significantly reduced, while a
sustained release profile is maintained.  When the coating level was increased
from 28 to 30%, both dissolution profiles were similar with an f2 of 78 (5%
average difference).  The maximum capability of the coating system to sustain the
drug release may be reached at a 28% theoretical coating level.  Coating levels
higher than 28% were not necessary to provide more sustained release of CPM.
Beads that were coated with the EC dispersion (35% theoretical coating
level) plasticized with 24 %w/w water insoluble plasticizer, AMG, for 24 hours,
showed a reduction in the amount of CPM release when the coated beads were
cured for at least 2 hours at 60˚C (Figure 3.40).  The slowest release rate of CPM
was obtained from coated beads cured for 6 hours.  However, if coated beads
were cured for 24 hours at the same temperature, the amount of CPM release was
significantly increased.  Similar to the previous system, a longer curing time does
not show any benefits to facilitate film formation process.
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Figure 3.41 shows the influence of coating level and curing time at 60˚C
on the release of CPM from matrix beads coated with an EC dispersion (20-35%
theoretical coating levels), plasticized with 24 %w/w water insoluble plasticizer,
DBS, for 24 hours.  Similar to the systems previously described, the amount of
CPM release was delayed when the higher coating level was applied to the
uncoated beads.  Additionally, the coated beads cured for 24 hours at 60˚C
displayed higher amounts of CPM release compared to coated beads cured for
only 6 hours at the same temperature.  However, this result is more pronounced
when a lower coating level is applied.  Specifically, the amount of CPM release
was significantly increased when coated beads at 20% weight gain were cured for
24 hours, whereas the amount of drug release was slightly increased when coated
beads at 35% weight gain were cured for 24 hours.  Similar results were observed
in all systems investigated, even though different plasticizers, plasticization times,
and coating levels were used in each formulation.  These findings were further
investigated in studies to follow.
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Figure 3.36 Influence of curing time at 60˚C on the release of CPM from matrix
beads coated with EC dispersion plasticized with 30 %w/w of TEC
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Figure 3.37 Influence of curing time at 80˚C on the release of CPM from matrix
beads coated with EC dispersion plasticized with 30 %w/w of TEC
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Figure 3.38 Influence of curing temperature on the release of CPM from matrix
beads coated with EC dispersion plasticized with 30 %w/w of TEC
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Figure 3.39 Influence of coating level (percent weight gain) on the release of
CPM from matrix beads coated with EC dispersion plasticized with
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Figure 3.40 Influence of curing time at 60˚C on the release of CPM from matrix
beads coated with EC dispersion plasticized with 24 %w/w of AMG
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Figure 3.41 Influence of curing time at 60˚C on the release of CPM from matrix
beads coated with EC dispersion plasticized with 24 %w/w of DBS
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Following the studies on curing time and temperature, further studies were
designed to elucidate the cause of increased drug release when coated beads were
cured at a longer time.  In order to slow down the amount of drug release from
beads cured at longer times, a subcoating solution of HPMC E5, plasticized with
2 %w/w PEG 400 for 2 hours, was applied to the uncoated CPM beads at a 2%
theoretical coating level prior to the application of the EC dispersion.  Application
of HPMC subcoat should not have an impact on the amount of drug release from
the beads since it is only used as a protective agent.  Figure 3.42 shows the
comparison of release profiles of uncoated and subcoated beads.  Both release
profiles were nearly identical, indicating an immediate release behavior.
Additionally, the dissolution profiles of CPM coated beads at a 35% theoretical
weight gain, with and without a 2 %w/w HPMC-E5 subcoat, were almost
identical (Figure 3.43).  The subcoating application had no impact on drug release
from the final coated beads.
Figure 3.44 shows the influence of curing time at 60˚C on the release of
CPM from matrix coated beads with 2% weight gain of subcoating solution, and
36% weight gain of EC dispersion, plasticized with 30 %w/w TEC for 2 hours.
The amount of CPM release was delayed when coated beads were cured at 60˚C
for a longer time up to 12 hours.  If beads were cured for longer than 12 hours, the
amount of drug release was increased.  These results were similar to the previous
studies of the coated beads without a protective subcoating application.  Similarly,
the rate of CPM release was slowest when coated beads were cured at 60˚C for 12
hours.
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Figure 3.42 Dissolution profiles of CPM uncoated beads and subcoated beads
(coated with 7.5 %w/w of HPMC-E5 plasticized with 2 %w/w of












Figure 3.43 Comparison of dissolution profiles of CPM beads without and with 2
%w/w subcoat (7.5 %w/w of HPMC-E5 plasticized with 2 %w/w of
PEG 400 for 30 minutes) prior to EC dispersion (plasticized with 30
%w/w of TEC for 2 hours) at 35 % theoretical weight gain and cured
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Figure 3.44 Influence of curing time at 60˚C on the release of CPM from matrix
beads coated with 2% HPMC-E5 subcoating and EC dispersion
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The influence of curing conditions on the release of CPM from the same
coated beads formulation (36% coating level) is shown in Figure 3.45.  Two
curing temperatures, 40˚C and 60˚C, were used to cure the EC coated beads with
an HPMC-E5 subcoat at different curing times.  At 40˚C, a longer curing time is
necessary to complete the film formation of the coated beads.  However, the
amount of drug release from the coated beads cured at 40˚C from 24 to 72 hours
remains unchanged.  The release of CPM was not sustained when cured at 40˚C,
even though a longer curing time was used.  This indicates that the completion of
film coalescence is a function of both curing temperature and curing time.  The
curing temperature of 40˚C, which is close to the bed temperature during the
coating process, is not sufficient to complete film coalescence of the EC coated
beads.  Furthermore, this temperature is too close to the glass transition
temperature of the plasticized EC.  Generally, the optimum curing temperature
should be higher than the glass transition temperature of the polymeric material to
accelerate the film formation process and to avoid aging problems of the coated
products [Ghebre-Sellassie et al., 1988; Lippold et al., 1989; Gilligan and Li Wan
Po, 1991; Bodmeier and Paeratakul, 1991a; Wesseling and Bodmeier, 1999b].  At
60˚C curing, the slowest rate of CPM release from the EC coated beads with an
HPMC-E5 subcoat was obtained when beads were cured for 12 hours.  This is
similar to previous results in other systems.  In another words, complete film
coalescence was obtained when coated beads were cured at 60˚C for 12 hours.
Similar to the 36% theoretical coating level, an increase in the amount of
CPM release was observed from beads coated with the EC dispersion at different
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levels (with 2% HPMC-E5 subcoat) and cured at 60˚C for 24 hours (Figure 3.46).
However, this result was less pronounced at higher coating levels.  In this coating
system, at least a 24% theoretical coating level was necessary to obtain a
sustained release profile of CPM.
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Figure 3.45 Influence of curing conditions on the release of CPM from matrix
beads coated with 2% HPMC-E5 subcoating and EC dispersion
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Figure 3.46 Influence of curing time at 60˚C on the release of CPM from matrix
beads coated with 2% HPMC-E5 subcoating and EC dispersion
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SEM is an effective tool for evaluating film coatings and revealing the
surface morphology of the beads [Mehta and Jones, 1985].  SEM micrographs
shown in Figure 3.47 compare the surface morphology of beads coated with EC
dispersion at 35% weight gain and cured at 60˚C for 24 hours, with and without
an HPMC-E5 subcoat.  The surface of the coated beads without an HPMC-E5
subcoat is smoother, but more porous than the surface of the coated beads with an
HPMC-E5 subcoat.  Pores on the surface of the beads could be the result of the
high aqueous solubility of CPM such that it could leach from the matrix core.
When uncoated beads were coated with HPMC-E5, many of those pores were
filled with the subcoating solution.  However, these pores may be responsible for
the faster dissolution obtained from the coated beads, with and without
subcoating, cured at 60˚C for longer than 12 hours.
The surface morphology of CPM beads, coated with a 2% HPMC-E5
subcoat and 36% EC dispersion followed by curing at 60˚C from 0 (uncured) to
72 hours, is shown in Figure 3.48.  The surface of coated beads was rough,
especially when the coated beads were cured for short periods of time.  Even
though the coated film became smoother and more completely coalesced when
cured for longer periods of time (48 and 72 hours), a higher number of pores or
film disruptions were observed (Figures 3.48 and 3.49).  The disruption of the
coated film caused a faster release of the CPM from the coated beads.  When
comparing between the SEM micrographs in Figure 3.48 and the release profiles
of CPM from the coated beads shown in Figure 3.44, the results suggested that the
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optimum curing condition without film disruption for CPM coated beads should
be 60˚C for 12 hours.
Results indicate that an additional application of HPMC-E5 subcoat does
not help by slowing down the amount of drug release from beads cured at longer
periods of time.  The influence of curing conditions on CPM release from the
coated beads is independent of coating level and subcoating application.
In the following study, the influence of different drug type on the curing
conditions was investigated.  Theophylline anhydrous was selected as a lipophilic





Figure 3.47 Comparison of Surface morphology of CPM beads with and without
application of HPMC E5 subcoating prior to EC dispersion
(plasticized with 30 %w/w of TEC for 2 hours, 35 % theoretical
weight gain) and cured at 60˚C for 24 hours
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Figure 3.48 Surface morphology of CPM beads coated with 2% HPMC-E5
subcoating and EC dispersion plasticized with 30 %w/w of TEC for
2 hours (36 % theoretical weight gain)
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Figure 3.49 Surface morphology of CPM beads coated with 2% HPMC-E5
subcoating and EC dispersion plasticized with 30 %w/w of TEC for
2 hours (36 % theoretical weight gain), and cured at 60˚C for 72
hours.
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A coating study to investigate the influence of curing conditions on the
release of theophylline from EC coated beads was carried out.  Uncoated
theophylline beads were coated with 7-19.72% EC dispersion, plasticized with 24
%w/w water insoluble plasticizer, DBS, for 24 hours and then oven-cured at
either 60˚C or 80˚C for different periods of time.  Due to the limited aqueous
solubility of theophylline, a lower coating level of 9-11% was sufficient to obtain
a sustained release profile.  Dissolution studies were conducted in pH 3.0 buffer
for the first 3.5 hours followed by adjustment to pH 7.4 for the remainder of the
dissolution.
The influence of curing time at 60˚C on the release of theophylline from
the matrix beads coated with 19.72% EC dispersion is shown in Figure 3.50.
When the curing time was increased from 0.5 to 2 hours, the amount of
theophylline release was significantly reduced, due to higher film coalescence.
However, the faster drug release was observed when the coated beads were
exposed to a high temperature of 60˚C for longer periods of time, such as 24, 48
or 72 hours.  These results were similar to previous studies on CPM beads.  This
may due to a loss of film integrity when coated beads were exposed to extreme
curing conditions.  The results shown in Figure 3.51 shows more pronounced
differences when the coated beads were cured at either 40˚C or 60˚C for longer
than 24 hours.  The results in Figure 3.51 also indicated that the curing rate of
beads exposed to 60˚C was faster than the curing rate of beads exposed to 40˚C.
This was because, at 60˚C the coated beads were held above the Tg of the
plasticized EC polymer.
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The influence of coating levels and curing time at 60˚C and 80˚C, on
theophylline release, is shown in Figures 3.52 and 3.53.  Similar to CPM, slower
drug release was observed, when the coating level was increased.  For both curing
temperatures, the rate of theophylline release was faster when the coated beads
were cured for 24 hours.  This indicated that the 24-hour period at 60˚C or 80˚C
was not a suitable curing condition for the EC coated beads, since the film may be
disrupted, resulting in a faster release.  The effect curing temperatures at 60˚C and
80˚C on drug release was compared in Figure 3.54.  A slightly faster curing rate
was obtained when the coated beads were exposed to 80˚C for 2 hours.  The
curing rate is a function of the curing temperature rather than the coating levels.
SEM micrographs, shown in Figure 3.55, review the surface morphology of
theophylline beads coated with an 11% EC dispersion and cured at 80˚C for 24
hours.  When cured at 80˚C for 24 hours, film disruptions or pores were found on
the surface of the theophylline coated beads.  This indicated that a faster drug
release from the coated beads exposed to the extreme curing conditions was
caused by a disruption of the film.
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Figure 3.50 Influence of curing time at 60˚C on the release of theophylline from
matrix beads coated with EC dispersion plasticized with 24 %w/w of
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Figure 3.51 Influence of curing condition on the release of theophylline from
matrix beads coated with EC dispersion plasticized with 24 %w/w of
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Figure 3.52 Influence of curing time at 60˚C on the release of theophylline from
matrix beads coated with EC dispersion plasticized with 24 %w/w of
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Figure 3.53 Influence of curing time at 80˚C on the release of theophylline from
matrix beads coated with EC dispersion plasticized with 24 %w/w of
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Figure 3.54 Influence of curing condition on the release of theophylline from
matrix beads coated with EC dispersion plasticized with 24 %w/w of
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Figure 3.55 Surface morphology of theophylline beads coated with EC
dispersion plasticized with 24 %w/w of DBS for 24 hours (11%
theoretical weight gain) and cured at 80˚C for 24 hours
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In another coating study of theophylline, a different type of plasticizer,
AMG, was used to plasticize the EC dispersion.  The influence of curing time at
60˚C on the release of theophylline from the EC-AMG coated beads is shown in
Figure 3.56.  Similar to the previous coating system, when DBS was used as a
plasticizer, a faster release was observed when the coated beads were exposed to
60˚C for 24 hours.  Similar results were observed at all coating levels.  When the
coating level was higher than 7%, sustained release profiles were obtained from
the coated beads cured at 60˚C for 6 hours.  As was shown by this investigation,
the influence of curing conditions on theophylline release was independent of the
coating level and the plasticizer type.
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Figure 3.56 Influence of curing time at 60˚C on the release of theophylline from
matrix beads coated with EC dispersion plasticized with 24 %w/w of
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Overall, the results of the curing study indicated that the curing time and
temperature influenced release of both water-soluble and slightly water-soluble
drugs from matrix beads coated with an aqueous EC dispersion.  When an
elevated curing temperature was used, a shorter curing time was needed to
complete the film formation.  The recommended curing conditions, which would
ensure complete film coalescence without disrupting film integrity of coated
beads, were either 6 to 12 hours at 60˚C or 1 to 2 hours at 80˚C.  Faster drug
release profiles were obtained for coated beads cured for long periods of time,
especially at a high curing temperature.  Additionally, the SEM micrographs
showed a loss of film integrity (i.e. pores) for the coated beads exposed to those
extreme curing conditions.  From the previous study reported in the literature, the
curing step was shown to have no influence on the drug release from beads coated
with another EC dispersion, Surelease®.  This may be due to the differences in
coating composition and preparation between Aquacoat® ECD and Surelease® and
the differences in film formation mechanism [Shah et al., 1994; Wesseling and
Bodmeier, 1999b].  Aquacoat® ECD dispersion contains EC polymer, cetyl
alcohol (stabilizer), and sodium lauryl sulfate (stabilizer/emulsifier).  At those
extreme curing conditions used in this study, these stabilizers, especially cetyl
alcohol, may not be stable or efficiently functioned as a stabilizer for the EC
polymer.  Cetyl alcohol within the film may start melting and creating the pores
when the coated beads were exposed to a higher temperature than its melting
point of 49˚C [Budavari et al., 1996], especially when the beads were cured for
longer periods of time.  The squeezing out of cetyl alcohol and sodium lauryl
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sulfate from the microcapsules coated with Aquacoat® ECD dispersion plasticized
with 19.4% DBS after post-treatment of 68˚C for 1 hour and storage time of 3-4
months was also reported [Lippold et al., 1990].
The influence of curing conditions on drug release from the dosage forms




The influence of plasticizer type and plasticization time was investigated
in this study for their effect on the release of water-soluble and slightly water-
soluble drugs from coated beads.  Plasticizers, including water miscible (i.e. TEC)
and water-insoluble (i.e. AMG and DBS) types, were plasticized for either 2 or 24
hours with the EC dispersion prior to application onto the uncoated beads
containing CPM or theophylline.  The coated beads were cured at 60˚C for 6
hours as recommended in section 3.2.2.1.  Dissolution studies were carried out to
determine the influence of plasticization on drug release.
For CPM beads, the influence of plasticization time of 24 %w/w AMG on
drug release from coated beads is shown in Figure 3.57.  Dissolution profiles of
beads containing different coating levels indicated that the plasticization time had
a significant influence on the amount of CPM release from the coated beads.
Specifically, when a 24-hour mixing time was used to plasticize AMG with the
EC dispersion, the release of CPM was slower.  A longer plasticization time for
AMG and EC dispersion was necessary to achieve a sustained release profile for
CPM.  Therefore, the coating level and processing time could be reduced while
maintaining similar sustained release profiles.  Figure 3.58 shows the effect of the
coating level, ranging from 25-35%, on the release of CPM from the same coating
formulation previously described.  Similar to other studies, when the coating level
was increased, the amount of drug release was significantly decreased.  In this
coating system, at least 30% coating level was necessary in order to obtain a
sustained release profile for CPM.
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In another coating study, a separate plasticizer, DBS, was used at the same
level as AMG and plasticized with the EC dispersion for 24 hours.  A long
plasticization time was recommended for DBS to permeate completely into the
polymer network to lower the film forming temperature and enhance the
flexibility of the film.  The high solubility value of EC in DBS determined at 20˚C
was greater than 10%, which was in agreement with the similar solubility
parameters of EC (21.1(J/cm3)1/2) and DBS (18.8 (J/cm3)1/2) [Lippold et al., 1990;
Lippold et al., 1999].  The influence of coating level on the release of CPM from
beads, plasticized with DBS for 24 hours, is shown in Figure 3.59.  At a coating
level between 20-25%, the rate of CPM release was extremely slow, when
compared to the release of the system containing AMG as a plasticizer.  For a
coating system containing AMG, at least 30% coating level was required for a 10-
hour release product; whereas less than 20% coating level was required for a
coating system containing DBS (Figure 3.60).  This indicated that DBS was more
efficient than AMG in terms of plasticization with the EC polymer.
In addition, CPM within the matrix of the beads may function as a
plasticizer due to its high solubility in the film.  This plasticization behavior of
CPM has been reported for Eudragit®RS30D.  The Tg of Eudragit
®RS30D
polymer decreased with increasing levels of CPM in the film.  CPM was soluble
in the film, where it was incorporated into the polymer network, functioning as a
plasticizer.  Finally, it helped promote particle deformation and coalescence of the
film upon drying [Wu and McGinity, 1999].
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Figure 3.57 Influence of plasticization time of 24 %w/w AMG with EC
dispersion on the release of CPM from matrix coated beads cured at
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Figure 3.58 Influence of coating level on the release of CPM from matrix beads
coated with EC dispersion plasticized with 24 %w/w AMG for 24
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Figure 3.59 Influence of coating level on the release of CPM from matrix beads
coated with EC dispersion plasticized with 24 %w/w DBS for 24
















Figure 3.60 Influence of plasticization type on the release of CPM from matrix
beads coated with EC dispersion plasticized for 24 hours and cured







0 2 4 6 8
Time (hours)
25 %wt gain (AMG) 30 %wt gain (AMG) 35 %wt gain (AMG)
25 %wt gain (DBS) 30 %wt gain (DBS) 35 %wt gain (DBS)
257
For theophylline beads, the coating level necessary to obtain a sustained
release profile was significantly lower than CPM beads as previously described in
the results of the curing study.  In the coating formulation containing 24% AMG
plasticized with the EC dispersion for 24 hours, a coating level between 7 and
11% was necessary to sustain the release of theophylline from the coated beads,
as shown in Figure 3.61.  If the same coating formulation was used to coat CPM
matrix beads, a coating level of at least 30% was necessary to obtain similar
release profiles (Figure 3.58).  Therefore, the type of drug substance used to
prepare the core beads has a major impact on the release of the drug from a
multiparticulate system.  Specifically, the release of drug from the system mainly
depends on the aqueous solubility of the drug.
The effect of plasticization time of 2 or 24 hours on the release of
theophylline from coated beads is shown in Figure 3.62.  Unlike the CPM release
profiles shown in Figure 3.57, a slower release of theophylline was obtained from
beads coated with an EC dispersion, plasticized with 24% AMG for only 2 hours.
When a plasticization time of 24 hours was used, faster drug release was obtained.
This result was similar for all coating levels.  Therefore, the 2-hour mixing time
of AMG with the EC dispersion was sufficient to plasticize the EC polymer and
was used in further studies of theophylline coated beads.
Finally, another type of plasticizer, TEC, was used at 24% to plasticize the
EC dispersion for 2 hours.  Due to the miscibility of TEC and the aqueous EC
dispersion, a plasticization time of 2 hours was sufficient to incorporate the
plasticizer into the polymer chains.  The results shown in Figure 3.63 indicated
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that at least an 11% coating level was necessary to obtain a 10-hour release profile
of theophylline.  From the dissolution profiles of previous systems containing
AMG, shown in Figures 3.62 and 3.64, a coating level of less than 11% was
sufficient to obtain a similar release profile for theophylline.  This indicated that
AMG was more efficient as a plasticizer for the EC dispersion.  Therefore, 24%
AMG was used to plasticize the EC dispersion for 2 hours in further studies of
theophylline coated beads.
Overall, the results of the plasticization study indicated that the plasticizer
type and plasticization time influenced release of both water-soluble and slightly
water-soluble drugs from matrix beads coated with an aqueous EC dispersion.
Different types of plasticizer used in the coating formulation appeared to
influence the release rate of the drug, by altering the water permeability of the
film [Saettone et al., 1995].  A suitable plasticizer type as well as the optimum
plasticization time were dependent on each coating system, and were primarily
dependent on the nature of the drug substance.  The influence of plasticization on
drug release from the dosage forms was independent of coating level.
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Figure 3.61 Influence of coating level on the release of theophylline from matrix
beads coated with EC dispersion plasticized with 24 %w/w AMG for















Figure 3.62 Influence of plasticization time of 24 %w/w AMG with EC
dispersion on the release of theophylline from matrix coated beads
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Figure 3.63 Influence of coating level on the release of theophylline from matrix
beads coated with EC dispersion plasticized with 24 %w/w TEC for
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Figure 3.64 Influence of plasticization type on the release of theophylline from
matrix beads coated with EC dispersion plasticized for 2 hours and
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3.2.2.3 Water Soluble Additives
As was shown from previous results, the rate of theophylline release from
beads coated at high coating levels was very slow.  This was due to the limited
solubility of theophylline during dissolution.  In this study, the influence of water-
soluble additives on the release of a slightly water-soluble drug, theophylline,
from EC coated beads, was investigated.  Theophylline uncoated matrix beads
were coated with an EC dispersion containing a plasticizer and a water-soluble
additive.  After coating, the coated beads were cured at 60˚C for 6 hours as
recommended in section 3.2.2.1.  Dissolution studies were carried out to
determine the influence of the water-soluble additive on drug release.
Figure 3.65 shows the effect of incorporation of a water-soluble additive
on the rate of theophylline release from coated beads.  A water-soluble additive,
HPMC-E5, was added at a level of 5% to the EC dispersion, plasticized with 24%
AMG for 2 hours.  When comparing the dissolution profiles of coated beads with
and without the incorporation of HPMC-E5, the amount of drug release from
beads containing theophylline was increased by the addition of HPMC-E5.  This
result was more noticeable at low coating levels (11 and 13%).  However, when
the coating level was increased to 17%, the incorporation of HPMC-E5 had no
effect on the release of theophylline.  This could be due to the level of HPMC-E5
incorporated in the coating dispersion was not sufficient to enhance the drug
release.  The influence of coating levels on theophylline release from matrix
beads coated with the same coating formulation and the incorporation of 5%
HPMC-E5, is shown in Figure 3.66.  Similar to other studies, when the coating
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level was increased, the amount of theophylline was significantly decreased.
When HPMC-E5 was added to the coating formulation, at least a 9% coating level
was necessary to obtain a sustained release profile.  At higher coating levels, a
higher level of HPMC-E5 may be required to enhance the amount of theophylline
release from the coated beads.  The influence of 20 %w/w HPMC-E5
incorporated into the coating formulation is shown in Figure 3.67.  When the level
of HPMC-E5 was increased to 20 %w/w, the rate of theophylline release
drastically increased.  At an 11% coating level, the rate of theophylline release
was significantly slower.  At the same coating level, the use of 20 %w/w HPMC-
E5 in the coating formulation caused dose dumping and lack of sustained release
of theophylline.  The dissolution profiles of theophylline coated beads with the
incorporation of 5 and 20 %w/w of HPMC-E5 are compared in Figure 3.68.  With
an increase in HPMC-E5 concentration, the coating became more permeable and
more porous upon exposure to water (dissolution medium), therefore dramatically
increasing the release rate of drug from the coated beads [Thombre et al., 1989].
Similar results were reported for beads coated with an EC dispersion containing
HPMC (Pharmacoat®603) and TEC or DEP.  The drug release rates increased
with increasing levels of HPMC from 10 to 30% [Frohoff-Hulsmann et al.,
1999a].
The extent of drug release from the coated beads was dependent on the
level of HPMC-E5 incorporated into the formulation.
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Figure 3.65 Influence of coating levels on the release of theophylline from
matrix beads coated with EC dispersion plasticized with 24 %w/w
AMG for 2 hours and 5 %w/w HPMC-E5, and cured at 60˚C for 6
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Figure 3.66 Influence of HPMC-E5 on the release of theophylline from matrix
beads coated with EC dispersion plasticized with 24 %w/w AMG for
2 hours and 5 %w/w HPMC-E5, and cured at 60˚C for 6 hours (11-
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Figure 3.67 Influence of HPMC-E5 at 20 %w/w on the release of theophylline
from matrix beads coated with EC dispersion plasticized with 24
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Figure 3.68 Influence of HPMC-E5 levels on the release of theophylline from
matrix beads coated with EC dispersion plasticized with 24 %w/w














The influence of the types of water-soluble additives, at 5 %w/w, on the
release of theophylline is shown in Figure 3.69.  At a 9% coating level, EC coated
beads containing PEG 8000 had a higher rate of theophylline release than EC
coated beads containing other water-soluble additives, including HPMC-E5,
sucrose and mannitol.  Similar results were also observed at other coating levels.
Therefore, PEG 8000 functioned as an effective water-soluble additive in the
formulation, at a low level.  In order to obtain a sustained release profile, a higher
coating level was necessary when PEG 8000 was used as an additive in the
formulation.
The influence of plasticizer type on the release of theophylline from beads
containing 5 %w/w PEG 8000 as an additive is compared in Figure 3.70.  For
both 13 and 15% coating levels, the coated beads containing DBS as a plasticizer
had a slower rate of drug release, even though 5 %w/w of PEG 8000 was
incorporated into the coating formulations to enhance the drug release.  In order to
enhance the dissolution of theophylline from the coated beads, a higher level of
PEG 8000 than was needed.
Theophylline coated beads with DBS or AMG as a plasticizer and PEG
8000 as a water-soluble additive showed two-phased release profiles, similar to
the results reported in the literature.  During the first phase of the release profile,
the release was fast and characterized by drug diffusion through water-filled pores
created after the migration of the water-soluble additive.  During the second
phase, those pores gradually closed or the permeability of the coating significantly
decreased due to the dramatic reduction in the free volume between the polymer
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chains.  Therefore, the slower drug release was obtained during the second phase
of the release profile [Gunder et al., 1995; Lippold et al., 1989; Frohoff-Hulsmann
et al., 1999a; Frohoff-Hulsmann et al., 1999b].
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Figure 3.69 Influence of water soluble additive type on the release of
theophylline from matrix beads coated with EC dispersion
plasticized with AMG for 2 hours and 5 %w/w water soluble














Figure 3.70 Influence of plasticization on the release of theophylline from matrix
beads coated with EC dispersion plasticized with 24 %w/w AMG for
2 hours or 24 %w/w DBS for 24 hours and 5 %w/w PEG 8000, and
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The results of this study showed that enhanced release of a slightly water-
soluble drug (i.e. theophylline) was achieved by the inclusion of a water-soluble
additive, which rapidly dissolved in the dissolution medium leaving small
channels or pores for the drug to pass through, thus increasing the permeability of
the membrane and modifying the dissolution rate.  Therefore, the incorporation of
these additives into the EC coating dispersion can be used to modify the
dissolution rate of drug from solid dosage forms.  The amount of drug release
from EC coated beads was influenced by the water-soluble additive type and
level.
The influence of the water-soluble additive on the film formation of EC
was explained by Miller and Vadas.  When a water-soluble additive was
introduced into the EC aqueous dispersion, it was distributed throughout the
continuous aqueous phase.  Following film drying, the water-soluble additive was
deposited on the interfaces between latex particles and may interfere with the
coalescence of the film.  Therefore, when high levels of these additives were used
in the coatings, the initial coalescence could be incomplete and further gradual
coalescence may be time dependent [Miller and Vadas, 1984].
The mechanism of the water-soluble additive's ability to enhance the drug
release can be explained by a rapid dissolution of a water-soluble additive after
exposure of the coated beads to an aqueous dissolution medium.  The dissolution
medium or solvent penetrated into the beads to dissolve the water-soluble
additive, which then migrated out and left pores in the coated film.  At the same
time, the dissolution of the drug within the matrix was initiated.  Finally, the
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dissolved drug diffused through the EC film into a dissolution medium, especially
via the water-filled pores previously created by the water-soluble additive




The use of cellulose ether polymers in oral controlled release dosage
forms, including matrix tablets and multiparticulate dosage forms was
investigated.  Hydroxypropyl methylcellulose (HPMC) and ethylcellulose (EC)
polymers were used to formulate and control the release of active ingredients
from the hydrophilic matrix tablets and film coated beads, respectively.
Formulations and processing parameters were developed and optimized in order
to achieve desired rate of drug release from each drug delivery system.
For the matrix tablet delivery system, alprazolam (ALP), a lipophilic drug,
was used as a model active ingredient.  The preformulation studies for ALP were
carried out to investigate its physiochemical properties.  The studies included drug
solubility, thermal properties, particle size and particle size distribution, surface
morphology, and crystallinity.  An approximate aqueous solubility of ALP
determined at 37±0.5˚C was 44 µg/ml (1 part of ALP per 22727 parts of water),
indicating a water-insoluble nature of the drug.  The solubility of ALP was pH
dependent.  Particularly, ALP had a higher solubility in an acidic pH solution than
in an alkaline media.  Solubility results also helped determine sink conditions,
which are an important experimental parameter that must be controlled during
dissolution studies, of ALP in different dissolution media.  For the dissolution
studies of ALP matrix tablets, 0.1 N HCl solution (pH 1.1) was used as a
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dissolution medium because ALP had a higher solubility and sink conditions for
ALP release could be achieved in this medium.  In contrast, purified water or
alkaline media should not be used for dissolution studies of ALP, since ALP
dissolution did not occur under sink conditions, due to its low solubility.  DSC
results demonstrated a sharp endothermic peak for ALP at 232-233˚C, which
corresponded to its melting point.  Results also indicated the crystalline nature of
the drug and an irreversible melting process.  The average Particle size of ALP,
determined by laser light scattering and SEM, was in the range of 2-9 µm.
Similar to DSC results, SEM micrographs and powder X-ray diffraction patterns
indicated the crystalline structure of ALP.  Analytical methods including
ultraviolet spectroscopy and chromatographic analysis for ALP quantitation were
developed.  For UV analysis, a method was developed for quantitation of ALP in
solution and in dissolution media at a maximum wavelength of 264 nm.  The
linearity of the calibration curve in the range of 0.001-0.020 mg/ml was excellent
with a correlation coefficient (r2) of 0.999.  For chromatographic analysis, a
reverse-phase HPLC method at 222 nm was developed for quantification of ALP
contained in matrix tablet formulations.  The linearity of the calibration curve in
the range of 0.005-0.06 mg/ml was excellent with a correlation coefficient (r2) of
0.999.  The precision of the both methods was less than 1%RSD.
Lipophilic drugs, such as ALP, are difficult to completely extract and
quantitate from tablets containing HPMC polymer due to their highly lipophilic
nature and the gelling properties of the HPMC polymer.  An efficient method to
achieve complete recovery of alprazolam from powder blends and tablets
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containing different excipient types and different molecular weight types of
HPMC was developed and qualified.  The method consisted of using hot water to
swell the HPMC polymer followed by the addition of cold water to completely
dissolve HPMC, and then adding a strong solvent (ACN) to dissolve the
alprazolam and extract the drug from the HPMC solution.  This method may be
useful to recover other lipophilic drugs from hydrophilic matrix tablets containing
HPMC.
For controlled release tablet formulations, the influence of different
formulation parameters on the release of ALP from an HPMC matrix tablet was
investigated.  Formulation parameters, including tablet size, drug loading,
polymer levels, excipient type and level, molecular weight type of HPMC, and
dissolution media, were optimized during screening and formulation development
of the matrix tablets.  In vitro dissolution studies and similarity factor assessments
were used as tools during formulation development.
Variations in tablet size influenced both the amount and extent of ALP
release from a matrix tablet as well as the amount of HPMC necessary in the
formulation to maintain a sustained release profile.  A high level of HPMC was
necessary for smaller tablets to obtain a desirable sustained release profile.  When
the tablet size was increased, resulting in an increased surface area for drug
release, the rate of drug release was slower due to the change in the surface area-
to-volume ratios and the amount of initial gel formation.  Th optimum tablet size
of 11 mm was selected to prepare 400 mg tablets throughout formulation
development.
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The amount of drug loading in a matrix tablet did not have an impact on
the amount of ALP release.  Similar release profiles were obtained from tablets
containing either 5 or 10 mg ALP.  The 10-mg ALP was loaded into a 400-mg
matrix tablet.  However, obtaining content uniformity of each tablet prepared by
direct compression was a challenge.  Therefore, a blending method to achieve
good content uniformity was developed.  The content uniformity of 10 tablets was
within 90-110% of label amount of ALP with a low magnitude of RSD, indicating
that the blending method developed was efficient to obtain a uniform distribution
of ALP in each tablet.  Additionally, the HPMC level was shown to be the most
important factor to control drug release from a matrix tablet.  When the HPMC
level in the formulation was increased, the amount and extent of drug release
significantly decreased.  This was due to an increase in polymer concentration
resulting in an increased viscosity of the gel as well as the formation of a gel layer
with a longer diffusional path.
While maintaining the HPMC and drug level constant in the controlled
release tablet formulations investigated, it was found that the type and level of
excipient influenced the rate and extent of ALP release.  The similarity factor was
useful to compare dissolution profiles of tablets containing different excipients.
The percent average difference, based on f2 values, between dissolution profiles of
formulations containing a soluble excipient compared to formulations containing
an insoluble excipient was in the range of 15-20%, indicating dissimilarities in the
release profiles.  The percent average difference between dissolution profiles of
formulations containing a similar type of excipient (i.e. soluble or insoluble
279
excipients) was in the range of 5-10%, indicating similar profiles.  The insoluble
excipients, especially DCP, caused the drug to be released at a slower rate and to
a lesser extent than the soluble excipients investigated.  Intermediate release
profiles were obtained when binary mixtures of LAC and DCP were used in the
formulation.  The release mechanism of ALP from each tablet formulation was
described by either Hixson-Crowell cube root kinetics equation or
Peppas’equation (non-Fickian (anomalous) diffusion).  Differences in excipient
type or level in the formulations did not have an impact on the release mechanism
of ALP from the tablets.
The influence of two different molecular weight types of HPMC,
including HPMC-K4MP and HPMC-K100LVP, on the release of ALP from a
matrix tablet was investigated.  The rate of ALP release from a tablet formulation
containing a low molecular weight type HPMC, HPMC-K100LVP, was faster
than the amount of ALP release from a similar tablet formulation containing a
high molecular weight type HPMC, HPMC-K4MP.  Even though both HPMC
types possess a similar degree of methoxyl substitution and hydroxypropyl
substitution and similar gelation rates, they are different in terms of their degree
of polymerization resulting in different molecular weights, which is reflected in
the viscosity of an aqueous solution.  Specifically, HPMC-K4MP has a molecular
weight or nominal viscosity about 40 times greater than HPMC-K100LVP.
To investigate the influence of dissolution media on the release of ALP
from the matrix tablets, USP buffer pH 6.0 or purified water was used as a
dissolution medium rather than 0.1 N HCl solution (pH 1.1).  Drug release
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profiles of the same tablet formulation in different media were compared.  No
dose dumping of ALP occurred at any pH, which may confirm safety for oral
administration of ALP tablets during the in vivo clinical study.  The extent of ALP
release in either USP buffer pH 6.0 or purified water was significantly lower than
the extent of drug release from the same tablet formulations in 0.1 N HCl
solution.  Additionally, the extent of drug release in buffer pH 6.0 and purified
water was incomplete and less than 50% at 12 hours.  This was because the
dissolution of ALP in buffer pH 6.0 and purified water did not occur under sink
conditions.
Screening and formulation development studies demonstrated that rate of
ALP release from HPMC matrix tablets was influenced by tablet size, excipient
type, polymer level and type (MW distribution), and pH of the dissolution
medium.  However, drug loading did not have an impact on the release of ALP
from matrix tablets.
Finally, two controlled release tablet formulations containing different
HPMC molecular weight types or nominal viscosities (i.e. formulations K100LV-
27 and K4M-42) were developed.  Tablet size, shape and hardness were identical
for both formulations.  The K4M-42 tablet formulation containing 37 %w/w of
HPMC-K4MP had an equivalent in vitro dissolution with K100LV-27 tablet
formulation containing 45 %w/w of HPMC-K100LVP.  A clinical batch of each
formulation was successfully prepared according to cGMP.  Both clinical batches
were tested for initial product release prior to conducting the in vivo clinical
study.  The characterization of ALP tablets in terms of weight and hardness
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variations, content uniformity, batch composite, and in vitro dissolution, met the
predetermined acceptance criteria.  Stability studies following the recommended
ICH guidelines indicated that in vitro dissolution profiles of both tablet
formulations remained unchanged for at least 6 months at 40°C/75 %RH and 12
months at 25°C/60%RH (f2 = 67-91, 2-5 %average difference).  Tablet potency
results for all stability conditions were within 90-110% of label claim.  No
degradation peaks were observed during HPLC analysis of tablets from all storage
conditions.  However, tablets tended to become slightly softer (lower hardness)
when expose to a high temperature and humidity condition (i.e. 40˚C/75%RH).
At 25˚C/60%RH, the average tablet hardness remained unchanged for at least 12
months.  Overall results demonstrated that both tablet batches manufactured under
cGMP were within predetermined specification and were stable for at least one
stability period following the completion of the clinical study, as mandated by
clinical study requirements.  Therefore, these two clinical formulations, which
were equivalent in vitro (Initial dissolution: f2 = 91, 2 %average difference), were
tested for bioequivalence during an in vivo clinical study.
In vivo clinical results indicated that molecular weight types of HPMC did
not influence in vitro or in vivo performance of controlled release tablets
containing lipophilic ALP.  Series of sustained release tablets provided
bioequivalent results in both fed and fasted states.  In vitro dissolution conditions
sufficiently mimicked in vivo dissolution conditions and produced similar relative
release profiles for all formulations.  Similar literature results, postprandial
administration of SR tablets resulted in a decreased Tmax and an increased Cmax,
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possibly due to an increase in polymer erosion of the HPMC matrix tablet
resulting from mechanical attrition.  During pharmcodynamic assessment, no
significant differences in SDMT scores were noted for both tablet formulations
containing different MW types of HPMC.  Also, no gender effects were observed
during the study.  Food delayed absorption of ALP by approximately 3 hours.
In further studies, the erosion mechanism as well as the rate of erosion of
the ALP matrix tablets should be investigated in more detail in order to explain
the release mechanism of ALP from the matrix tablets.  The pharmacokinetic and
pharmacodynamic approaches of ALP in the controlled release matrix tablets
should be carefully evaluated in order to obtain a better understanding of
absorption, distribution, metabolism and elimination mechanisms of ALP in the
human subjects.  Studies on other lipophilic and hydrophilic drugs may be
necessary to investigate if the similar formulation parameters have a similar
impact on the release of the drug from HPMC matrix tablets.  Additionally, the
concept that different molecular weight types of HPMC have no impact on in
vitro and in vivo performance of controlled release matrix tablets should be
proven with other lipophilic drugs and hydrophilic drugs.
For the multiparticulate delivery system, chlorpheniramine maleate (CPM)
and theophylline anhydrous were used as models for the water-soluble and
slightly water-soluble drugs, respectively. Uncoated matrix beads containing
either CPM or theophylline, and microcrystalline cellulose were prepared by an
extrusion/spheronization technique using purified water as a binder.  Immediate
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released profiles were obtained from each type of uncoated beads.  The rate of
drug release was reduced when a higher coating level was applied to the uncoated
beads.  The influence of processing parameters on drug release from EC coated
matrix bead formulations was investigated.
The curing temperature and curing time influenced release of both CPM
and theophylline from beads coated with an aqueous EC dispersion.  The curing
process results in a reduction of drug release when compared to drug release from
uncured dosage forms.  However, a faster drug release was observed when the
coated beads were exposed to a high temperature of 60˚C for longer periods of
time, such as 24, 48 or 72 hours.  Additionally, the SEM micrographs showed a
loss of film integrity (i.e. pores) for the coated beads exposed to these extreme
curing conditions.  Therefore, the optimum curing conditions should be
determined in order to ensure complete film coalescence without disrupting film
integrity.  The completion of film coalescence is a function of both curing
temperature and curing time.  The optimum curing temperature should be higher
than the glass transition temperature of the polymeric material, to accelerate the
film formation process and to avoid aging problems of the coated products.  The
curing rates of coated beads were higher with higher storage temperatures because
the high temperature facilitates the coalescence of the film.  Specifically, the
curing rate of beads exposed to 60˚C was faster than the curing rate of beads
exposed to 40˚C.  This was because, at 60˚C the coated beads were held above the
Tg of the plasticized EC polymer.  The recommended curing conditions, which
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would ensure complete film coalescence without disrupting film integrity of
coated beads, were either 6 to 12 hours at 60˚C or 1 to 2 hours at 80˚C.
For CPM coated beads, a higher percent weight gain or coating level, up
to 36%, is necessary to achieve sustained release, because of its high aqueous
solubility.  Similar results were obtained when an HPMC-E5 subcoat was applied
to the uncoated beads prior to the EC dispersion application.  For theophylline
coated beads, a lower coating level of 9-11% was sufficient to obtain a sustained
release profile, due to the limited aqueous solubility of theophylline.  The type of
drug substance used to prepare the core beads had a major impact on the release
of the drug from a multiparticulate system.  Specifically, the release of drug from
the system mainly depended on the aqueous solubility of the drug.
The influence of curing conditions on drug release from the dosage forms
was independent of coating level, subcoating application, plasticization, or drug
type.
In addition to the curing conditions, the amount of drug release from EC
coated matrix beads was also influenced by plasticizer type and mixing time.
Plasticizers, including water miscible (i.e. TEC) and water-insoluble (i.e. AMG
and DBS) types, were plasticized for either 2 or 24 hours with the EC dispersion
prior to application onto the uncoated beads containing CPM or theophylline.
For CPM beads, plasticization time had a significant influence on the
amount of CPM release from the coated beads.  Specifically, when a 24-hour
mixing time was used to plasticize AMG with the EC dispersion, the release of
CPM was slower.  A longer plasticization time for AMG was necessary to achieve
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a sustained release profile for CPM.  DBS was found to be more efficient than
AMG in terms of plasticization with the EC polymer.
Unlike the CPM release profiles, a slower release of theophylline was
obtained from beads coated with an EC dispersion, plasticized with 24% AMG
for only 2 hours.  When a plasticization time of 24 hours was used, faster drug
release was obtained.  The 2-hour mixing time of AMG with the EC dispersion
was sufficient to plasticize the EC polymer and was used in further studies of
theophylline coated beads.  AMG was found to be more efficient as a plasticizer
for the EC dispersion than TEC.  Therefore, 24% AMG was used to plasticize the
EC dispersion for 2 hours in further studies of theophylline coated beads.
Results of the plasticization study indicated that the plasticizer type and
plasticization time influenced release of both water-soluble and slightly water-
insoluble drugs from matrix beads coated with an aqueous EC dispersion.
Different types of plasticizer used in the coating formulation appeared to
influence the release rate of the drug, by altering the water permeability of the
film.  A suitable plasticizer type as well as the optimum plasticization time were
dependent on each coating system, and were primarily dependent on the nature of
the drug substance.  The influence of plasticization on drug release from the
dosage forms was independent of coating level.
Dissolution profiles for theophylline beads demonstrated that the rate of
theophylline release from beads coated at high coating levels was extremely slow.
This was due to the limited solubility of theophylline during dissolution.
Enhanced release of a slightly water-soluble drug (i.e. theophylline) was achieved
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by the inclusion of a water-soluble additive, which rapidly dissolved in the
dissolution medium leaving small channels or pores for the drug to pass through,
thus increasing the permeability of the membrane and modifying the dissolution
rate.  Therefore, the incorporation of these additives into the EC coating
dispersion can be used to modify the dissolution rate of drug from solid dosage
forms.  Additionally, the amount of theophylline released from EC coated beads
was manipulated by the inclusion of different types and levels of water-soluble
additives.
The mechanism of the water-soluble additive's ability to enhance the drug
release can be explained by a rapid dissolution of a water-soluble additive after
exposure of the coated beads to an aqueous dissolution medium.  The dissolution
medium or solvent penetrated into the beads to dissolve the water-soluble
additive, which then migrated out and left pores in the coated film.  At the same
time, the dissolution of the drug within the matrix was initiated.  Finally, the
dissolved drug diffused through the EC film into a dissolution medium, especially
via the water-filled pores previously created by the water-soluble additive.
This model is also applicable for formulation scientists, in order to
manipulate and control the release of a slightly water-soluble drug substance.
Overall, results demonstrated the amount of drug release from EC coated
matrix beads was influenced by drug type, plasticization, water-soluble additives,
and curing conditions.  Further studies should include the investigation of the
drug release mechanisms from the EC coated matrix beads with and without the
incorporation of a water-soluble additive.  Stability or aging studies of the EC
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coated matrix beads should be carried out in order to determine the optimum
storage conditions for maintaining the release of the drug over extended periods
of time.  Other aqueous EC dispersion products, such as Surelease®, m y be used
for sustained release coating.  The influence of the similar processing parameters
should be investigated to determine if similar results are obtained.
In conclusion, different molecular weight types of HPMC did not
influence in vitro or in vivo performance of controlled release tablets containing
lipophilic ALP.  Controlled release tablets provided bioequivalent results in both
fed and fasted states.
Drug release from the EC coated matrix beads containing either a water-
soluble or slightly water-soluble model drug was influenced by plasticizer type,
plasticization time, and curing conditions.  The amount of theophylline released
from EC coated beads was manipulated by the inclusion of different types and
levels of water-soluble additives.
For both controlled release drug delivery systems, formulation and
processing parameters must be investigated and optimized in order to achieve
desirable release profiles and stabilize the amount of drug released throughout the
shelf-life of the product.  This research study provided useful information for
formulation scientists on preformulation, formulation optimization, and
characterization during development of controlled drug delivery systems
containing cellulose ether polymers.
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Appendix A
Symbol Digit Matching Test (SDMT)
Subject Initials & Number ___________________




              ATTENTION!!!
Are you healthy, non-pregnant individual between the ages of
18 and 65?
Would you be willing to take part in a scientific study testing the
effects of two different tablets of the same medicine?
For $800 ($200 / visit X 4 visits) would you be willing to be
hospitalized for 24 hours a week for four weeks?
You would be requires to undergo scheduled blood sampling and
complete tests which study mental alertness.
If you answered “YES” please contact Dr. Robert Talbert in the











CSD Calcium sulfate dihydrate
DBS Dibutyl sebacate
DCA Dicalcium phosphate anhydrous
DCP Dicalcium phosphate dihydrate
DEX Dextrose
DSC Differential scanning calorimetry
EC Ethylcellulose






SEM Scanning electron microscopy
SUC Sucrose
TEC Triethyl citrate
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